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ABSTRACT 
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Doctor of Medicine 
 
REGULATION OF THE SYNTHESIS OF TISSUE INHIBITORS OF 
METALLOPROTEINASE-1 AND –2 BY HEPATIC AND PANCREATIC STELLATE 
By Dr Peter Raymond McCrudden 
 
Hepatic stellate cells (HSC) play a central role in fibrosis development by production of 
extracellular matrix and also by secretion of matrix metalloproteinases (MMPs) and Tissue 
inhibitors of metalloproteinases (TIMPs) including TIMP-2 and MMP-2. TIMP-2 has been 
shown to interact with Gelatinase A in conjunction with MT1-MMP (MMP-14). TIMP-2 has 
been traditionally considered to be constitutively expressed. There is some evidence that 
TIMP-2 expression is slightly enhanced in fibrotic disease and activation in tissue culture. 
Little is known in terms of TIMP-2 expression in the recently described pancreatic stellate 
cells (PSC). HSC were cultured on plastic having been isolated from rat and human liver 
resections. After culture on plastic northern analysis was performed for TIMP-2 mRNA 
expression. TIMP-2 promoter activity was examined in rat pancreatic stellate cells (PSC) and 
rat hepatic stellate cells. Early work led to subcloning the promoter into a different vector 
though subsequent promoter studies were unsuccessful. In vivo work in 
immunohistochemistry studies suggest there is increased TIMP-2 expression in evaluation of 
rat pancreas and liver in addition to human liver and pancreas specimens. By ribonuclease 
protection assay TIMP-2 was noted to be upregulated in human fibrotic liver compared to 
normal human liver tissue. In conclusion there is some evidence that TIMP-2 regulation may 
be altered in fibrotic liver states as well as in pancreatic inflammatory disease. 
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CHAPTER 1 
INTRODUCTION   20
1. Introduction 
 
1.1 Background to liver disease and hepatic fibrosis 
 
Chronic injury, which can lead to fibrosis in the liver, occurs in response to a variety of 
insults including viral hepatitis (especially hepatitis B and C), alcohol abuse, drugs, metabolic 
diseases due to overload of iron or copper, autoimmune attack of hepatocytes (autoimmune 
hepatitis) or of the bile duct (primary biliary cirrhosis), and finally to certain congenital 
abnormalities (4-6). 
 
The injury is typically present months or years before a significant scar develops although the 
time course may be accelerated in congenital liver disease.  Evidence is accumulating that 
liver fibrosis is reversible, whereas cirrhosis, the end stage consequence of fibrosis, has until 
recently been held to be generally irreversible. 
 
Research into the understanding of fibrosis is therefore focussed primarily on events that lead 
to the early accumulation of scar in the hope of identifying therapeutic targets to slow its 
progression.  The prevalence of chronic liver insults imposes a significant health care burden.  
For example, the prevalence of hepatitis C virus (HCV) infection in the United States is 
estimated at 1.8% of the country’s population (an estimated 3.9 million persons infected 
nationwide) (7); an estimated 250 million people are infected worldwide with hepatitis B 
virus (HBV) and here in the United Kingdom 6,000 deaths annually are attributable to liver 
cirrhosis (8;9). 
 
Hepatic fibrogenesis is proving to be an important biological and clinical context for 
emerging concepts in molecular biochemistry that is relevant for many other tissues. 
 
1.2 Anatomy of the liver 
 
Positioned beneath the right hemi-diaphragm the classical division of the large right lobe and 
small left lobe bears no relation to the true functional division on the basis of blood supply 
into almost equal right and left lobes.  The liver has a dual blood supply from the hepatic 
artery, which is usually a branch from the coeliac axis and from the portal vein formed from 
the confluence of the mesenteric and splenic veins.  The hepatic artery supplies 25% of the   21
blood supply but 50% of the oxygen; the remainder is delivered by the low-pressure portal 
supply. 
 
At the microanatomical level the liver essentially consists of a series of channels or sinusoids, 
running between plates of hepatocytes.  These are lined by endothelial cells, which contain 
unusually large fenestration, allowing the sinusoid part of each hepatocyte surface to have 
free access to almost all the constituents in plasma.  Hepatic stellate cells and Kupffer cells 
are also present in the sinusoids.  Biliary canaliculi form between the contiguous surfaces of 
the hepatocytes, and here, and on the sinusoid surface, there are extensive microvilli in the 
cell membrane to increase the capacity for transmembrane transfer.  Branches of the hepatic 
artery, portal vein and bile ducts within the liver are carried in portal tracts.  The smallest of 
these, carrying terminal branches, supply groups of sinusoids, which together form a 
functional unit, the acinus.  Blood from each acinus then passes into a number of different 
efferent veins (Figure 1.1).   22
Figure 1.1 (a-c) structure of the liver sinusoid  
(ADAPTED FROM (10) 
 
 
 
Figure 1.1b  Schematic diagram of the 
liver acinus. Blood passes from hepatic portal 
vein (light blue) and hepatic artery (red) 
towards a central vein (darker blue). 
Figure 1. 1a  Low power view of human 
liver, pa= portal space containing Portal venule, 
bile ductile and portal venule  CV=central vein 
 
 
Figure 1.1c Hepatocytes are arranged in a ‘sheet’ like manner, radiated from a central vein located 
centrally in every lobule. 
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1.3 Structure of the normal liver sinusoid  
 
Traditionally the basic unit of the liver structure has been the lobule.  This is based on 
anatomical criteria, indeed in some species eg the pig, there is a distinct fibrous capsule 
surrounding each lobule.  It is defined as the parenchyma surrounding a central vein, bordered 
peripherally by 3-6 portal tracts (Figure 1.1a-c).  This does not describe the functional unit of 
the liver, which is the acinus.  The acinus is defined as the parenchymal mass supplied by a 
single terminal portal tract (11).  Blood flows from the portal vein and hepatic artery into the 
sinusoids from which the surrounding parenchyma is supplied.  Blood then drains into the 
peripheral efferent veins (the central veins of the lobule) thence to the hepatic artery.  One 
efferent vein supplies several acini.  The hepatocytes of the acinus can be divided into 3 
zones, these reflect both heterogeneity of the hepatocyte function, and pattern of injury in 
disease (12).  Zone 1 hepatocytes are closest to the portal tracts and zone 3 to the efferent 
vein. 
 
The sinusoids are wide vascular channels that have a unique structure.  This is believed to 
derive from the necessity to allow efficient and controlled interaction of substances between 
the blood and the hepatocytes.  The sinusoid is lined by a specialized fenestrated endothelium.  
Kupffer cells (tissue specific hepatic macrophages) are distributed sporadically through the 
sinusoid, but are most dense peripherally (13).  These cells play a central role in host defence; 
they are phagocytic and have receptors for endotoxin.  Pit cells are similarly distributed and 
are granular lymphocytes with natural killer activity.  Between the endothelium and the 
palisades of hepatocytes lies the ‘space of Disse’.  This term is in some respects a misnomer 
because although there is no electron dense basement membrane it contains a loosely woven 
matrix consisting of types I, III and IV collagens, lamins, proteoglycans and fibronectin, i.e. 
the components of a basement membrane-like matrix (14-19).  In addition the hepatic 
lipocytes are located within the Space of Disse, and may project into the recess between 
adjacent hepatocytes (20;21).  When visualized in 3 dimensions HSC can be considered to 
encircle the sinusoid with cellular processes (22).  The role of the HSC as a source of matrix 
components and a regulator of matrix turnover will be considered below.  There is 
accumulating evidence that the normal basement membrane-like matrix within the space of 
Disse is important in determining the phenotype of these sinusoidal cells (23-26).  The portal 
tracts consist of a stroma rich in type I and III collagen that is in continuation with the liver   24
capsule (27).  The vascular bundles contain lymphatics and nerves and are the only site of 
fibroblasts in the normal liver (cf lipocyte activation below) (28). 
 
1.4 The extracellular matrix of normal and diseased liver 
 
The extracellular matrix (ECM) is the insoluble substance of the mesenchyme and basement 
membrane matrices.  ECM is tissue specific and is important in tissue structure, repair and 
wound healing.  The ECM has traditionally been viewed as an inert tissue scaffolding 
providing structural support for tissue but recently this view has been challenged by the 
demonstration of complex cell matrix interactions which will be discussed below.  On the 
basis of this evidence ECM is now considered to be a dynamic modulator of tissue phenotype 
and function in addition to its structural role.  During the process of wound repair the 
composition of ECM becomes altered to fulfill repair needs.  In certain situations matrix 
synthesis is accelerated leading to accumulation of matrix with associated changes in relative 
composition.  In the liver this results from chronic injury in response to diverse aetiologies 
such as infection (hepatitis B and C, human immunodeficiency coinfection with hepatitis C 
etc) and toxins (eg alcohol) etc.  Liver fibrosis can be viewed as the final common pathway of 
most chronic liver disease.  The accumulation of matrix leads to structural changes and to 
changes in cell matrix interactions giving rise to the disease picture so familiar to clinicians.  
The changes of ECM seen in liver injury and fibrosis will be described. Basic changes are 
depicted in Figure 1.2   25
Figure 1.2 normal and fibrotic liver: how the distribution of collagen changes in fibrosis 
 
 
 
Figure 1.2 Comparisons between normal and fibrotic liver demonstrate differential changes in collagen 
especially collagens types I, III and V. (This Powerpoint slide was donated by Dr David Smart). 
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In this section components of the liver ECM (collagens, glycoproteins and proteoglycans) will 
be described. 
 
1.4.1 Collagens are a group of proteins that are widely distributed through the body 
representing about one third of the total protein (29).  In the normal liver collagens account 
for 5-10% of the total protein, however this proportion may increase to as much as 50% in 
advanced fibrosis/cirrhosis.  A total of 14 collagens have been described to date, of these 
collagens I, III, IV, V and VI have been identified in the liver (29).  Structurally collagens are 
composed of a triplet of similar or identified polypeptide subunits.  These polypeptides are 
folded into a left handed triple helix, permitted by the presence of the repetitive amino acid 
sequence (Gly-X-Y)n where one third of the X and Y positions are hydroxyproline and 
proline respectively (30;31).  This structure allows helix formation by virtue of the 
comparatively small hydrogen side chains of glycine which permits folding.  The triple helix 
is subjected to post translational modifications before secretion.  Classification of the collagen 
macromolecules is made according to their resulting configuration after assembly post 
secretion.  Banded collagen (fibrillar or interstitial) are so termed because they are arranged in 
quarter staggered overlap, side to side.  This alignment results in the presence of alternate 
light and dark bands on electron microscopy.  Types I, III and V are fibrillar collagens.  This 
structure confers a high strength to fibrillar collagens, which comprise the body’s major 
structural proteins.  The predominant collagens in both normal and fibrotic liver are types I 
and III (32;33), however there are changes in both the amount and relative composition such 
that type I collagen accounts for over 70% of total liver collagen which is increased at least 
six fold in fibrotic liver compared to normal (29;32;33).  This reflects the change in collagen 
expression which occurs as HSC becomes activated.  The biosynthesis of types I and III 
collagens are similar and relatively well understood, less is known for type V. 
 
1.4.2 Type I collagen is normally formed from two alpha-1 chains and a single alpha-2 chain.  
Following translation, the peptides are subjected to considerable post translational 
modification.  Within the endoplasmic reticulum lysine and proline residues are hydroxylated.  
Hydroxylases which mediate this are themselves up regulated in experimental fibrosis 
(34;35).  At this stage, hydroxy-lysine residues become glycosylated and inter-chain cross 
links are formed.  Collagens are secreted from an insoluble cell membrane (36) bundles and 
fibres are formed by the serial fusion of cell membrane compartments, which may arise from 
more than one cell (37). The length and alignment of collagens may result from the sequence   27
of terminal pro peptides and other non-helical domain cleavage and degradation (29;38;39).  
After assembly, further tensile strength is conferred on fibrils by the formation of cross links 
(29). 
 
1.4.3 Type V collagen has a broadly similar structure to types I and III.  It is not subjected to 
the same level of extracellular processing and retains a non-helical globular unit (29).  Type V 
collagen has a broadly similar structure to types I and III.  It is not subjected to the same level 
of extracellular processing and retains a non-helical globular unit (29).  The function of type 
V collagen may be as a nidus for fibril formation (29).  The presence of heterotrophic 
collagen fibrils containing types I and II have been demonstrated in the liver (40).  The 
expression of the gene for collagen is regulated by a variety of cytokines.  Transforming 
growth factor beta (TGFβ) up regulates mRNA expression (41-43), and stabilizes procollagen 
mRNA (44).  The cytokine has been demonstrated to be a key mediator in several fibrotic 
disorders and there is accumulating evidence of a central role in liver fibrosis.  Both 
acetaldehyde (45) and enhanced HSC activation increase expression of procollagen I.   
 
1.4.4 Collagen expression is down regulated by interferon-gamma (46) and dexamethasone 
(47;48).  Two other important collagens are present in normal liver: types IV and VI both of 
which are non-fibril forming.  They represent 1 and 0.1% of total liver collagen respectively.  
Collagen IV and VI are more flexible than I and III by virtue of their relatively large non-
helical domain and the interruptions of the triplet sequence through the length of the molecule 
(29).  Type IV collagen is composed of three polypeptide chains with a globular N-terminal 
domain and carboxy terminals which are not cleared during processing.  These moieties are 
important in the assembly and structure of the basement membrane matrix, for which type IV 
collagen forms the major structural protein (29).  Type IV collagen will form a three 
dimensional tetrameric framework, via disulphide bonding between adjacent carboxy terminal 
and hydrophobic grouping of the globular amino termini (49-51).  Lateral associations of type 
IV collagen have been demonstrated in human and murine tissues.  Onto this framework, 
other basement membrane components become laid down.  Indeed, type IV collagen 
incorporates structural features which mediate interactions with other matrix components 
(proteoglycans and glycoproteins) and cell receptors (52).  Type IV collagen is found in small 
quantities in the space of Disse.  Although fibrosis is associated with an increase in the rate of 
deposition of type IV collagen, it remains a minor component, in comparison to the fibrillar 
collagens.  Type VI collagen is not a component of basement membrane.  Like type IV it has   28
large non-helical domains, and has a dumb bell shape of two globular regions joined by a 
short helical domain (29).  It has repetitive A domains of von Willebrand factor which 
mediate homotypic assembly via lateral alignment into macromolecule chains, and 
heterotypic associations with fibrillar collagens (53).  When aggregated it is stabilized by the 
formation of disulphide bonds.  In addition, the presence of the Arg-Gly-Asp sequence in the 
helical region suggests that this component may have a significant role in integrin mediated 
cell matrix interaction (54).  As type VI collagen is found in greatest abundance in close 
proximity to blood vessels it may have a role in anchoring the vessel to its surrounding 
matrix.  Type IV collagen is found in the space of Disse in health and its deposition is 
upregulated in fibrosis (29). 
 
Glycoproteins are a heterogeneous group of molecules which comprise, by weight, the major 
substance of the ECM, in both health and fibrosis.  They are complex molecules which sub 
serves as cytokine binding reservoirs and cell receptor ligands in addition to fulfilling 
structural functions.  They comprise laminin, entactin, fibronectin, tenascin, undulin and 
elastin. 
 
Laminin is composed of three polypeptide chains that inter link to form an asymmetric cross 
structure (29;54).  There is some heterogeneity of laminin as a result in variation of chain 
length and content, with specific tissue isoforms (52;55).  Laminin has, together with other 
matrix components, biological activity.  In the case of specific cell receptor sequences the 
interaction may be important in the maintenance of differentiated parenchymal cell function.  
Eight cell adhesive recognition sequences that bind to cellular receptors, including 
hepatocytes (56) have been described in laminin (54).  Binding sites also exist for other 
matrix components such as type IV collagen, entactin and heparan sulphate proteoglycan (29).  
Laminin also contains 25 endothelial cell growth factor (EGF) like repeats (57) which may 
become biologically active during degradation. 
 
Entactin, also known as nidogen, is a ubiquitous component of basement membranes.  It is a 
150 kilo Dalton (kDa) glycoprotein which is dumb-bell shaped (29) and binds, non-covalently 
to lamina to type IV collagen (29).  Entactin is expressed by activated HSCs (53). 
Fibronectins are V shaped proteins, formed of two 220kDa subunits (56).  They exist in two 
major forms in the body, the plasma and basement membrane types, derived from alternative 
splicing of the single fibronectin gene (58).  Fibronectins bind, via specific domains, to   29
fibrillar collagens, heparin, fibrinogen, syndecan and integrin tenascin receptors (29).  
Fibronectins are important in wound healing and clot organization (29).  Their deposition is 
increased in liver injury with a concomitant change towards increased proportion of cellular 
fibronectin (29).  Fibronectin may also be important in cell matrix interactions that maintain a 
differential cell phenotype. 
 
Tenascins are six armed proteins (54).  Within each arm there are EGF-like and fibronectin-
like domains (54;59).  Tenascin appear to be important in interfering with cell fibronectin 
interactions.  They are expressed transiently during certain stages of development and injury 
(54).  In addition certain isoforms, generated by alternative splicing, are expressed in specific 
tissues or developmental stages (54;60).  By interfering with cell adhesion to fibronectin, 
tenascin like thrombospondin and osteonectin are part of a group of glycoproteins which 
modulate cell-matrix interactions to enhance cellular motility (54).  Tenascin has been 
localized to the margins of healing wounds, and the space of Disse during hepatic fibrosis 
(61). 
 
Undulin shares some sequence homology with tenascin, and is present in matrix when 
tenascin is absent (62).  It is found in association with type I collagen fibres, and binds to 
collagens I, III, V and VI (29), in addition to cell membrane receptors.  For those reasons it is 
believed that undulin is important in the maintenance of collagen (and matrix) structure (29).  
The distribution of undulin within the liver is in association with collagen bundles in the 
portal tract, and single collagen filaments in the space of Disse. 
 
Whilst elastin is a prominent component of cirrhotic matrix (63) its role in the liver matrix is 
undetermined.  30
1.5 Identification of Hepatic Stellate Cells (HSCs) as the primary source of Extracellular 
Matrix 
 
Hepatic Stellate Cells (HSCs) were first recognized in 1876 by the anatomist von Kupffer.  
He described star shaped cells identified using a gold chloride staining procedure (64).  They 
were described as phagocytic and their cytoplasmic droplets were thought to be due to fatty 
degeneration (65).  Ito described in 1952 a population of cells distinct from liver macrophage 
cells (Kupffer cells); these cells were termed Ito cells (66).  In 1980 Wake noted that the cells 
would convert glycogen to lipid rather than acquire lipid by phagocytosis – he then termed 
them “fat storing cells” (65). (Figure 1.3) 
 
Figure 1.3The Hepatic Sinusoids in Cross section and changes in the sinusoid during 
fibrotic liver injury 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: The changes that occur in the subepithelial space of Disse include changes in cellular and matrix 
components. HSC activation to a fibrogenic phenotype leads to accumulation of  scar tissue (predominantly 
fibrillar collagens). This change in extracellular matrix contributes to alterations in other cell types including 
hepatocyte necrosis, the loss of hepatocyte microvilli and endothelial fenestrae. Overall the change from a low 
density to higher density matrix in the space of Disse and the loss of hepatocyte villi and endothelial fenestrae 
compromise  molecular  exchange  between  hepatocytes  and  sinusoidal  lumen  causing  deterioration  in  liver 
functions in toto. Figure taken from (67). 
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Figure 1.4 Hepatic stellate cell activation 
 
A 
 
B 
Figure 1.4 Hepatic stellate cell activation. (A) As a result of liver injury, quiescent vitamin-A-rich hepatic 
stellate  cells  undergo  ‘activation’  towards  proliferative,  fibrogenic  and  contractile  myofibroblasts.  During 
resolution of liver injury, hepatic stellate cells might revert to a quiescent phenotype and/or be selectively cleared 
by apoptosis. (B) The major phenotypic changes seen after activation of hepatic stellate cells are illustrated, 
along with the key mediators involved (both up regulators and down regulators). CCN2, cysteine-rich connective 
tissue growth factor; CTGF, connective tissue growth factor; EC, endothelial cell; ECE, endothelin converting 
enzyme; ET1, endothelin-1; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; IGF, insulin-like 
growth  factor;  MCP-1,  monocyte  chemotactic  peptide;  MMP-2,  matrix  metalloproteinase-2;  MT1-MMP, 
membrane type 1 matrix metalloproteinase; NKT cells, natural killer T cells; PDGF, platelet-derived growth 
factor; VEGF, vascular endothelial cell growth factor; TGFα, transforming growth factor α; TGFβ, transforming 
growth factor β; TIMP, tissue inhibitor of metalloproteinase. 
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1.6 Cellular sources of Extracellular Matrix (ECM) 
 
HSC comprise up to 15% of the total number of resident liver cells (5;67).  In normal liver 
they are the principal storage site for retinoids (68;69).  Stellate cells constitute a 
heterogenous group of cells that are functionally and anatomically similar but different in 
their expression of cytoskeletal filaments, their retinoid context, and their potential for ECM 
production (70;71).  Studies using electron microscopy, immunohistochemistry, in situ 
hybridization and cell isolation techniques have established the stellate cells as the key 
effector cell in hepatic fibrogenesis.  Figure 1.4 above summarizes some of the features of 
stellate cell activation. With progressive fibrosis HSCs proliferate and transform into a cell 
with a prominent rough endoplasmic reticulum.  This facility to increase protein production 
prompted the suggestion that HSCs might be the source of the concurrently observed increase 
in collagen production seen in fibrosis with repeated liver injury (72;73).  Stellate cells 
become spindle shaped with microfilament bundles with a typical appearance of alpha smooth 
muscle actin (αSMA) taking on a myofibroblast appearance, a phenotype associated in other 
cells with matrix production (64;74;75).  The synthesis of collagen was originally thought to 
be from the liver parenchymal cells (hepatocytes) but in 1989 in situ hybridization studies on 
an experimental model of liver fibrosis confirmed that type I, type III and type IV procollagen 
expression takes place predominantly in non parenchymal cells (76).  With 
immunocytochemistry the intracellular collagens fibronectin and laminin were located in 
HSCs (77). 
 
Subsequently different liver cells types were examined for their respective potential in matrix 
production (78) lending further evidence that HSC are the cells responsible for matrix 
production in the liver. Recent studies have underscored the heterogeneity of mesenchymal 
populations in liver ranging from classic stellate cells to portal fibroblasts (79), with the 
variable expression of neural (80), angiogenic (81), contractile (75), and even bone marrow 
derived markers (82). Moreover, experimental genetic ‘marking’ of stellate cells by 
expressing fluorescent proteins downstream of either fibrogenic or contractile gene 
promoters, illustrates the plasticity of fibrogenic cell populations in vivo (83). In view of this 
capacity for ‘trans differentiation’ between different mesenchymal cell lineages and possibly 
even epithelial cells (84), the key issue is not necessarily where fibrogenic cells arise from, 
but rather whether they express target molecules such as receptors or cytokines in sufficient 
concentrations in vivo to merit their targeting by diagnostic agents or anti-fibrotic compounds.   33
 
Freshly isolated HSCs contain type III and IV collagen and laminin transcripts but no type I 
collagen or fibronectin (24;85).  In contrast cultured HSCs contain high levels of type I, III 
and IV collagen and fibronectin transcripts (85).  The mRNA transcripts of collagen purified 
from parenchymal cells almost certainly result from HSC contamination (86).  Endothelial 
cells contain small amounts of type IV collagen mRNA; Kupffer cells do not contain any of 
these transcripts (78). 
 
HSCs are the principal source of (non collagenous) glycosaminoglycans and proteoglycans in 
normal and fibrotic liver (87).  Variations in synthesis of these proteins are observed between 
normal and fibrotic liver, and between fresh and cultured HSCs (87). 
 
1.7 Cellular features of Quiescent HSCs 
 
The phenotypic features of the hepatic stellate cell differ according to the level of activation.  
In normal liver HSCs make up 5-15% of the total liver cell population (88;89).  HSCs lie in 
the space of Disse between the specialized hepatic sinusoidal endothelium and the palisades 
of hepatocytes (90).  Recent work on their embryological origin suggests that they are neural 
crest derived because they express glial fibrillary acidic protein, nestin and synaptophysin 
(91).  A neural crest origin is further supported by studies in rat neural crest stem cells which 
differentiate into myofibroblasts that express smooth muscle alpha actin, a marker of 
activated stellate cells (92). 
 
These observations raise the possibility of using neural crest – specific promoters to drive 
transgene expression selectively in stellate cells in vivo and the prospect of reconstituting 
stellate cells from the neural crest precursor as part of efforts to repopulate liver. 
 
The perivascular orientation and long cytoplasmic processes of stellate cells facilitate their 
interactions with neighbouring cell types.  These processes are adjacent to hepatic nerves, 
which can respond to alpha-adrenergic stimulation with an influx of cytosolic calcium and 
release of osmolytes (93). 
 
Ultrastructurally, HSCs are characterized by the presence of cytoplasmic fat droplets, well 
developed rough endoplasmic reticulum, a Golgi complex, multi-vesicular bodies, one or two   34
centrioles and few rather small lysosomes.  These lysosomes are sometimes associated with 
fat droplets.  Fat storing cells are the main storage sites for retinal esters (vitamin A) in the 
mammalian body (94). 
 
The size and quantity of lipid droplets vary between individual HSCs (87;95).  As well as 
retinol esters, the lipid droplets contain smaller quantities of triglycerides, cholesterol esters, 
cholesterol and phospholipid (95). 
 
1.8 Cellular features of HSC activation 
 
Following liver injury of any aetiology HSCs undergo a process known as “activation”; which 
is a term denoting the transition of quiescent cells into proliferative , fibrogenic and 
contractile myofibroblasts (96-98).  Sources of mediators causing injury may be circulating 
(i.e. endocrine), transferred between cells (paracrine) or act within the same cell (i.e. 
autocrine). In particular, oxidant-stress-mediated necrosis leading to stellate cell activation 
may underlie various liver diseases, including hemochromatosis, alcoholic liver disease, viral 
hepatitis and non-alcoholic steatohepatitis (NASH) (99-101). See Table 1.1   35
Table 1.1 The characteristics of quiescent and activated HSCs 
 
   
Quiescent HSCs (qHSCs) in 
culture 
 
 
Activated HSCs (aHSCs) in 
culture 
 
Morphology 
 
 
Rounded 
 
Star-shaped / spread out 
 
 
Proliferation 
 
 
Low 
 
High 
 
 
Retinoid storage 
 
High content 
 
Reduced 
 
 
Matrix synthesis 
 
Low levels 
 
Enhanced production due to 
increased  
- collagen-I, III and IV 
mRNA and  
- increased protein 
synthesizing capacity 
 
 
Collagen secreted 
 
Collagen III > I 
 
Collagen I > III > IV 
 
 
Activation Markers 
 
None 
 
↑alpha Smooth Muscle Actin 
(αSMA) 
 
↑Platelet Derived Growth 
Factor (PDGF) receptor and 
cytokine expression 
 
 
↑ Transforming growth 
factor-beta (TGF-β1) 
 
 
Table 1.1 HSCs are compared between the quiescent and activated state. 
Adapted from (10;71;102).   36
HSCs accumulate in areas of liver necrosis and their numbers appear to correlate with the 
stage of necroinflammation (103;104).  Ultrastructurally, activated HSCs show increased 
cytoplasmic volume surrounded by abundant collagen bundles and contain characteristic 
bundles of microfilaments with focal condensations, hypertrophied rough endoplasmic 
reticulum suggesting increased protein synthesis, and a prominent Golgi apparatus (105).  The 
intracytoplasmic lipid droplets usually decrease with HSC activation although 
intracytoplasmic lipid accumulation is seen in HSC activation associated with 
hypervitaminosis A, extrahepatic cholestasis and early alcoholic liver injury (106;107). 
 
1.8.1 Mechanism of HSC activation 
 
Studies of the role of the hepatic stellate cell in liver fibrogenesis have been enhanced by the 
demonstration that the process of activation can be modeled by plating primary HSC cultures 
onto uncoated tissue culture plastic, glass or collagen (24;108-110).  The ultrastructural 
changes and associated increased collagen synthetic capabilities are similar to the changes 
observed in vivo, leading to the suggestion that primary cultures of HSCs are a valuable tool 
for studying their role in chronic liver disease (111).  The process of stellate cell activation 
occurs in a reproducible sequence and can be placed into a discrete biologic context.  Early 
events have been termed initiation (also referred to as the “pre-inflammatory” stage) (67).  
Initiation includes the rapid changes in gene expression and phenotype that render the cells 
responsive to cytokines and other local stimuli.  Initiation is associated with transcriptional 
events and induction of immediate early genes.  It results from paracrine stimulation due to 
rapid, disruptive effects of liver injury on the homeostasis of neighbouring cells and from 
early changes in ECM composition (67).  Once initiation has been set in process by paracrine 
stimulation, transcriptional events begin a cascade of cellular responses.  HSC activation is 
initiated from stimuli originating from injured hepatocytes, neighbouring endothelial cells and 
Kupffer cells in addition to rapid, subtle changes in ECM composition (112;113). 
Perpetuation incorporates those cellular events that amplify the activated phenotype through 
enhanced cytokine expression and responsiveness; this component of activation results from 
autocrine and paracrine stimulation, as well as from accelerated ECM remodeling. Some of 
these changes are summarized in Figure 1.5.   37
Figure 1.5 Phenotypic features of hepatic stellate cell activation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Phenotypic features of hepatic stellate cell activation during liver injury and resolution. During liver 
injury quiescent HSC undergo a phenotypic transformation termed ‘activation’ which encompasses the change to 
a myofibroblast-like phenotype. Reproduced from (67). 
 
 
Hepatocytes and Kupffer cells are a potent source of reactive oxygen intermediates (ROI) 
(114).  These compounds exert paracrine stimulation of stellate cells.  Moreover, their activity 
is amplified in vivo by depletion of anti oxidants as typically occurs in diseased liver.  When 
conditioned medium from hepatocytes undergoing oxidative stress is added to cultured 
stellate cells their proliferation and collagen synthesis is increased (115).  Over expression in 
stellate cells of the enzyme cytochrome P4502E1, which generates ROI, stimulates collagen I 
gene expression; this effect is attenuated by antioxidants (116).  Endothelial cells also play an 
important role in early cell activation.  Injury to sinusoidal endothelial cells stimulates 
production of a splice variant of cellular fibronectin (EIIIA isoform) which has an activating 
effect on stellate cells (117).  Endothelial cells also convert latent transforming growth factor 
beta-1 (TGFβ1) to the active, fibrogenic form through the activation of plasmin (118).  Using 
molecular approaches a number of differentially up-regulated genes have been identified 
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Non 
activated 
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during the process of activation (119-121).  These consist of a transcription factor (119), and 
adhesion molecule (ICAM-1) (120) and, interestingly, the prion protein (121).  In an effort to 
identify regulatory genes during early stellate cell activation has resulted in the cloning of a 
Krupel-like factor (KLF) zinc finger gene (KLF6).  KLF6 mRNA is rapidly induced in liver 
injury in vivo and in culture (119) and can trans-activate genes regulating ECM accumulation 
(121).  At least two other KLF proteins also regulate stellate cell activation.  Sp1, the first 
member of the KLF family, binds more actively to its consensus motif in activated versus 
quiescent stellate cells (122;123). 
 
Basic transcription element binding protein 1 (BTEB1) mediates the increase in collagen gene 
expression, which occurs in response to UV radiation or expression of the transcription factor 
c-Jun (124). 
 
 
1.8.2 Perpetuation: the Paracrine and autocrine driven cytokine activity and ECM 
remodeling that sustain the activated phenotype 
 
Perpetuation of stellate cell activation involves key phenotypic response mediated by 
increased cytokine effects and remodeling of ECM (118).  Increased cytokine responses 
through multiple mechanisms occur (118) and in particular increased expression of cell 
membrane receptors and enhanced signaling are important (125).  Especially important are 
receptor tyrosine kinases (RTKs) which mediate many of the stellate cells responses to 
cytokines, and which are up-regulated during liver injury (126). 
 
Continued ECM remodeling during this phase underlies virtually all cellular responses 
characterizing progressive liver injury. The low density subendothelial matrix is progressively 
replaced by one rich in fibril-forming collagen.  This fundamental shift in ECM composition 
affects the behaviour of hepatocytes, sinusoidal endothelium and stellate cells. 
 
Fibril forming ECM also accelerates stellate cell activation.  These effects are mediated not 
only through interactions with integrins, the classic ECM receptors, but also binding to at 
least one RTK (receptor tyrosine kinase).  Several integrins and their downstream effectors 
have been identified in stellate cells, including α1β1, α2β1, α5β1 and α6β4  (125).  Recently, a 
subfamily of receptor tyrosine kinases, discoidin domain receptors (DDRs) has been   39
characterized, which unlike other RTKs signal in response to fibrillar collagens rather than 
growth factors (127;128).  With the identification of discoidin domain receptor –2 (DDR-2) 
mRNA in stellate cells (126), a mode of matrix cell interaction in liver has emerged that may 
explain why fibril forming matrix (especially collagen type 1) provokes activation of stellate 
cells during sinusoidal fibrosis.  Thus, as the subendothelial basement membrane is replaced 
by fibrillar collagen stellate cell activation may be perpetuated via binding of collagen to the 
DDR-2 receptors (126;127). Collagen breakdown products produced by the action of MMPs 
may also involve HSC proliferation by stimulation of α5β3 integrin on the cell (129). 
 
HSC proliferation is stimulated by a number of mitogens, which usually signal through 
receptor tyrosine kinases. Amplification of HSC proliferation is a consequence of the 
increased secretion of mitogens in combination with the induction of their cognate HSC 
tyrosine kinase receptors.  Mitogens that stimulate HSC activation include platelet derived 
growth factor (PDGF) (130), thrombin (131), endothelin-1 (132), epidermal growth factor and 
TGFα (133), IL-1α (134) and recently VEGF, whose effect is synergized in vitro by the 
addition of fibroblast growth factors (126).  Lipid peroxidation products consequent upon 
cellular oxidative stress have also been shown to induce HSC activation (135).  HSC 
proliferation is inhibited by TGFβ (133) and interferon gamma (IFNγ) (136;137).  The 
mitogenic effect of PDGF can be inhibited by retinoids (138). 
 
Chemotaxis is another HSC activity that with proliferation, contributes to the HSC 
accumulation at the site of the liver injury.  Chemotaxis is thought to be mediated primarily 
by PDGFα (139) and MCP-1 (140).  HSC fibrogenesis results in net ECM accumulation.  The 
increased fibrillar matrix synthesis is primarily and most potently mediated by TGFβ (141).  
The activity of TGFβ is enhanced by increased HSC production of TGFβ resulting in 
autocrine stimulation (142), increased activation from its latent to active form (143;144) and 
by increased TGFβ receptor expression on HSCs (145). 
 
Other fibrogenic mitogens include oncostatin M (146), retinoids (144), IL-1β, IL-4 (147) and 
acetaldehyde (148).  In contrast, TNFα (149), IFNγ (136;147) IL-10 (150) and IL-1α (134) 
inhibit collagen gene expression in HSCs.  Increased collagen production by HSCs may also 
result from post transcriptional events including increased collagen mRNA stabilization 
(151).   40
1.8.3 mRNA stability 
 
One aspect of regulation of protein synthesis that is overlooked is the rate of translation. 
There are several independent metabolic steps that determine the level of a protein in 
eukaryotic cells. The steady state level of mRNA encoding the specific proteins is determined 
by the rate of transcription, percentage of transcripts that are ultimately processed and 
transported to the cytoplasm, and the half life of the mRNA in cytoplasm (152). 
 
1.8.3.1 Regulation of mRNA degradation 
 
Despite the fact that most mRNAs decay via a common pathway (153) there is a wide range 
of half lives for different mRNAs, ranging from minutes to hours. The stability of a particular 
mRNA is determined by cis elements, which may be present in the 5` untranslated region 
(UTR), the coding region or in the 3` UTR (154). Regulation of the half life of mRNA is 
probably accomplished by alteration of factors that interact with specific sequences in the 
mRNA. Major strategies for degrading mRNA appear to be conserved from yeast to humans. 
The most common decay pathway occurs as a result of shortening of the poly(A) tail.  
 
Efficient translation of a mRNA requires that it contains both a 5` 7 methyl guanine (7mG) 
cap and a poly(A) tail, both of which are critical for efficient translation initiation (155;156). 
The poly(A) binding protein (PABP)-poly(A) is a complex found at the end of the 3` end of 
all mRNAs except histone mRNA (157;158). This results in a circular mRNA and may form 
part of the physiological translation initiation complex in mammalian cells. When the poly(A) 
tail reaches a critical minimal length, the PABP presumably disrupts the circular mRNA 
structure. The mRNA is then de capped and becomes accessible to exonucleases that can 
degrade the mRNA 5` to 3`. There are also enzymes that can degrade the mRNA 3` to 5`. 
 
The rate of the initial step is degradation of specific mRNAs; it can be modulated by cis and 
trans elements that specifically bind to regions in the mRNA and cause degradation of 
specific transcripts in response to certain stimuli. For example, AU-rich elements located in 
the 3`UTR of many mRNAs generally destabilize the mRNA by binding specific proteins 
(159;160). Since the normal location of an mRNA is on polyribosomes on which it is being 
actively translocated it is not surprising that the initial steps in mRNA decay occur while the 
mRNA is associated with polyribosomes.   41
 
As a result many mRNAs are stabilized by inhibitors of protein synthesis. Degradation of an 
mRNA requires several enzymatic processes: deadenylation, de capping, and exonuclease 
activity. Recent results have indicated that many of these activities may be contained in a 
single complex, termed the exosome or degradosome (155). 
 
Type I collagen mRNA stability appears to be the best studied in liver and HSC. (161). The 
transcriptional rate of collagen α1(I) gene was increased only threefold in activated HSC, 
demonstrating that most of the regulation leading to the 60-70 fold increased in collagen 
mRNA was post translational (151). The half life of the α1(I) mRNA was increased 16x fold 
in activated HSCs compared with quiescent cells (161). 
 
1.8.4 HSC and Matrix degradation 
 
HSCs play an important role in the regulation of matrix degradation, which then affects ECM 
homeostasis. Primarily SMA filaments mediate HSC contractility.  Molecular studies indicate 
that HSC activation and SMA activation are closely linked (162).  Transcription factors that 
regulate activation such as c-myb and NFK β, also bind to the SMA promoter, inducing SMA 
transcription (135).  The long HSC processes wrap around and contract the sinusoids, 
impeding blood flow.  It is possible that this decreased blood flow may have an impact on the 
dynamics of blood flow in the hepatic portal system and arguably may be a contributing 
factor to portal hypertension in patients who have cirrhosis of the liver. 
 
In normal liver HSC contraction can be initiated by neurotransmitters released from 
adrenergic nerve endings.  In contrast, chronic diseased liver has a depletion of intra-hepatic 
nerves and nerve endings (163;164).  Moreover, HSCs possess endothelin receptors which are 
up regulated with HSC activation.  Endothelin 1 (ET-1) is a key contractile stimulus toward 
stellate cells which in part is autocrine-derived (165).  Up-regulation of ET-1 production is 
accompanied by increased endothelin converting enzyme-1 which activates the latent ET-
1(166), in addition to its potent contractile effect, also regulates stellate cell proliferation 
(132;167).  Endothelin receptors can be stimulated via an autocrine or paracrine mechanism 
(168).  HSC relaxation is mediated by prostaglandin E2, iloprost, adrenomedullin and nitric 
oxide.  HSCs produce nitric oxide, which can inhibit contractility by an autocrine mechanism 
(169).   42
 
At least two G protein-coupled receptors mediate the effects of ET-1.  Unlike receptor 
tyrosine kinases which are generally induced during activation, ET receptor types A and B are 
expressed on both quiescent and activated stellate cells (165).  However, the relative 
prevalence of ETA and ETB receptors changes with the cellular activation and each mediates 
divergent responses (132). 
 
The proliferative effect of ET-1 in quiescent cells correlates with increased Ras/EAK activity, 
which is blocked with ETB agonists (132).  In contrast, the growth effect of ET-1 in activated 
cells is mediated by the ETB receptor (170) via a prostaglandin/cAMP pathway that leads to 
down regulation of ERK and c-Jun kinase (JNK) (170). 
 
Once activated, HSCs are capable of cytokine production resulting in autocrine stimulation as 
mentioned before.  Conditioned HSC medium stimulate the proliferation, transformation and 
matrix synthesis of primary HSC cultures (171).  
 
The cytokines produced by HSCs include TGFβ1 (172), PDGF (173), fibroblast growth factor 
and hepatocyte growth factor.  HSCs can also amplify inflammation through the release of 
neutrophil and monocyte chemoattractants such as colony stimulation factor and MLP-1 
(140).  Anti inflammatory cytokines produced by HSCs have also been identified.  IL-10 
down regulates inflammation by inhibiting macrophage production of TNFα (150;174). 
 
Other cells participate in and regulate the process of HSC activation, both in the initiation and 
perpetuation phases.  Kupffer cells are an important source of cytokines involved in paracrine 
HSC stimulation.  Kupffer cell infiltration occurs just prior to, and co-incident with, the 
appearance of activated HSCs (97;175).  Kupffer cell conditioned medium can stimulate HSC 
matrix synthesis, cell proliferation and release of retinoids (130;176).  Endothelial cells also 
participate in cytokine mediated HSC stimulation by their conversion of latent TGF beta to its 
active pro fibrogenic form through the activation of plasmin (144). 
 
Upon injury endothelial cells produce a splice variant of cellular fibronectin that is able to 
stimulate HSC activation (117).  Platelets are a potent source of paracrine HSC stimulation by 
their generation of PDGF, TGFβ and epithelial cell factor L1 (177).  Lipid peroxides, 
produced by hepatocytes, also stimulate HSC activation (178).  This injurious effect is   43
compounded in cirrhosis, as the levels of antioxidants are depleted (179) and chronic hepatitis 
C virus (HCV) infection (180) has been reported to increase lipid peroxide production by 
hepatocytes.  Potentially, this initiates HSC activation and results in liver fibrosis.  Ethanol 
induced hepatocyte lipid peroxidation also stimulates collagen production (181).  Exposure of 
HSCs in culture to conditioned medium from hepatocytes undergoing oxidative stress 
increases HSC production and collagen production (115).  A 60 kDa cytosolic protein has 
been identified and partially characterized from parenchymal cell conditioned medium that 
stimulates HSC proliferation (182). 
 
Inflammatory cells particularly T - lymphocytes and natural killer cells secrete IFN gamma 
which inhibits HSC proliferation and collagen synthesis (136;137;147;183). 
 
Interleukin 10 (IL-10) has recently been identified as an anti-fibrogenic cytokine, primarily 
produced by T-lymphocytes (150;174;184).  Liver fibrosis is more severe in the IL-10 
deficient mouse (174).  In addition to its direct anti fibrogenic effect in HSCs, IL-10 inhibits 
Kupffer cell function, which may have an indirect anti-fibrogenic effect (185). 
 
1.8.5 Phenotypic characterization of quiescent and activated HSCs 
 
HSCs are not readily recognized in routine haematoxylin and eosin histological sections. 
 
Quiescent rat HSCs can be recognized by toluidine blue, basic fuchsin and oil-red-o staining, 
which allows detection of the characteristic lipid droplets (88;186).  The lipid droplets can 
also be detected by their unique autofluorescent properties, as the vitamin A has a 
characteristic rapidly fading blue green fluorescence at 328nm (187).  Staining for vitamin A 
directly with gold chloride has been demonstrated but the results are occasionally inconsistent 
(188).  A small proportion of HSCs have no or little lipid (95;189). 
 
HSCs can also be identified immunohistochemically using antibodies to cytoskeletal proteins.  
The majority of rat HSCs are desmin positive (190).  HSCs are vimentin positive but so are 
Kupffer and endothelial cells, thus it is not useful for phenotypic identifications (141).  Rat 
HSCs in normal liver contain an intermediate filament, glial fibrillary acid protein (GFAP) 
(191;192).  GFAP +ve cells are seen fairly evenly in the liver lobule.   44
Activated rat HSC can be identified by the expression of α-SMA (193).  In chronic liver 
injury, GFAP expression diminishes, and is mainly detected at the margins of the fibrotic 
septae, less so inside the septa.  GFAP expression also rapidly diminishes when primary 
HSCs are activated on tissue culture plastic (192).  Recently, nestin has been identified as a 
marker of rat HSCs.  Whilst nestin is not seen in normal liver parenchyma (91), nestin 
positive HSCs are observed in the vicinity of and inside the fibrous septa in a small proportion 
of the α-SMA positive and desmin positive HSCs, after prolonged carbon tetrachloride 
induced liver injury (6 weeks) (91).  In primary culture of freshly isolated HSCs no 
expression of nestin was detected (91) in contrast to activation in tissue culture plastic where 
transient expression is noted around day 13 (91).  The latter result differs from in vivo 
observations.   
 
The expression of nestin, vimentin and GFAP by HSCs prompts a comparison with astrocytes 
which also by the process of gliosis, have an important role in wound healing (194).  
Activated rat HSCs also express neural cell adhesion molecule (NCAM) (195).  In normal 
liver NCAM is expressed in nerve structures although in acute and chronic liver injury 
NCAM positive cells are present in the hepatic parenchyma. 
 
NCAM positive cells can be seen in the fibrous septa and occasional cells of the hepatic 
parenchyma (195).  HSC expression of NCAM, nestin and GFAP, normally expressed by 
cells of neural origin, lend weight to the possibility of HSCs being of neural crest origin, 
rather than mesenchymal origin. 
 
Quiescent human HSCs can also be identified by their vitamin A content as described for rat 
HSCs above.  Immunohistochemical phenotyping is less advanced in the human than the rat 
but despite this current research pinpoints certain differences in patterns of HSC expression of 
some antigens.  Desmin is not expressed by human HSCs (186).  In normal human liver 
GFAP expression is limited to a small sub-population of HSCs located at the edge of the 
portal tracts (105).  NCAM expression is seen in normal human liver, in a predominantly 
periportal locations (195).  Most researchers report that HSCs only rarely express α-SMA in 
normal human liver (196); however with different immunostaining technique, there are some 
reports that α-SMA is positive in the majority of HSCs in normal human liver (197;198).  α-
SMA is the primary marker of activation in human stellate cells (96;196).  Isolated HSCs are 
initially α-SMA negative, and early in culture develop α-SMA expression coincident with   45
activation (147).  α-SMA is also expressed by myofibroblasts of portal fibroblast origin (199-
201).  In cirrhotic human liver GFAP expression is up regulated in contrast to normal liver 
with positive cells lying at the edge of the regenerative nodules (105).  NCAM expression in 
human chronic liver disease has to date not been studied. 
 
1.9 ECM degradation: role in cirrhosis 
 
The matrix metalloproteinase are a family of zinc and calcium dependent endopeptidases, 
secreted by connective tissue cells that have activity against the major constituents of matrix 
and non fibrillar collagens.  The MMPs are considered to be the mediators of extracellular 
matrix turnover and there is increasing evidence of their expression by HSCs and Kupffer 
cells (69;202-205). 
 
The MMPs can be grouped according to their respective enzyme substrate.  The first are the 
collagenases which are central to the process of remodeling of fibrotic tissue as they cleave 
the native helix of fibrillar collagens I, II and III to render the collagen susceptible to 
degradation by other MMPs, to which they were previously resistant (206-208).  Three types 
of collagenases have been described, neutrophil collagenase and the recently described human 
collagenase-3 (209), and interstitial collagenase or MMP-1.  As noted earlier, there is a 
predominance of collagens Type I and III in fibrotic liver (96), and thus the expression of 
interstitial collagenase activity would be necessary to initiate collagen degradation.  It has 
previously been considered that only collagenases have activity against fibrillar collagens but 
a member of the third group Gelatinase A has also been shown to have degradative activity 
against collagen I (210). See Table 1.2   46
Table 1.2 The metalloproteinase family  
Adapted from (211) 
 
Name  MMP  Size 
(kDa) 
 
Source  Substrate Profile 
COLLAGENASES         
Interstitial  MMP-1  55  connective 
tissue cells 
(CT) 
 
collagens I, II, III, 
proteoglycans 
Neutrophil  MMP-8  75  neutrophils  collagens VIII, X 
 
Collagenase-3  MMP-13  65  tumour cells  collagens I,III 
 
 
GELATINASES 
       
Gelatinase A  MMP-2  72  stromal cells, 
HSC 
collagens I, III, IV, V, X, XI, 
elastin, gelatin, fibronectin 
 
Gelatinase B  MMP-9  95  KC, CT cells  gelatin, denatured collagens, 
collagen IV 
 
 
STROMELYSINS 
       
Stromelysin-1  MMP-3  57  CT, 
macrophages
endothelial 
cells 
 
proteoglycans, casein, 
collagens III, IV, V, 
gelatinase B 
Stromelysin-2  MMP-10  57  macrophages  as above but less activity 
 
Stromelysin-3  MMP-11  51  tumour 
stromal cells 
 
 
Matrilysin  MMP-7  28  monocytes  as MMP-3 and 
 elastin 
 
 
OTHERS 
       
Metalloelastase  MMP-12  57  macrophages  elastin, fibronectin 
 
Membrane-type1  MMP-14  63  tumour 
stromal cells 
gelatinase A, MMP-13, 
fibronectin, collagens I, III 
 
Membrane-types 2-4  MMP-15 
16, & 17 
  stromal cells  Functionally active gelatinase   47
The second group: the stromelysins have a large substrate profile with activity against 
collagens (II, IV, IX, X, XI), denatured collagens (gelatin), laminin and fibronectin.  There is 
evidence that they may activate procollagenase (212-214). 
 
The third MMP group are the gelatinases; gelatinase A has activity against gelatins, collagens 
IV, V, VII, X, and XI and elastin and may have interstitial collagenase activity (210;213-215). 
Gelatinase B shares the same substrate profile but has not been demonstrated to have 
interstitial collagenase activity. 
 
The fourth group and most recently described is the membrane type MMP, (MT-MMP) 
comprising three members.  Functionally these enzymes activate gelatinase (216-218). 
 
The extracellular activity of MMPs is regulated at various levels: 
1) By transcriptional activation at the level of the gene, 
2) Cleavage of the pro piece, and  
3) By extracellular inhibition by the specific tissue inhibitors of metalloproteinase or 
TIMPs, or by more general protease inhibitors such as alpha 2 macroglobulins. 
 
MMPs are regulated at the level of the gene by a series of growth factors and cytokines 
(212;219-221).  These include IL-1, TNF-α, PDGF and basic-FGF and EGF.  MMPs are 
differentially regulated, in addition, by certain cytokines.  TGFβ1 is a key player in liver 
fibrosis: it is expressed by Kupffer cells and HSC, during liver injury (142;145;176;222).  
Activated HSCs express TGFβ1 receptors and mannose 6 phosphate receptors, necessary for 
activation of the latent cytokine (223). 
 
Moreover HSCs express TGFβ mRNA and secrete the cytokine in an autocrine manner.  In 
response to TGFβ, fibroblasts down regulate interstitial collagenase expression while up 
regulating the expression of gelatinase A, TIMP-1, and collagen 1 (176;224-226).  TGFβ1 
occupies a central role in pre-fibrogenesis and is believed to be a pivotal cytokine in the 
fibrotic process.   
The second level of control lies in the conversion of the pro-MMP species (the form in which 
all MMPs are secreted) to the active moiety, by cleavage of the pro piece (206;225;227).  In 
vivo, this function is probably mediated by plasmin (213;215).  In addition, two further 
special mechanisms of activation exists, membrane type matrix metalloproteinase (MT-MMP)   48
functions to activate 72kDa gelatinase at the cell membrane (216) while active stromelysin 
will further cleave activated interstitial collagenase to result in a 5-8 fold enhancement in 
activity (220;228). 
 
1.10 The Tissue Inhibitors of Metalloproteinase (TIMP) 
 
The TIMPs function as an important regulatory brake in the activity of MMPs by stabilizing 
the proenzyme and by inhibition of the active species.  To date four TIMPs have been 
described, each is a separate gene product (229-233). 
 
As a family these inhibitors share common structural features.  There is 40% amino acid 
sequence homology between TIMP-1 and TIMP-2, and both have a three looped structure 
stabilized by six disulphide bonds, the result of 12 conserved cysteine residues, which are also 
present in TIMP-3 (212;229;231;233;234).  TIMP-1 and TIMP-2 are secreted into the 
intracellular milieu whilst TIMP-3 is detected in association with extracellular matrix (229). 
 
The binding of TIMPs to active MMPs is essentially irreversible under physiological 
conditions.  Binding occurs in a stoichiometric manner and the TIMPs reportedly block the 
active site of the metalloproteinases (214;235;236).  This binding is noncovalent however and 
in vitro, the enzyme inhibitor complexes can be separated with the TIMP retaining its 
inhibitory activity (237).  TIMP-1 and –2 inhibit the active forms of every metalloproteinase 
(229).  As with the four TIMPs, TIMP-3 has its own distinctive characteristics. A TIMP-3 
mutation leads to Sorsby’s fundus dystrophy, a retinal degenerative disease (238). Although 
other TIMPs are soluble upon secretion from the cell, TIMP-3 remains bound to the ECM 
(232;239) through sulphated preoteoglycans moietieis (240). Evidence exists that either very 
high TIMP-3 expression or the loss of TIMP-3 promote apoptosis (241;242). Studies using 
site directed mutagenesis and recombinant truncated TIMPs indicate that there are two 
separate functional domains to the molecule.  The N-terminal of the TIMP molecule is 
necessary for inhibitory activity against active MMPs; indeed truncated TIMPs with intact N-
terminal portions retain inhibitory activity.  The C-terminal domain in contrast is key to the 
interaction with prometalloproteinases (243-246).   
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Both TIMP-1 and TIMP-2 bind to specific progellatinase species therefore preventing their 
activation by stromelysin (206;247), in addition TIMP-1 will inhibit the formation of 
gelatinase B homo dimers and interstitial collagenases and gelatinase B homo dimers (206). 
 
Transcriptional regulation of the TIMPs is mediated by cytokines and growth factors, several 
of which mediate MMP expression and which have been implicated in HSC activation and 
synthetic functions.  These effectors may coordinate and differentially regulate both the 
MMPs and the TIMPs.  Thus, TGFβ1 will up regulate TIMP-1 and gelatinase A whilst down 
regulating TIMP-2, interstitial collagenase and stromelysin (225;248;249) and TNFα will co-
coordinately up regulate TIMP-1 and interstitial collagenase (250).  Studies mapping the gene 
promoters of TIMPs and MMPs show some common regulatory motifs that differ in 
individual TIMPs/MMPs in terms of their frequency and position in relation to the 
transcription start site.  For example, the murine TIMP-1 and interstitial collagenase (MMP-1 
promoters both have AP-1 and PEA-3 binding sites in different configurations (248;251).  An 
AP-1 site is noted in the promoters of stromelysin and gelatinase B but not in gelatinase A 
(MMP-2). 
 
The human TIMP-2 gene in chromosome 17 is flanked by 5’AP-1 and AP-2 consensus 
sequences and several SP-1 sites in association with a TATA box (252).  The AP-1 consensus 
site in the TIMP-2 promoter is further upstream from the transcription start site than that 
found in the TIMP-1 promoter and is not associated with a PEA-3 motif.  As in TIMP-1 and 
TIMP-2, the TIMP-3 promoter has multiple SP-1 sites which confer a high basal expression 
in growing cells (253).  The spatial distribution and differing binding sites in the promoters of 
TIMP-1 and TIMP-2 may explain in part the differential expression observed in response to 
cytokines such as TGFβ1 and TNFα.  The promoters also provide a mechanism whereby 
TIMPs can be co-regulated and independently regulated to inhibit MMP activity in a wide 
variety of physiological (eg growth and development) and pathological processes (eg 
arthritides and liver fibrosis).  From the discussion so far it can be proposed through relatively 
small changes in the ratio of TIMP: MMP concentrations, alterations in matrix degradation 
can be effected and regulated.   50
1.11 Evidence for change in matrix degradation during liver fibrosis 
 
Models of liver fibrosis have established that collagenase activity in liver tissue sections and 
homogenates decreases with the progression of experimental fibrosis: this would promote net 
collagen deposition.  This may reflect a decrease in matrix remodeling as fibrosis progresses.  
These models have included human and primate alcoholic liver injury and carbon 
tetrachloride mediated rat liver injury (254-258). See Figure 1.6 
 
 
Figure 1.6 Time course of MMP2 and TIMPs 1&2 with HSC culture 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 As HSC become progressively more activated their expression of MMP-2 increases. Levels of MMP-
2 in the supernatant are much higher than other MMPs and coincide with phase of HSC proliferation in culture. 
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As indicated above, a number of detailed studies have indicated the number of MMPs 
expressed by HSCs during the process of activation.  Both human and rat HSCs express 
gelatinase A and Rat HSCs express stromelysin (259-261). 
 
Gelatinase A expression increases with activation whilst Stromelysin is transiently expressed 
reaching a peak at day 3-4 in cultured HSCs.  In both cases the enzyme can be immuno 
localized to HSCs, and specific activity detected in the cell culture supernatants.  There is 
evidence for expression of both of these enzymes during acute liver injury in perisinusoidal 
cells (262;263). 
 
Interstitial collagenase has been localized to the cytoplasm of HSCs during activation by 
culture on plastic (264).  Subsequent molecular studies have failed to demonstrate interstitial 
collagenase mRNA expression in fully activated HSCs although it can be detected in freshly 
isolated cells (262).  However interstitial collagenase mRNA expression can be induced in 
activated HSCs by exposure to TNFα and IL-1 (265;266).  In addition, cultured HSCs have 
been demonstrated to release interstitial collagenase activity in response to polyunsaturated 
lecithin (267). 
 
There is therefore evidence from tissue culture studies to suggest that HSCs possess the 
ability to remodel matrix during the process of activation and specifically to mediate 
remodeling of interstitial collagens by expression of interstitial collagenase.  HSCs may not 
be the only cells with the ability to do this.  Kupffer cells have been shown to express 
gelatinase B (205), while sinusoidal endothelial cells may be a source of stromelysin (263). 
 
1.12 Evidence for TIMP expression in progressive liver fibrosis 
 
To address the concept that TIMP expression may promote fibrosis by reducing collagenase 
activity in progressive liver fibrosis, the gene expression of TIMP-1 and TIMP-2 and MMPs 
have been studied in HSC activation both in tissue culture and in vivo. When HSCs are 
cultured on tissue culture plastic there is an increase in the transcription of TIMP-1 mRNA in 
activated cells compared to quiescent (freshly isolated) cells (268).  TIMP-1 can be immuno-
localized to HSC and also detected extracellularly in HSC cell culture supernatants by ELISA.  
When HSC conditioned media is subjected to gelatin Sepharose chromatography TIMP-1 
bound to gelatinase A is separated: removal of TIMP-1 is associated with a twenty fold   52
increase in gelatinase activity.  Returning TIMP-1 to the media results in re-inhibition (268).  
Both TIMP-1 and TIMP-2 are found in HSC conditioned media and TIMP-2 mRNA is 
observed in northern analysis of activated HSC total RNA (268;269). 
 
HSC may not be the sole source of TIMPs in the liver: TIMP-1 and TIMP-2 are detected in 
HepG2 hepatoma cell lines (269-271).  In these studies TIMP-1 expression was found to 
increase in the presence of IL-6, an acute phase cytokine, suggesting that TIMP-1 may be 
released by hepatocytes in acute liver injury. 
 
In a model of fibrotic liver from murine schistosomiasis expression of interstitial collagenase, 
detected immunologically, remains relatively constant (272-274), whilst collagenase activity 
decreases emphasizing the importance of expression of collagenase inhibitors during 
fibrogenesis.  Further evidence for the important roles of TIMPs in fibrogenesis come from 
the analysis of serum in patients with hepatic inflammation and established cirrhosis reveals 
an increase in TIMP-1 levels by ELISA (275-277).  In addition when TIMP-1 and TIMP-2, 
interstitial collagenase and gelatinase A mRNA expression in fibrotic liver compared to 
normal were studied by ribonuclease protection analysis TIMP 1 and TIMP 2 transcripts were 
increased in fibrotic liver, as are gelatinase A transcripts (266;269).  In contrast interstitial 
collagenase transcripts were only marginally increased in primary sclerosing cholangitis and 
primary biliary cirrhosis (269).  TIMP-1 was also immuno localized to perisinusoidal cells in 
fibrotic liver in 75% of biopsies positive for interstitial collagenase suggesting that co-
expression of TIMP-1 with interstitial collagenases occurred (269). 
 
The development of fibrosis entails major alterations in both the quantity and quality of 
hepatic ECM.  Cirrhotic liver contains approximately six times more ECM overall than 
normal liver, and in the space of Disse collagen types III and V and fibronectin accumulate in 
early injury (14).  Culture studies have suggested that the neo matrix laid down in the space of 
Disse may itself contribute to the disease associated alterations in the phenotype of HSC, 
sinusoidal endothelial cells, and hepatocytes (25;278;279).  With progressive injury ECM 
spurs link the vascular structures, ultimately resulting in the architecturally abnormal nodules 
that characterize cirrhosis. 
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Complete recovery from liver fibrosis would involve remodeling and breakdown of these 
multiple ECM components, with degradation of the predominant component, collagen I, 
being particularly important for recovery of normal liver histology. 
 
1.13 Resolution of fibrosis 
 
In clinical circumstances, where there is a treatment available for the underlying liver disease, 
remodeling of the scar tissue can occur and a return towards architectural normality has been 
documented even in advanced fibrosis and cirrhosis.  This has been noted in treatment in 
autoimmune disease, venesection for patients with haemochromatosis and interferon therapy 
for patients with hepatitis B and C (280) (110;281-283). See figure 1.7a and 1.7b. 
 
 
 
Figure 1.7a Rat recovery model for resolution of fibrosis 
6 week CCl4 Rat Injury Model 
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Figure 1.7b Rat recovery model for resolution of fibrosis 
12 week CCl4 Rat Injury Model 
 
 
 
 
 
 
For ethical reasons, it is difficult to examine the molecular mechanisms of resolution of 
fibrosis in humans however recovery has been examined in a rat model which permit frequent 
sampling and control over the chronology and extent of the fibrotic lesion.  In a model of 
experimentally induced cholestasis the typical features of bile duct proliferation and periportal 
fibrosis developed three weeks after bile duct ligation with a notable increase in hepatic 
mRNA for collagens I and IV.  See Figure 1.7 However, following re-anastomosis of the bile 
duct to a jejunal loop there was resorption of periportal fibrosis and the liver ECM returned 
virtually to normal, except for a persistence of collagen IV in sinusoids.  In addition mRNAs 
for collagen I and IV became virtually undetectable (284). Figure 1.8 depicts some processes 
that promote recovery.   55
Figure 1.8 Mechanisms regulating HSC survival and apoptosis 
 
 
 
Figure 1.8 Summary of the processes mediating recovery from liver fibrosis and the mechanisms regulating 
HSC survival and Apoptosis (285) 
 
 
In another model incorporating the use of carbon tetrachloride to induce fibrosis recovery was 
again examined (286).  Liver fibrosis was noted after four weeks of intraperitoneal injection 
of carbon tetrachloride (CCL4) with extensive intervascular bridging with collagen fibres.  
The liver insult was then withdrawn and livers were examined at various times up to four 
weeks of recovery.  Histological analysis showed a noticeable dissolution of the collagenous 
fibrotic matrix and a return to liver structure to virtual normality.  The hepatic mRNA content 
of TIMP-1 and TIMP-2 and procollagen-I all diminished greatly in livers the first week of 
recovery which coincided with the most rapid phase of collagen degradation, as assessed by 
hydroxyproline content.  Interstitial collagenase activity increased in the liver homogenates 
during this time.  In addition there was prominent apoptosis of activated HSC during recovery 
particularly in the first three days coinciding again with the largest reduction in TIMP-1 and 
procollagen I mRNA.  Apoptosis therefore effectively removed the activated HSC, which 
were overproducing ECM and TIMPs.  The process of programmed cell death during wound 
healing and resolution of fibrosis has been seen in other cell systems.  Surplus mesangial 
cells, for example, from glomeruli during resolution of mesangial proliferative nephritis has   56
been noted to diminish through apoptosis (287).  Myofibroblasts are also removed by 
apoptosis during skin wound healing. 
 
1.14 Control of apoptosis in the liver 
 
HSCs activated in culture undergo spontaneous apoptosis in vitro, which can be greatly 
increased by serum deprivation and fas ligand (286;288;289).  Recent studies suggest that a 
further cytokine present in injured liver, nerve growth factor (NGF), induces HSC apoptosis 
in culture.  Mast cells, which become more abundant in fibrotic liver are a rich source of NGF 
(290).  The pro-apoptotic receptor fas and its ligand are also expressed by activated HSC 
(288).  It is possible that persistence of HSC in fibrotic liver might therefore require undefined 
survival factors to offset the effects of these apoptotic stimuli, and removal of survival factors 
when liver injury ceases would then allow relatively rapid removal of HSC. 
 
The role of cell-matrix interactions in regulating cell survival have most extensively been 
studied in epithelial cells in which deprivation of contact with the ECM is a potent pro-
apoptotic mechanism, a process that has been termed anoikis (291).  Preventing attachment of 
HSC to plastic induces apoptosis (292).  When HSCs are cultured on plastic or collagen I the 
cells are more susceptible to apoptosis induced by serum deprivation than HSC cultured on 
matrigel, a basement membrane – like matrix which reduces HSC proliferation and activation.  
Does ECM degradation therefore result in HSC apoptosis rather than HSC apoptosis facilitate 
ECM degradation? 
 
A second key question is: does liver fibrosis reach a point where it becomes irreversible? 
 
Recovery requires degradation of the existing fibrotic matrix, but this matrix itself may be 
modified to resist degradation as fibrosis progresses.  Newly secreted collagen fibrils can be 
cross- linked by both tissue transglutaminase and lysyl oxidase pathway: the activity of both 
pathways is increased during liver fibrogenesis (293-296).  Cross linking during maturation of 
collagen might reduce its susceptibility to collagenase (297).  Tissue transglutaminase can be 
released onto ECM from apoptotic hepatocytes which are found in increased numbers in 
fibrotic liver (298). 
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Recovery is unlikely if collagenolytic enzymes remain inactive following cessation of liver 
injury.  Interstitial collagenase mRNA expression (MMP-1 in humans, MMP-13 in rats) is 
similar in normal compared with cirrhotic livers, but has been demonstrated to increase in a 
recovery model possibly due to TIMP-1 activity decreasing, (262;269;286;286).  Previous 
studies suggest that collagenase activity becomes deficient during evolution of liver fibrosis in 
animal models and in humans (254;255;257;272;299), and studies described earlier suggest 
that this may be caused by TIMP over expression.  Continued inhibition of ECM degradation 
by TIMPs may block the ability to recover from fibrosis, even after the removal of the injury. 
 
As associated hepatic stellate cells are an important source of both ECM and TIMPs recovery 
from fibrosis might require either removal of the activated HSC population, as shown in rat 
models or possibly the phenotypical reversal of stellate cell activation, a process yet to be 
observed in vivo. 
 
1.15 Pancreas Fibrosis and Pancreatic Stellate Cells 
 
The pancreas can be functionally divided into 2 components: the endocrine gland which 
produces amongst other things insulin for glucose regulation and an exocrine gland for 
production of enzymes that aid digestion. The exocrine component consists of clusters of 
acinar cells (acini) that secrete the digestive enzymes. The enzymes drain from the acini via 
pancreatic ducts into the duodenum. A schematic is demonstrated in Figure 1.8 
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Figure 1.9 Schematic of the cellular components of the exocrine pancreas 
 
 
Figure 1.9 Schematic of the cellular components of the exocrine pancreas. The pancreas can be functionally 
divided into the exocrine and endocrine components. The exocrine component consists primarily of acini – 
clusters of acinar cells that feed into ductules. In normal pancreas quiescent PSCs are present in the periacinar 
space. These cells have long cytoplasmic processes that encircle the base of the acinus. Zymogen granules 
release their contents of digestive enzymes into the periacinar space into the pancreatic ductal system upon 
stimulation. 
 
Pancreatic Stellate Cell 
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Pancreatic Stellate Cells (PSCs) are one of several resident cells in the exocrine pancreas. 
Present in the periacinar space, they have long cytoplasmic processes that encircle the base of 
the acinus (figure 1.9). They can also be found in perivascular and periductal regions of the 
pancreas and serve as key participants in the pathobiology of the major disorders of the 
exocrine pancreas, including chronic pancreatitis and pancreatic cancer (300-303). In these 
disorders PSCs participate in disease pathogenesis after transforming from a quiescent state 
into an “activated” state (also known as a “myofibroblastic” state). There are obvious 
similarities (as well as some differences) to the Hepatic Stellate Cells as will be highlighted in 
the subsequent discussions. 
 
1.16 Clinical Setting of Pancreatic Disease 
 
70-80% of all cases of chronic pancreatitis result from alcohol abuse while the remainder of 
cases are associated with genetic disorders such as hereditary pancreatitis and cystic fibrosis 
and unknown cases for example idiopathic pancreatitis (304-307). Autoimmune pancreatitis 
has recently been described (308). 
 
The course of chronic pancreatitis results from repeated discrete episodes of acute pancreatitis 
which cause parenchymal injury and necrosis, with increasing amounts of fibrosis, chronic 
inflammation, and parenchymal cell loss with each successive episode. Parenchymal cells in 
both the exocrine pancreas and to a lesser extent the endocrine pancreas, are lost and this 
leads to irreversible exocrine (and eventually endocrine) insufficiency that leads to the disease 
known as chronic pancreatitis which can be characterised with abdominal pain, diarrhoea, 
weight loss, diabetes as a late presentation and ultimately an increased risk of pancreatic 
cancer (309;310). 
 
This series of events which has been noted from examining human pancreatic tissue during 
alcohol induced acute and chronic pancreatitis has been termed the “necrosis-fibrosis” 
sequence – and provides a framework for understanding chronic pancreatitis (311). 
 
Like chronic pancreatitis, adenocarcinoma of the pancreas has a remarkable fibrotic 
component (312-315). 
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1.17 Properties of PSCs 
 
Cells in the pancreas that were similar to HSCs in that they were fat-storing cells were first 
observed with the use of auto-fluorescence and electron microscopy in 1982 (300). There 
were identified when rats were given vitamin A, because cells with cytoplasmic fat droplets, 
such as HSCs, became auto fluorescent when vitamin A accumulates in these droplets (300). 
Two reports described the isolation and initial characterization of what have henceforth been 
termed pancreatic stellate cells or PSCs (302;303). PSCs can be distinguished from normal 
fibroblasts in that they express desmin and glial fibrillary acidic protein (GFAP) and have 
intracellular fat droplets (302;303). 
 
PSCs express intermediate filament proteins that usually characterise several cell types for 
example desmin which characterizes myocytes, GFAP - characteristic in astrocytes, vimentin 
seen in leukocytes/fibroblasts and endothelial cells and finally nestin seen in endothelial stem 
cells (316). This highlights that PSCs have a broad range of potential properties including 
contractility, the presence of cellular extensions to sense their environment, the potential to 
produce and alter ECM components and the potential to proliferate. The difference between 
quiescent and activated PSCs is denoted in Table 1.3. Activation of quiescent PSCs which 
occurs when primary PSCs are cultured and in the pancreas as a consequence of pancreatic 
injury is associated with several morphologic changes (302;303) including nuclear 
enlargement and enhanced prominence of the ER network (Table 1.3). Moreover, in situ 
hybridization and immunohistochemical studies indicated that activated PSCs express α-SMA 
and collagen type I, therefore highlighting these cells as a source of fibrosis in chronic 
pancreatitis and pancreatic adenocarcinoma (314;317;318). 
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Table 1.3 General features of quiescent versus activated PSCs 
 
  Quiescent  Activated 
Morphologic Features     
Vitamin A Auto fluorescence  + in fat droplets  Absent or remnant 
Endoplasmic reticulum  +  ++ 
Nucleus  Basal Size  Enlarged 
     
Molecular Markers     
Vimentin  ++  ++ 
Desmin  +  + 
GFAP  +  + 
Nestin  +  ++ 
α-SMA  -  + 
     
Properties     
ECM production  Limited  Prominent 
Cell proliferation  Limited  Increased 
Cell migration  Limited  Increased 
     
 
Table 1.3 In isolating PSCs there appears to be some heterogeneity of marker expression that may reflect 
multiple states of activation or differentiation, or different pools of fibrogenic cell type. All PSCs isolated from 
rat pancreas express vimentin, yet only 20-40% express desmin (319). 
 
Early efforts at PSC isolation produced cells that expressed α-SMA and collagen I, III and IV 
i.e. already  activated (320), however with techniques used in isolation protocols for HSC 
studies, (especially density gradient centrifugation) quiescent PSCs could be isolated 
(302;303). Quiescent PSCs express desmin, GFAP and intracellular fat droplets but not α-
SMA (See Table 1.3). 
 
Primary PSCs become activated during culture and attain a myofibroblast-like phenotype 
characterized by the disappearance of intracellular fat droplets, and the expression of α-SMA 
and ECM proteins (collagen I, III and fibronectin (302;303). PSCs also increase their 
expression of nestin upon activation (321). On the basis of these markers PSCs are estimated 
to contribute 4% of total pancreatic cells as opposed to HSCs which comprise around 8% of 
all hepatic cells (71;302). 
 
The early studies to date have examined the activation process of PSCs plated out on plastic. 
As in the study of HSCs a dilemma exists as to whether this activation model is representative 
of the in vivo environment (322). What is known is that PSCs cultured on plastic pass through   62
a series of temporal states of transformation (323). For example, rapidly proliferating PSCs in 
culture can either die by apoptosis or acquire a myofibroblastic differentiated state that is 
more resistant to apoptosis. 
 
Immortalized PSC cell lines from rats and humans has been developed (324-326), thus 
providing a tool for over expression and RNA interference studies, as well as a tool for high 
throughput screening for compounds that affect PSC activation. Immortalized cell lines have 
been generated by expression of either SV40 large T antigen alone in rat PSCs or SV40 large 
T antigen and human telomerase in human PSCs. The resultant immortalized cell line 
possesses a phenotype consistent with activated PSCs, which includes expression of α-SMA 
and ECM proteins. DNA micro arrays have been used to compare the gene expression profile 
of immortalized and primary culture rat PSCs. These revealed only a few overall differences 
including differences in the expression of genes encoding ECM related proteins, cytokines, 
integrins and intermediate filament proteins (325). Both rat and human immortalized cell lines 
responded to TGF-β1, PDGF, and the PPARγ ligand PGJ2 in a manner similar to that of their 
primary cell counterparts (325-327). 
 
1.18 Mediators of PSC activation 
 
Whilst initial activation could be distinguished from persistent activation, the events that 
cause both in PSCs are likely to be similar. Numerous growth factors, cytokines, hormones, 
intracellular signaling molecules and transcription factors as regulators of PSC activation 
have been described (328). Potential activation of PSCs in vivo included paracrine factors 
such as cytokines (IL-1, IL-6, IL-8 and TNF-α) growth factors (PDGF and TGF-β1) 
angiotensin II, and reactive oxygen species released by damaged neighbouring cells and 
leukocytes recruited in response to pancreatic injury (3;329-334).   63
Figure 1.10 Mechanisms of PSC activation 
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Figure 1.10 Mechanisms of PSC activation.  Exposure of the pancreas to ethanol, to its metabolites, and to 
insults that generate ROS all result in PSC activation by autocrine and paracrine products. The paracrine factors 
are derived from neighbouring cells such as acinar cells, ductal cells, endothelial cells, and leukocytes. Activated 
PSCs can migrate to sites of tissue damage, undergo regulated contraction, proliferate, phagocytose, and 
generate products that modulate the ECM by facilitating repair or promoting fibrosis (335-338). Persistent 
activation of PSCs promotes fibrosis, while redifferentiation to a quiescent state or simulation to undergo 
apoptosis facilitates tissue repair. 
 
Activated PSCs in turn can produce autocrine factors such as PDGF, TGF-β1 cytokines (IL-1, 
IL-6 and pro inflammatory molecules (COX-2) that can perpetuate the activated phenotype 
(3;333;339;340). See Figure 1.10 Activin-A, a member of the TGF-beta family of soluble 
factors, also functions in an autocrine manner, increasing collagen secretion and augmenting 
TGF-β1 expression and secretion (341). 
 
Endothelin-1 is expressed by rat PSCs in primary culture and can stimulate their migration 
and contraction (342). Whilst several inflammatory mediators (that have potential to impact 
or regulate PSCs) are released during pancreatitis there is evidence that PDGF, TGF-β1, and 
angiotensin II have major roles, PDGF induces proliferation of PSCs and contributes to their 
migration potential; angiotensin II induces PSCs to express alpha SMA and ECM proteins 
(329;332;343-345).  64
Oxidative stress and ethanol metabolites have also been suggested as potential perpetuators of 
the activated PSC phenotype. Ethanol can be metabolized in pancreatic acinar cells, resulting 
in toxic metabolites and oxidative stress that can induce pancreatic damage (346). Cultured 
PSCs exhibit ethanol – induced alcohol dehydrogenase activity in vivo, suggesting that PSCs 
can also metabolize ethanol (346). Ethanol and acetaldehyde promote activation of rat PSCs 
in vitro and cause lipid peroxidation in these cells (346;347). Furthermore, vitamin E which is 
an antioxidant prevents ethanol and acetaldehyde induced activation of PSC, thereby 
suggesting that oxidative stress regulates PSC activation. 4-hydroxy-nonenal for example is a 
highly reactive product of lipid peroxidation and activates primary rat PSCs in culture. These 
in vitro findings have been supported by histological analysis of pancreatic sections from 
patients with chronic pancreatitis, which showed 4-hydroxy-nonenal staining localized to 
activated PSCs within fibrotic areas and to acinar cells adjacent to areas of fibrosis (318). 
 
Multiple studies have identified several major signaling pathways involved in the regulation 
of PSC function (317;342;348-351). MAPKs are key mediators of activating signals initiated 
by growth factors, angiotensin II and ethanol (350;351). Other signaling pathways regulating 
PSC activation include P13K, RHO kinase, the JAK/STAT pathway, the activator protein-1 
and NF-κB pathways and the TGF-β1/SMAD related pathways (342;349;352). PPARγ 
ligands have been implicated in pathways leading to down regulation (317). Characterisation 
of these pathways further could lead to potential therapeutic targets for the modulation of PSC 
function. 
 
1.19 PSCs and pancreatic inflammation 
 
Activated PSCs in culture express several growth factors and cytokines, as well as receptors 
for these molecules which are known to participate in inflammatory and fibrotic processes. 
Although incomplete, current knowledge of pancreatitis is thought to be initiated by damage 
to acinar ductal and/or mesenchymal cells in the pancreas (306;353;354). The pathological 
processes that follow on from damage include interstitial oedema, necrosis of parenchymal 
cells, intra pancreatic trypsin activation, inflammatory cell infiltration, and activation and 
proliferation of PSCs. In human and rodent pancreas, activated PSCs are noted in areas of 
extensive necrosis and inflammation where an environment rich in cytokines, growth factors 
and reactive oxygen species prevails (355-357). Time course studies have established that 
what comes first is parenchymal necrosis and inflammation followed by PSC activation   65
suggesting that the former is a prerequisite for the latter (358-360). Hence autocrine and 
paracrine mediators are probably involved in PSC activation. In turn activation facilitates PSC 
proliferation, migration and ECM deposition, which leads to fibrosis or ECM remodeling as 
part of a repair processes. 
 
Analysis of pancreatic sections from patients with chronic pancreatitis and from experimental 
pancreatic fibrosis in rodents suggests PSCs play a central role in the development of 
pancreatic fibrosis. For example alpha SMA expressing cells are abundant in areas of fibrosis 
in pancreatic tissue sections from patients which chronic pancreatitis of different aetiologies 
(303;317;318;357). In these areas only alpha SMA expressing cells produce mRNA encoding 
procollagen α1, indicating that activated PSCs are probably the predominant source of 
collagens during pancreatic fibrosis (317). In support of this, spontaneous chronic pancreatitis 
in the Wister Bonn/Kobovi (Wbn/Kob) rat is characterized by inflammation and PSC 
activation in areas of pancreatic fibrosis (349). Moreover, in vivo, rat studies of 
administration of tri nitrobenzene sulphonic acid into the pancreatic duct as well as I.V. 
injection of dibutyltin dichloride , induces necrosis and inflammation of the pancreas 
followed by PSC activation and fibrosis (317;361). In addition, mouse pancreatitis induced 
with the use of cerulein (a cholecystokinin analogue and pancreas secretagogue) is also 
accompanied by PSC activation and fibrosis (305;362). 
 
The involvement of PSCs in the regulation of the inflammatory response during pancreatitis 
occurs, at least in part, through this production of chemokines and cytokines, as has been 
reported for myofibroblast-type cells in other tissues (363-366). PSCs have also been shown 
to have phagocytic activity in vivo and in cell culture (367) and therefore might also function 
as resident phagocytic cells during pancreatitis. 
 
PSC phagocytic activity is regulated by PPARγ expression of CD36, a scavenger receptor that 
promotes phagocytosis. Interestingly, pro fibrogenic cytokines such as TGF-β1, TNFα and 
IL-I, decreased the phagocytic capacity of PSCs activated in culture (367). It is clear from 
what has been discussed that the regulation of pro fibrotic and pro inflammatory properties of 
PSC during pancreatic inflammation is complex.   66
1.20 Inflammation and PSC modulation of ECM 
 
There is increasing evidence that PSCs have a key role in the extensive tissue fibrosis that 
accompanies chronic pancreatitis and leads to destruction of the pancreas and loss of exocrine 
function (344;355;357). Conversely, observational studies have shown that activated PSCs 
participate in tissue repair processes after acute necrotizing pancreatitis in humans and 
experimental acute pancreatitis in rodents (358-360;368). Activated PSCs, although their role 
is still not fully understood, appear to contribute to the provisional matrix at the site of injury 
that allows cell proliferation, migration, and assembly of new parenchymal cells 
(359;360;369). In addition PSCs can regulate ECM remodeling during pancreatic tissue repair 
through the production of ECM degrading proteases and their inhibitors, such as tissue 
inhibitor of metalloproteinase-I (TIMP-1) (3;370). In this context resolution of mouse cerulein 
induced pancreatitis involves transient activation of PSCs and deposition of ECM proteins as 
well as transient up-regulation of MMPs and TIMP-1 (360). It is likely that parallel processes 
of ECM remodeling by HSCs also mediate liver regeneration after experimental injury 
(371;372). 
 
In most studies in which PSCs are activated after damage to the pancreas, the inflammatory 
process resolves and activated PSCs progressively disappear after the cessation of the 
injurious agent. However, repeated pancreatic damage and failure of the mechanisms 
regulating tissue repair can both lead to chronic inflammation, persistent activation and 
proliferation of PSCs and finally to fibrosis. Consistent with this hypothesis, repeated 
episodes of acute experimental pancreatitis produces changes that resemble those found in 
chronic pancreatitis (305;373). In fact, fibrosis in the pancreas and other organs can be 
considered the consequence of a wound healing process responding to chronic injurious 
stimuli. In humans, repeated damage to the pancreas is associated with chronic alcohol 
consumption, pancreatic duct obstruction, metabolic disorders and genetic defects (306;374). 
The chronic injury results in the perpetuation of the activated PSC phenotype. Furthermore 
chronic pancreatitis is associated with reduced production of MMPs by PSCs which probably 
helps promote and sustain the fibrotic phenotype (3). 
 
In addition to the above, other mechanisms can explain the persistent activated state of PSCs 
during pancreatitis. For example activated PSCs express protease activated receptor-R (PAR-
2) which is cleared by trypsin (a key pathogenic protease in pancreatitis) to become active.   67
Active PAR-2 stimulates PSC proliferation and collagen synthesis (375). Changes in the 
composition of the ECM during repair processes can also modulate PSC activation. For 
example, activated PSCs revert to a quiescent state when cultured on a basal membrane like 
matrix, thereby suggesting that ECM composition regulates PSC behaviour (3;376). Studies 
of liver fibrosis have shown that extensive ECM degradation is accompanied by apoptosis of 
HSCs, as a result of either increased pro-apoptotic signaling a reduced survival signals from 
the ECM (296) but it remains to be shown whether this is also true in the pancreas. More 
recently, impaired extra cellular proteolysis of the ECM in mice lacking plasminogen has 
been associated with persistent PSC activation and accumulation of pancreatic collagens 
during the recovery phase of mouse cerulein-induced pancreatitis (360). Moreover, levels of 
pancreatic TGF-β1 plasminogen activating inhibitor 1 and TIMP-1, factors that promote 
fibrosis (296;329) were elevated persistently in plasminogen-deficient mice after treatment 
with cerulein but only transiently in similarly treated plasminogen sufficient mice (360). 
 
1.21 PSCs and pancreatic cancer 
 
Ductal pancreatic adenocarcinoma is the most common form of pancreatic cancer with a five 
year survival of less than 5% (377). Several tumours and especially pancreatic 
adenocarcinoma are characterized by tumour desmoplasia, a remarkable increase in 
connective tissue that infiltrates and envelops the neoplasm (378). Activated PSCs in the 
tumour desmoplasia of human pancreatic cancers express α-SMA and co localize with mRNA 
encoding procollagen alpha1-I (314) and are probably major contributors of the ECM proteins 
that constitute the desmoplasia (312;314;379-383). Of note, analysis of gene expression in 
human pancreatic adenocarcinoma, chronic pancreatitis, normal pancreas, and pancreatic 
cancer cell lines demonstrated that 107 genes predicted to be expressed in the stromal 
compartment were found in both pancreatic adenocarcinoma and chronic pancreatitis (380). 
Furthermore, isolation and characterisation of stromal cells from human pancreatic 
adenocarcinoma and alcohol induced chronic pancreatitis samples demonstrated that cells 
from both sources had the same characteristic morphology, cytofilaments expression, and 
capacity to synthesize ECM proteins (383). These results demonstrate that these two disorders 
contain common stromal elements and suggest similar mechanisms underlying the 
development of fibrosis in chronic pancreatitis and the desmoplasia in pancreatic 
adenocarcinoma. 
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Evidence is emerging that there is a symbiotic relationship between pancreatic 
adenocarcinoma cells and PSCs that results in an overall increase in the rate of growth of the 
tumours. E.g. culture supernatants from human pancreatic tumour cell lines stimulate PSC 
proliferation and production of ECM proteins (314;381-383). In addition the growth rate of 
tumour cells injected sub cutaneously into nude mice  (mice that lack T cells and are severely 
immunocompromised) is markedly increased when PSC are included in inoculum (384). In 
contrast to the tumours that form when only both cancer cells and PSCs are used have a 
desmoplasia similar to that observed in human pancreatic adenocarcinoma (383). Furthermore 
pancreatic tumour cells induced the proliferation of PSC by secreting PDGF and include PSC 
production of ECM proteins by secreting TGF-β1 and FGF-2 (383). Although studies using 
animals indicate that pancreatic tumours cells and PSC promote each others proliferation, 
supporting data from human pancreatic tumours are limited and inconsistent. One report 
shows that more extensive intratumoural fibroblastic cell proliferation correlates with a poorer 
disease outcome (385). Another report shows that patients with a better outcome have 
increased expression of connective tissue growth factor (CTGF) in fibroblasts surrounding the 
human pancreatic tumours cells (386). CTGF has been implicated in the pathogenesis of 
fibrotic disease, and its expression is predominant in PSCs and is regulated by TGF-β. These 
early findings are intriguing and suggest that further work is needed to delineate the role of 
PSCs and their regulation in pancreatic cancer. The mechanisms by which PSCs and the 
desmoplasia enhance the growth of tumour cells in the adenocarcinoma are complex and only 
partly understood. One role of the desmoplasia is to promote survival and prevent apoptosis 
of the tumour cells through a direct action of ECM proteins on the tumour cells (387;388). 
 
The pro survival effects of the ECM proteins laminin and fibronectin are mediated through 
their integrin receptors which are expressed by the tumour cells. In addition, the effects of 
fibronectin seem to be mediated through transactivation of IFG-1. Overall these interactions 
lead to the activation of pro survival and pro growth signaling pathways in pancreatic tumour 
cells (388;389). Another possible mechanism by which tumour desmoplasia might promote 
pancreatic adenocarcinoma cell growth is that PSCs and tumour cells produce MMPs and 
tissue serine proteases such as members of the plasminogen activating system, that degrade 
ECM proteins (360;370;390). In this context, MMPs and tissue serine proteases might 
promote tumour cell invasion and metastasis, as has been postulated in other cancers (390-
393). 
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1.22 Comparison of PSCs and HSCs 
 
Although PSCs and HSCs share several morphological and marker features, some differences 
exist. Unique, context-related features of HSCs include the portal perfusion and generally 
abundant vascular flow in the liver, and their proximity to encounter endothelial cell cross 
talk due to their hepatic location within the sub endothelial space (96). In addition, a genome-
wide assessment of gene expression that included 21,329 genes identified 29 that were 
differentially expressed between cultures of primary HSCs and PSCs (394). However the fact 
that the overwhelming majority of genes showed no difference in expression supports the 
notion that these 2 cells types are very similar. Recent studies have revealed that the bone 
marrow is the source of 68% of HSCs and 70% of myofibroblasts in mouse models of carbon 
tetrachloride and thioacetamide-induced fibrosis (395). Whether the same holds true in the 
pancreas remains to be determined, but a common origin in the bone marrow could account 
for the strong similarities between HSCs and PSCs. In addition to stellate cells, other potential 
sources of fibrosis exist in both pancreas and liver. E.g. the hepatic myofibroblasts which are 
distinguished from HSCs by their location with the liver and their expression of the ECM 
component fibulin-2 but not GFAP (70;396), and tissue fibroblasts, which express vimentin 
but not GFAP and desmin represent an additional source of ECM proteins (70;82;396-398).   
 
Subpopulations of fibroblastic cells which might reflect distinct levels of fibroblast activation 
can be distinguished in cirrhotic liver on the basis of differing levels of cellular retinol-
binding protein-1 and alpha SMA (399), and these cells might also produce ECM proteins. 
The origin of these liver myofibroblast type cells and similar cells in the pancreas remains to 
be conclusively determined. Bone marrow transplantation on a mouse model of pancreatic 
insulinoma demonstrated that the bone marrow is the source of 25% of pancreatic fibroblasts 
and is likely to contribute to tumour associated fibrosis (400). In addition, nestin-positive and 
nestin-negative precursors isolated from adult mouse pancreas are able to differentiate in vitro 
to yield multiple lineages of the pancreas, including PSCs (401). The relative contribution of 
bone marrow and resident precursors to the PSC population, as well as to the other 
myofibroblasts and fibroblasts related cell populations, remains to be determined.  
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The function of quiescent PSCs is still being investigated, but clues can be gleaned from 
studies involving HSCs (71;371;402). For example HSCs have been implicated in several 
important liver physiologic roles, under basal conditions, that include vitamin A storage; 
production and turnover of normal ECM proteins; and communication with hepatocytes via 
gap junctions and the production of paracrine factors to promote hepatocyte differentiation, 
and to regulated ductal and vascular pressures. Similar roles can be envisioned for PSCs in the 
inactive state. For example, perivascular and periductal PSCs (301) might regulate the 
pressure within these compartments by contraction mediated by endothelin-1 (342). The 
functions of PSCs by analogy to HSCs should be envisioned not only in isolation but also in 
the context and under the influence of their microenvironment. 
 
 
Although alcohol and/or its metabolites have been shown to similarly activate stellate cells of 
the pancreas and liver, it is unclear why substantial differences exist in an individual’s 
susceptibility to liver and pancreas fibrosis. Potential differences between the pancreas and 
the liver after injury, in addition to the apparent difference in the cellular microenvironment, 
include oedema formation during pancreatitis; different ethanol metabolism in acinar cells 
and hepatocytes; and different lipid metabolism between acinar  cells and hepatocytes (for 
example, “ fatty pancreas” has not been described). Given that the stellate cell is an integral 
element of the onset of these diseases, microenvironment differences and other genetic and 
epigenetic modifiers related to stellate and/or other resident and infiltrating cells are likely to 
be important (Figure 5), but this hypothesis remains to be tested. For example, comparison of 
the response of PSCs and HSC isolated from the same animal with parallel comparative 
responses in different genetic backgrounds has not been reported. Furthermore, attempts at 
assessing genetic polymorphisms (e.g. in enzymes such as cytochrome P450 2E1 and 
aldehyde dehydrogenase-2) that may promote susceptibility to alcoholic chronic pancreatitis 
or cirrhosis have not been overly revealing (403). However an understanding of genetic 
polymorphisms that predispose to chronic pancreatitis (307;374) or liver fibrosis (404;405) or 
even protect from chronic pancreatitis (406), is being pursued. A systematic and broad based 
genetic screening will be needed, using well defined animal models and patient cohorts. 
Proteomic comparisons between PSCs and HSC, which are likely to be forthcoming, should 
also provide additional insights.  
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1.23 Hypoxia, Oxygen and genes in health and disease: an introduction 
 
Excessive supply and reduced supply of oxygen to the tissues underlies the pathophysiology 
of many diseases. Excessive supply can produce toxicity; an extreme example of this is 
oxygen given to neonates and ultimately causes tissue death for example in myocardial or 
cerebral tissue. Reduced oxygen delivery, hypoxia, may lead to cell death. 
 
Investigation into the molecular understanding of oxygen regulation began with the cloning of 
the erythropoietin gene (407). Although produced in the kidney and liver, a tissue culture 
model to investigate this physiological system was designed following the discovery that 
oxygen regulated erythropoietin-gene transcription occurs in the human hepatoma cell lines 
Hep3B and HepG2 (408). Following this, it was possible to isolate an oxygen-regulated 
control element in the DNA 3` to the coding sequence of the erythropoietin gene (409) (410-
412). Was this control element and the mechanisms activating it specific to the erythropoietin 
gene and hepatoma cells, or could it operate more widely? Coupling the element to the 
promoter of other genes, such as alpha globin was found to confer oxygen regulation on the 
expression of these genes. Following transient transfection oxygen regulation of these 
artificial genes could occur in a wide variety of tissue culture cells. Not just those making 
erythropoietin, (413). Demonstrating that mechanisms impacting on the control element were 
expressed ubiquitously may have explained this. The generalized expression of a specific 
protein complex, hypoxia-induced factor-I (HIF-1) capable of binding to the erythropoietin 
control sequence provided support for this conclusion (414).  
 
If this system existed in other cells not connected with erythropoietin production the inference 
was that the mechanism served another purpose, presumably the control of other genes in 
response to hypoxia. This led to speculation as to what these other genes might be. Candidates 
included genes involved in the angiogenesis, control of vasomotor tone and energy provision. 
Experiments on the glycolytic genes phosphoglycerate kinase -1 (PGK-1) and lactate 
dehydrogenase-A (LDH-A) provided the first clear evidence for a link with the erythropoietin 
system. 
 
It was found that their mRNA accumulated in cells cultured in hypoxia conditions compared 
with normoxic controls. This phenomenon was dependent on specific DNA sequences   72
flanking these genes which were homologous to the erythropoietin control sequence and 
competed for binding of HIF-1 (415). 
 
The list of oxygen genes has now expanded greatly (416) to include genes involved in glucose 
transport (Glut-1 and Glut-3) (417;418), gluconeogenesis (PEPCK) (419), vascular growth 
factor (VEGF), (420) vasomotor regulation (iNOS, endothelin) (421) (422), iron metabolism 
(transferrin), coagulation (tissue factor), (418), retroviral transposons, VL30 (423) and 
catecholamine synthesis (tyrosine hydroxylase) (424). The involvement of HIF-1 is common 
to many but not all of these. 
 
Affinity purification of HIF-1 led to the cloning of two genes which encode basic helix-loop-
helix PAS domain transcription factors, which dimerize to form the DNA binding complex 
(425). One of these proteins, HIF-1α was novel, the other was known previously as aryl 
hydrocarbon receptor nuclear translocator (ARNT). 
 
Mutant hepatoma cells that fail to produce HIF-1 because of ARNT deficiency show 
substantially reduced hypoxic gene regulation, confirming the importance of HIF-1 in this 
response (426). Another protein with 48% homogeneity to HIF-1α called endothelial PAS 
domain protein (EPAS-1) appears to dimerize with ARNT and be regulated by hypoxia (427). 
This raises the possibility that a family of proteins exist that may serve similar but not 
identical functions in different tissues. 
 
1.23.1 HIF-1 activation by Hypoxia 
 
HIF-1α and ARNT mRNA levels do not change dramatically between normoxia and hypoxia 
culture conditions, suggesting that control is mediated at a translational or post translation 
level. Current evidence suggests that hypoxia relief of normoxia destabilization of HIF-1α 
protein may play a central role (428;429). 
 
Other mechanism may be involved in hypoxia regulation of the complex. For example HIF-
1α has been shown to bind to P300 (430), a non-DNA binding transcriptional activator, 
involved in a wide variety of responses. Whether this binding is itself regulated by hypoxia is 
unknown but it clearly has the potential to increase the power of transcriptional activation. 
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ATF-1 and CREB-1 may bind constitutively to the HIF-1 DNA recognition site (431) but the 
functional relevance of these observations is also unclear. 
 
1.23.3 The sensor control 
 
To elucidate what controlled these responses a haem protein sensor was proposed because 
hypoxia induction can be minimized by exposure to cobalt, nickel or manganese ions, can be 
abrogated by exposure to carbon monoxide and reduced by the haem synthesis inhibitor 4,6-
dioxoheptanoic acid (432). 
 
Hydrogen peroxide which is itself generated in an oxygen dependent manner by cells, can 
abolish the activation of HIF-1 and the consequent hypoxia up-regulation of erythropoietin, 
although whether it does so in the physiological range is not yet clear. 
 
1.23.4 Hypoxia studies in the liver 
 
Little has been published recently with regard to MMP and TIMP expression in the liver in 
hypoxia versus normoxia. Human HSCs were studied in normal oxygen condition and 
hypoxia (1%). Shi reported that in hypoxia the expression of HIF-1α and VEGF was induced. 
Western blotting demonstrated the expression of alpha SMA to increase with hyoxia 
stimulation. The expression of MMP-2 and TIMP-1 genes was also increased. Hyoxia also 
elevated the expression of collagen type-1. The analysis of TGF-B / SMAD signaling 
pathway showed that hypoxia potentiated the expression of TGFβ-1 and the phosphorylated 
status of Smad-2 (433). 
 
Brenner et al (434) documented the effects of alcohol on fibrogenesis. Although the major 
mechanisms of fibrogenesis are independent of the origin of liver injury, alcoholic liver 
fibrosis features distinctive characteristics including the pronounced inflammatory response 
of immune cells due to elevated gut derived endotoxin plasma levels, increased formation of 
reactive oxygen species (ROS), ethanol induced pericentral hepatic hypoxia or formation of 
cell toxins and pro-fibrogenic ethanol metabolites (eg acetaldehyde or lipid oxidation 
products). These factors are together responsible for increased hepatocellular cell death and 
activation of HSC (435). 
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In the knowledge that hypoxia leads to enhanced production of angiogenic factors, such as 
vascular endothelial growth factors (VEGF), HSC were studied in hypoxia. Low oxygen 
conditions led to the expression of VEGF mRNA which was dose dependent and time 
dependent. The expression of VEGF mRNA correlated with the secretion VEGF protein in 
conditioned media. VEGF mRNA expression could be enhanced by mimics of hypoxia 
conditions using S-Nitroso-N-acetyl-D-L, penicillamine (SNAP), nitric oxide (NO) and cobalt 
chloride. The hypoxic induction of VEGF may be of mechanistic importance in the 
pathogenesis of hepatic wound healing and hepatic carcinogenesis (436). 
 
The expression of MMP-2 and TIMP-2 in rat cultured HSC was detected by 
immunocytochemistry. MMP-2 was enhanced in hypoxia while the expression of TIMP-2 
was decreased. Over time the relative amount of MMP-2 was highest in the 6hr group with a 
contrary curve in TIMP-2. It was concluded that hypoxia promotes the expression of MMP-2 
and inhibits the expression of TIMP-2 in HSC. This observation was more noticeable at early 
stages of hypoxia (437). 
 
The same group repeated their work, again in hypoxia but also in hyperoxia. MMP-2 
expression rose in hypoxia as before with a concomitant fall in TIMP-2 expression – the 
greatest changes being at 6hrs. With hypoxia the protein contents of MMP-2 and TIMP-2 
were both increased at 12hrs versus control. MT1-MMP was also increased (438). 
 
1.24 Inhibition of Tissue inhibitors of Metalloproteinases 
 
As has been described, the inhibition of MMPs in the extracellular space represents a 
regulatory mechanism of matrix: the major inhibitors being the TIMPs which are capable of 
binding to and inhibiting the MMPs (214). In liver cirrhosis decreased collagenolytic activity 
has been observed along with increased levels of TIMP-1 (285). Studies by Iredale et al 
suggested that the decrease in collagenolytic activity during the development of liver fibrosis, 
in a rat model, was due to overexpression of TIMP-1 mRNA (90). TIMP-1 and TIMP-2 have 
been shown to be upregulated 3-7 fold in a variety of liver diseases which correlated with 
liver hydroxyproline content (439). Previous work by colleagues in the Southampton liver 
group have suggested that TIMP-2 may be increased in fibrotic liver disease in conjunction 
with MT1-MMP (440), yet traditionally TIMP-2 expression has been conceptually viewed as 
constitutive.   75
1.25 Hypothesis 
 
Liver cirrhosis is characterized by increased net deposition of fibrillar and non fibrillar 
collagens, glycoconjutes and proteoglycans. This can occur either through excessive 
production, failure of degradation or a combination of the two. HSC have been shown to be 
the major producers of ECM and matrix metalloproteinases in the diseased liver. Activity of 
MMPs is tightly regulated. Gelatinase A which has actions against fibrillar and non-fibrillar 
collagens, has been found to be produced by activated HSC in vitro and in vivo. In liver 
cirrhosis its mRNA is upregulated. The activation of gelatinase A involves the complex of 
MT1-MMP/TIMP-2/gelatinase A at the cell surface and can be inhibited by excess TIMP-2. 
The hypothesis examined in this thesis is that TIMP-2 expression is upregulated during HSC 
activation and progressive liver fibrosis in vivo and in vitro. It is proposed that potential novel 
pathways exist of TIMP-2 regulation in HSC. 
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1.26 AIMS 
 
The aims of this thesis were: 
 
1.  To determine the key sequences of the TIMP-2 gene promoter which regulate TIMP-2 
expression during hepatic stellate cell (HSC) activation and pancreatic stellate cell 
(PSC) activation. 
 
2.  Determine at what level the enhanced expression of TIMP-2 mRNA observed in 
activated HSC and activated PSC is regulated using Nuclear Run On assays (studies of 
mRNA production). 
 
 
3.  Perform studies of the TIMP-2 promoter activity in HSC and PSC in collaborative 
work with Dr Yves De Clerk. 
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CHAPTER 2 
 
GENERAL METHODS 
   78
2: Materials and General Methods 
 
 
2.1 Materials 
 
This chapter sets out to document the general methods used repeatedly throughout the course of 
this thesis including the method development for individual techniques where appropriate.  Unless 
otherwise stated, chemicals and reagents were obtained from Sigma, Poole, UK. General solutions 
and buffers etc are listed in Appendix I. 
 
2.1.1 General Methods 
 
I would like to thank and acknowledge the help and hard work of Dr Julie Trim & Dr 
Marianna Gaca who both helped supervise me on a day to day level with certain techniques 
such as Northern Blotting, DNA sequencing, transfection techniques etc. Dr Matt Wright was 
an enourmous help in teaching me techniques involving plasmid DNA preparation. 
 
2.1.2 Immunohistochemistry 
 
This method relies on the binding of specific antibody to the antigen on the tissue and then the 
antigen location can be visualized using a marker to the antibody-antigen complex.  Here, the 
primary antibody was detected using a three stage streptavidin-biotin complex technique.  A 
biotinylated secondary link antibody binds to the primary antibody and when the tertiary layer 
of avidin-biotin enzyme complex finally binds to the secondary antibody an intense colour 
was produced when streptavidin peroxidase conjugate and DAB chromogen added. Negative 
controls were performed by repeating the experiments withouth the primary antibody. 
 
Materials 
Absolute Methanol, BDH, Poole, UK 
Alcohol (70%, 100%) 
3,3`– diaminobenzidine tetrahydrochloride (DAB), Dako 
DMEM, Invitrogen Life Technologies, Paisley, UK 
DPX, Poole, UK   79
Harris haematoxylin* 
Hydrochloric acid (1%) / Alcohol (70%) 
PBS 
Primary Antibody:  Non-immune rabbit IgG, 18140, Sigma, UK 
      Monoclonal Mouse anti-human Desmin (1:50) – N1526  
Clone- D33 (Dako, Abingdon, Oxon, UK) 
      Mouse monoclonal antibody to rat α-SMA  
- A5228 Clone 1A4, Sigma,  
Monoclonal Mouse anti-Human Ki 67 – N1633 Clone-MIB-1 (Dako, 
Abingdon, Oxon, UK) 
Monoclonal Mouse anti- NGF receptor p75- NCL-NGFR (Novocastra 
Laboratories Ltd, UK) 
Rabbit Anti-Nerve Growth Factor-Beta polyclonal antibody- 
AB1526SP (Chemicon International, USA) 
Secondary Antibody:  Monoclonal antibody to biotin – 11 297 597 001 (Clone 33) (Roche 
Diagnostics, Mannheim, Germany) 
Secondary Antibody:  Polyclonal swine Anti-Rabbit immunoglobulin/Biotinylated – E0353 
(Dako, Abingdon, Oxon, UK) 
Strept AB Complex/HRP – K0377 (Dako, Abingdon, Oxon, UK) 
The archival human chronic pancreatitis tissues used in this project were all fixed in formalin 
and embedded in paraffin.  Formalin fixation can cause the epitopes of the antigen to undergo 
substantial changes and can even crosslink with other unrelated proteins.  This results in the 
partial or complete loss of the immunoreactivity by the antigen and/or the “masking” of the 
antigen.  Initially the attempts to improve the immunoreactivity were by the use of tryptic 
digestion prior to staining.  However, the use of enzymes may entail the risk of destroying the 
epitopes.  Later methods included microwave heating (441) and the use of citrate buffer 
(pH6.0) together with the effect of heat further improved the technique of antigen retrieval 
(442).  More recently, it has been reported the combined use of heat and enzyme (protease) 
digestion produced a superior staining than when only one of the measures were used (443).  
Prior to antigen retrieval, the tissues have to be deparaffinized by soaking the slides in xylene   80
twice in 10 min each and then rehydrated through graded alcohols to 70%.  Endogenous 
peroxidase was inhibited with 0.5% hydrogen peroxidase in methanol for 10 min.  
 
For freshly isolated PSC studies, cells were cultured into 1 well-chambers glass slides (Lab-
Tek®) at a density of 10,000 cells per well.  The cells were harvested after 7 days and the 
slides were washed with sterile PBS.  The slides were air dried and stored at -20
0C until 
immunostaining was performed.  The slides were defrosted and again air dried to remove the 
condensation, the cells were then fixed by adding absolute methanol to denature the proteins.  
Once the methanol had evaporated, the primary antibody may be applied.  Sections were then 
washed in Tris-buffered saline (TBS), pH 7.6 before the addition of the primary antibodies at 
optimal dilutions as follows: α-SMA (1:50) and desmin (1:50).  For negative controls, the 
primary antibody was replaced with non-immune IgG and TBS alone.  After incubation with 
the primary antibodies, sections were washed in TBS (3x5 min) and incubated with 
biotinylated anti-mouse anti-serum (Roche Diagnostics, Mannheim, Germany) for 30 min.  
Sections were washed as before, and then incubated with streptavidin complexed with 
biotinylated horseradish peroxidase (Dako, UK) for 30 min.  After washing with TBS as 
described above, sections were exposed to 3`-3`- Diaminobenzidine (Sigma) for 8 min, 
followed by TBS rinse.  Finally the sections were counter stained in Harris’ hematoxylin, 
dehydrated through graded alcohol and mounted. 
 
2.1.3 Method 1: Preparation of slides 
 
Microscope slides were coated with 3-Aminopropyltriethoxysilane (APES) for In-Situ 
hybridization and immunocytochemistry according to the protocols of V.an Prooijen-Knegt et 
al. (444).  
 
In brief the following equipment and reagents were required:  
 
1. 3-Aminopropyltriethoxysilane (APES) -Sigma, cat no: A3648. Store at +4
0C 
2. Technical grade acetone (in inflammable cupboard) 
3. RO water 
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Slides were racked into large stainless steel units and washed on a routine cycle (65°C).  
Excess water was shaken off and the slides dried in the glass drying cabinet overnight. 800ml 
of 2% APES in acetone (16ml of APES to 800ml of acetone) was made up in the fume hood.  
Each rack was immersed, in the fume hood, in 800ml of each solution in the plastic staining 
troughs as follows:  
 
a. 2% APES solution -5 seconds 
b. Acetone (1) -5 seconds 
c. Acetone (2) -5 seconds 
d. RO water (1) -5 seconds 
e. RO water (2) -5 seconds 
 
Racks were then placed on absorbent paper to drain and then transferred to the glass drying 
cabinet overnight to dry.  Slides were then stored for use. 
 
 
2.1.4 Method 2: Antigen Retrieval -Proteolytic Enzyme -Pronase Pre-treatment 
 
In fixed paraffin-embedded tissue sections demonstration of some antigens is  
enhanced after pre-treatment with the proteolytic enzyme pronase. The effectiveness of 
proteolysis for antigen retrieval is related to the length of fixation and the type of fixative 
used. The following reagents were used: 
1. Pronase -Dako cat no S2013 2 
2. TBS pH 7.6  
3. 1% Pronase Stock Solution was made up by dissolving l00mg pronase in 10ml of TBS then 
stored in 0.1m1 aliquots at -20°C: stable for one year.  Repeated freezing and thawing was 
avoided. 
 
Sections were mounted on APES coated slides and dried for 24 hours at 37°C before staining.  
Sections were de-paraffinised and endogenous peroxidase blocked in the usual way and 
placed in water until required.  The 0.05% Pronase working solution was prepared by thawing 
one vial of 0.1ml of Pronase Stock Solution, adding 1.9ml of TBS and mixing well.  Slides 
were drained and covered with 200µl of 0.05% pronase, incubated at room temperature for 
approximately 15-20 min (depending on the length and type of formalin fixation).  The slides   82
were then washed in TBS twice for 5 min before continuing with the immunostaining 
technique. 
 
2.1.5 Method 3: Antigen Retrieval - heat mediated – microwave pre-treatment using 
citrate or EDTA buffer 
 
In fixed paraffin-embedded tissue sections demonstration of some antigens is  
enhanced after pre-treatment in a microwave oven using a pre-selected buffer (citrate, EDTA 
or urea) (445). 
 
The following equipment and reagents were used: microwave oven, Panasonic NN-6450 (800 
watts). Solutions included the following: 
  
I.  0.01M citrate buffer (pH6.0) prepared as follows: 
  Citric acid crystals 2.1g  
  RO water 1000m1  
  Adjust pH to 6.0 with 1M sodium hydroxide (approximately 25ml). 
 
OR 
 
  EDTA 1mM pH 8.0 prepared as follows:  
  EDTA 0.37gm  
  RO water 1000 mL 
  Adjust to pH 8.0 with 0.1M NaOH (approximately 8ml) 
 
The antibody register was consulted for recommended buffer to be used for each antibody.  
Sections were mounted on APES coated slides and dried for at least 24 hours at 37
0C before 
staining.  Sections were de-paraffinised and endogenous peroxidase blocked in the usual way 
and placed in water until required.  The plastic staining racks were filled with 24 slides and 
placed in the polythene box. Each box was filled with 330m1 of prepared buffer and covered.  
The microwave was set to medium power and run for 25 min. Each box was removed and 
filled quickly with cold running water then left in running water for 2-3 min before being 
returned to the staining trays and washed in TBS twice for 5 min each before continuing with 
the immunostaining technique.   83
2.1.6 Method 4: Antigen Retrieval -Heat-mediated -Pressure Cooker Pre-treatment 
 
In fixed paraffin-embedded tissue sections demonstration of some antigens is enhanced after 
pre-treatment in a pressure cooker using a pre-selected buffer (citrate, EDTA or urea) (446). 
 
The following equipment was required: Stainless steel pressure cooker (Tefal Optima, 8/13Ib 
pressure), hot plate, stainless steel staining racks with wide slots, 8 inch Spencer-Wells type 
forceps.  The following solutions were made up: 
 
I.   0.01M citrate buffer (pH6.0) prepared as follows:  
  Citric acid crystals 2.1g  
  RO water l000ml  
  Adjust pH to 6.0 with IM sodium hydroxide (approximately 25ml).  
 
OR 
 
  EDTA lmM pH 8.0 prepared as follows: 
  EDTA 0.37gm  
  RO water 1000 ml  
  Adjust to pH 8.0 with 0.1M NaOH (approximately 8 ml)  
 
The antibody register was consulted for recommended buffer to be used for each antibody.  
Sections were mounted on APES coated slides and dried for at least 24hours at 37°C before 
staining. Sections were de-paraffinised and endogenous peroxidase blocked in the usual way 
and placed in water until required. Slides were placed in stainless steel staining racks in such 
a way that pairs of slides were used back to back (providing larger gaps between sections and 
preventing bubbles from becoming lodged).  
When the buffer boiled freely, slide rack(s) were placed into the pressure cooker  
chamber using the large forceps and fitted to the lid carefully.  The regulator valve was set to 
13lb pressure and pressure was allowed to build up.  Timing was commenced for 2 min when 
a steady stream of steam escaped from the regulator.  The slides were removed, placed back 
in staining trays and washed twice for 5min in TBS before proceeding with the 
immunostaining.   84
2.1.7 Method 5: Demonstration of Enzyme Peroxidase using Biomed Liquid DAB 
Substrate Kit 
 
The peroxidase label on the final stage reacts with hydrogen peroxidase and  
Diaminobenzidine (DAB) to form an insoluble brown precipitate at the site of 
antigen/antibody reaction (447). The following reagents were obtained concentrated in kit 
form (Sigma) and stored between 2-8°C: 
 
2 x 4ml of 3, 3'-diaminobenzidine chromogen solution. 
20ml of l0X concentrated substrate buffer.  
2 x 3ml of hydrogen peroxide substrate solution. 
2.5ml of working solution (allowing 200µl per slide) was prepared as follows:  
Add 0.25ml of l0X substrate solution to 2.25ml RO water 
Add 2 drops of chromogen and mix 
Add l drop of Hydrogen Peroxide (H2O2) substrate solution and mix 
 
Enough working solution (2-5 drops) was used to entirely cover the tissue section only and 
slides were then incubated at room temperature for 3-10 min. In most cases, colour 
development was completed in 5 min. However, development time varied due to the amount 
of specific antigen/antibody binding in the specimen and the ambient temperature of the 
room.    85
2.1.8 Method 6: Streptavidin-Biotin Peroxidase Complex (StABCPx) immunostaining 
technique for fixed, paraffin embedded sections using monoclonal or polyclonal 
antibodies 
 
Antigen binds to either a monoclonal or polyclonal antibody which is then detected using a 
three stage Streptavidin-Biotin peroxidase complex technique. The enzyme label peroxidase 
is then demonstrated using the chromogen diaminobenzidine (DAB) or 3-amino-9-ethyl-
carbazole (AEC) (448). 
 
The following solutions were made up: 
 
1. Inhibitor for endogenous peroxidase (0.5% H2O2 in methanol)  
Hydrogen peroxide (30%) 0.2m1 
Methanol 11.8m1 
 
2. TRIS buffered saline pH 7.6 (TBS): 
Sodium chloride 80g  
TRIS hydroxymethyl methylamine (TRIS) 6.05g  
IM hydrochloric acid 38m1  
RO water to 10L  
 
3. Bovine serum albumin (BSA): 
To one aliquot (mL) of 10% BSA (-20
0C), add 9m1 TBS.  
 
Sections were de-paraffinised twice in low toxicity processing solvent (BDH laboratories) for 
5 min each and rinsed in 100% alcohol for 1 minute followed by 70% alcohol for a further 
minute.  Endogenous peroxidase was inhibited by treating with freshly prepared inhibitor 
(Reagent 1) for 10 min.  Slides were then washed well in RO water.  The antibody register 
was consulted before proceeding for recommended techniques of antigen retrieval. If antibody 
retrieval was not necessary, 1% BSA in TBS for 30 min (Reagent 3) was applied, the slides 
drained and primary antibody applied.  Methods for antigen retrieval are outlined above.   
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The primary antibody was applied in correctly diluted in TBS and incubated either at room 
temperature for 30 min or at 4°C for 18-24 hours (overnight). Again the antibody register was 
consulted for recommended incubation time for each antibody. For slides incubated overnight 
at +4
0C a period of 15 min was incorporated to allow warming up to room temperature before 
washing prior to a wash in TBS three times for 5 min each. 
 
Biotinylated sheep anti-mouse Ig (BAM) for monoclonal antibodies or biotinylated swine 
anti-rabbit Ig (BAR) for polyclonal antibodies were applied at the current dilution in TBS, for 
30 min at room temperature.  Peroxidase labeled complexes were prepared at this stage by 
adding the equivalent of 2µl of solution A, 2µl of solution B to 396µl of TBS making a 1:200 
dilution and left on the bench to complex.  Slides were washed in TBS three times for 5 min 
each prior to the application of the prepared Streptavidin/ Biotin peroxidase complexes for 30 
min at room temperature. Slides were then washed again in TBS three times for 5 min each.  
DAB substrate was applied for 5 min prior to a final rinse in TBS, followed by a wash in 
running tap water for 2 min. Slides were then rinsed in 70% alcohol, counterstained with 
Harris' haematoxylin for 1-2 min, rinsed in tap water for one minute and differentiated in 1% 
acid alcohol for 5 seconds before being ‘blued’ in running tap water for at least 5 min. The 
slides were then dehydrated clear and mounted in DPX.  
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2.2 Isolation and Culture of Hepatic Cells 
 
Appropriate home office licenses were obtained and local ethics committee approval obtained 
before any animal work was undertaken. In order to study the cellular origins of TIMP-2 in the 
liver, it was essential to obtain highly pure and functionally intact hepatic cell populations from 
normal liver.  Parenchymal cells constitute the predominant fraction of cells (65%) in the normal 
mammalian liver (449), the rest being made up of endothelial cells, HSC and KC in roughly 
equal proportions.  A number of methods for the isolation of purified populations of the different 
cell types in the liver have now been described, all involve sequential perfusion of the liver via 
the portal vein with a calcium free buffer to dissociate intercellular calcium dependent 
desmosomal junctions (450).  This is followed by perfusion with collagenase diluted in a calcium 
containing buffer, to allow enzymatic activity.  Collagenase digestion on its own allows isolation 
of both parenchymal and non-parenchymal cells from the same liver (450) but has the drawback 
of yielding relatively impure cultures even after subsequent purification (451).  More aggressive 
digestion of the liver by the addition of pronase gives much purer populations of HSC and KC 
from a single liver (451) (452;453).  The disadvantage of such aggressive digestion is that it 
damages membrane receptors for up to 24 hours after isolation (451). 
 
The following methods describe the isolation technique used for rat hepatic cells; the different 
techniques for human hepatic cell isolation will be discussed later.  The majority of the cells 
isolated in the first half of my stay in the liver unit were carried out by Jan Gentry MLO, in the 
second half rat HSC were obtained through the work of colleague researchers Matt Wright, 
David Smart and Julie Trim – I am extremely grateful to them all for their important work. 
 
2.2.1 Method of Isolation of Rat Hepatic Stellate Cell 
 
Rat hepatic cells were isolated by the method of Friedman (454) with modifications as described 
by Arthur (455).  Male Sprague-Dawley rats (450-750g body weight) were anaesthetized by 
intraperitoneal injection of Hypnorm (Jansen) and midazolam.  A simultaneous injection of 2500 
units of heparin was also administered intraperitoneally to prevent intra portal thrombosis.  The 
anaesthetized animal's belly was swabbed with videne scrub before a section of skin was 
removed and the portal vein was exposed at laparotomy. Two sterile 3.5/0 silk sutures were 
placed behind the portal vein in preparation to secure a 17.5G intravenous cannula (Wallace, 
UK) pre-primed with 2500 units of heparin.  This was then inserted into the portal vein so that   88
the tip of the catheter was still in the main portal vein before its division to ensure an even 
perfusion of the liver.  Perfusion was immediately commenced with sterile, calcium-free Hanks 
Balanced Salt Solution (HBSS) pH 7.4 (Imperial, UK) and the inferior vena cava was severed to 
allow resistance-free perfusion and for all the portal blood to be flushed out.  Adequate perfusion 
was signaled by blanching of the whole liver which was then carefully removed (whilst ensuring 
constant perfusion was maintained) and placed in a covered, 10 cm diameter sterile Petri dish. 
 
Perfusion of 200ml calcium-free HBSS was followed by 100ml of 0.275 % pronase (S. Griseus, 
Boehringer, UK) in HBSS and then 225ml 0.008 % collagenase B (Boehringer) in HBSS. All 
perfusions were carried out at a constant flow rate of 10ml/min and a delivery temperature of 
39°C (normal rat body temperature).  When the perfusion was complete the liver was transferred 
to a sterilized laminar flow cabinet and the capsule was opened.  The digested slurry was 
dispersed in 100ml (total volume) 0.02% pronase/HBSS containing 2.4mg/ml deoxyribonuclease 
(Boehringer).  After incubation for 30 min in a shaking oven at 37°C, the cell suspension was 
filtered through a sterile nylon gauze (125µm, John Staniar and Co., Manchester, UK) to remove 
fibrous and vascular remnants and washed threefold at 500g for 7 min in 200ml HBSS 
containing 1.2mg/ml deoxyribonuclease to prevent cell clumping in the presence of free DNA in 
solution from damaged cells.  After the third wash, the supernatant was relatively clear of cell 
debris and the cell pellet was re suspended to a total volume of 44.4ml in HBSS containing 
2.4mg/ml deoxyribonuclease before separation by density gradient centrifugation. Buoyant HSC 
were separated from the resulting cell suspension over a discontinuous 2 layer Nycoprep 
(Nycomed, Birmingham, UK) gradient prepared as described by Hendriks et al (456).  This 
consisted of a 4 ml lower layer of 17.2% Nycoprep (w/v) in HBSS and a 7.4ml upper layer of 
cell suspension in HBSS/0.5% deoxyribonuclease containing Nycoprep (final concentration 
11.5%) carefully overlaid in 15ml centrifuge tubes (Greiner) finally covered with 0.5ml of 
HBSS.  To prepare the lower layer 16ml of HBSS was added to 24ml of a 27% Nycoprep and 
4ml of this was placed in ten 15ml centrifuge tubes.  The upper layer was made up by adding 
29.6ml of Nycoprep to exactly 44.4ml of the filtered and washed cell suspension in HBSS/0.5% 
deoxyribonuclease giving a final Nycoprep density of 11.5%.  After centrifugation at 1400xg for 
20 min in a Beckman TJ-6 centrifuge. HSC were isolated from the top of the 11.5% layer and 
KC from the 11.5%/17.2% interface. 
 
Further purification was obtained by the use of centrifugal elutriation (Beckman JE2-21 
centrifuge fitted with a JE6-B rotor, Beckman Instruments, Geneva, Switzerland). Centrifugal   89
elutriation is a well documented method of separating particles mainly by their size. It involves 
circulating a suspension of cells through a specialized chamber in a centrifuge rotor flowing 
against the direction of centrifugal force.  At a given flow rate and rotor speed, cells in the 
suspension will be sorted according to their size and density, with the smallest cells at the front 
(closest to the rotor spindle). HSC which are the lightest cells can therefore be continuously 
collected leaving behind heavier contaminants in the chamber.  Different cell populations require 
specific rotor speeds and flow rates as previously described (457) (458) (459) (460-463).  HSC 
were purified at a rotor speed of 1500rpm with a flow rate of 18ml/min in HBSS; KC at a rotor 
speed of 2500rpm, flow rate 45ml/min.  Cells were collected in a total volume of 150ml and 
were then pelleted down before re suspension in Dulbecco Modified Eagles Medium (DMEM, 
Gibco) containing antibiotics and 16% foetal calf serum (FCS) in preparation for cell culture. 
 
2.2.2 Preparation of Human Hepatic Stellate Cells 
 
I am grateful to Drs Matt Wright and Julie Trim for their work in developing the isolation of 
human HSC in the department.  This technique was adapted from the method of Pinzani (464).  
12 normal human liver preparations were obtained from the resection margin of partial 
hepatectomies performed to resect isolated hepatic metastases (kindly provided by Professor 
Primrose, Professor of surgery, Southampton General Hospital).  Ethics approval for this work 
was obtained through the local Southampton University Ethics Committee. Each patient was 
counselled by a member of the surgical team prior to their operation and written consent was 
sought on each occasion. Inclusion criteria for example consisted of a diagnosis of a primary 
malignant condition such as colorectal cancer with liver metastase for patients over the age of 18. 
For normal liver preparations exclusion criteria included diffuse parenchymal liver disease. For 
each patient data was available regarding their clinical condition and their concurrent medication 
list. Each specimen was carefully inspected for evidence of tumour involvement and rejected if 
any was seen.  The liver was then perfused manually with calcium free HBSS until it was cleared 
of visible blood. The liver was then placed on a sterile Petri dish and it was perfused with 100ml 
of calcium containing HBSS at 37°C to which 1g pronase, 80mg collagenase and 1mg DNAse 
had been added.  Maceration was performed by repeated cutting with sterile scalpel blades whilst 
the liver was still in the enzyme solution.  The resulting cell suspension was purified by 
separating over a discontinuous 2 layer gradient and by centrifugal elutriation as above. 
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2.2.3 Assessment of Cell Number and Viability 
 
The viability of all cells, immediately after isolation, was routinely determined by exclusion 
using 0.05% (w/v) Trypan blue dye.  Viable cells stay small, round and refractile.  Non-viable 
cells become swollen, enlarge and stain dark blue.  Both the total cell count of cells/ml and 
percentage of viable cells were determined.  Cells were counted using a hemocytometer with 
Neubauer ruling and total number calculated by correcting for total volume of cells and trypan 
blue dilution factor.  Cell viability was generally good with >98% of cells viable in most 
isolations. 
 
2.2.4 Cell Culture 
 
Purified HSC and KC elutriation fractions were washed and re suspended in DMEM containing 
16% foetal calf serum (FCS), penicillin (20mU/ml), streptomycin (20mg/ml) and gentamicin 
(20mg/ml) (PSG).  Cell viability and total yield in this suspension were calculated on a 
hemocytometer (as above).  Cells were seeded at a plating density of 1.33 x10
6 cells/ml on 
uncoated 50ml (25cm
2) plastic flasks (Greiner) in 5ml of culture medium (DMEM, 16% FCS, 
PSG). The cells were maintained in culture in a humidifying incubator at 37°C in 5% CO2.  
The culture medium was changed every 48 hours. 
 
2.2.5 Characterization of Hepatic Stellate Cells 
 
Isolated hepatic stellate cells have a very characteristic morphology under phase contrast 
microscopy (Leitz inverted microscope).  Initially in culture on uncoated plastic, they are round 
cells with few cytoplasmic processes for the first 24 hours after plating.  During the first two 
days they gradually adhere to the plastic, become spindle shaped and develop cytoplasmic 
processes, giving them a more stellate appearance. In addition they contain abundant retinoid 
vesicles within their cytoplasm which permits their identification by autofluorescence under UV 
light.  After further culture on plastic, stellate cells gradually lose their retinoid droplets.  This 
process is widely described as characteristic of their activation into a myofibroblast-like 
phenotype (457;462;465-469) and is associated with expression of desmin and α-SMA 
(457;462;470-474). Having attained this activated phenotype, stellate cells then proliferate so 
that by 7-14 days in the standard culture methods used in this thesis they had reached confluence.  
The rate of morphological transformation in culture was consistently found to be inversely   91
proportional to the initial plating density of viable cells, making it imperative to standardize 
plating density.  In order to assess purity of cell culture, HSC were identified either by vitamin A 
autofluorescence or by indirect immunofluorescence for desmin, whilst contaminating KC were 
identified by staining for endogenous peroxidase (470;472;473;475-478). 
 
2.2.6 Cell Purity 
 
Highly pure populations of rat HSC were obtained as assessed by vitamin A autofluorescence at 
day 2 (>98% n=5), and desmin staining at day 4-7 (>99% n=6) (262).  The major contaminants 
were KC demonstrated by endogenous peroxidase staining at day 2 (<2% n=6) (205).  As HSC 
proliferated at later time points in culture, KC had minimal influence on the purity of HSC.  
 
2.2.7 Pancreatic Stellate Cells Isolation 
 
Materials 
Collagenase P, Roche Diagnostics 
Pronase, Roche Diagnostics 
Deoxyribonuclease, Roche Diagnostics 
Dulbecco Modified Essential Medium (DMEM), Invitrogen Life Technologies, Paisley, UK 
Foetal Calf Serum (FCS), Invitrogen Life Technologies, Paisley, UK 
Hanks Balanced Salt Solution (HBSS) plus calcium (1.4g Calcium Chloride/l), Invitrogen 
Life Technologies, Paisley, UK 
Optiprep, Invitrogen Life Technologies, Paisley, UK 
Penicillin/Streptomycin PSG), Invitrogen Life Technologies, Paisley, UK 
Gentamicin (PSG) 
Trypan blue solution (0.4% w/v) 
 
Rat pancreatic stellate cells extraction in our department was initially performed by Dr. David 
Fine using a modification of the method previously described (479) for the isolation of 
pancreatic acinar cells.  This technique was later modified by a member of the Liver Group, 
Fiona Walker and then by Dr Fanny Shek to enhance the yield and purity of the preparation. 
Pancreata from Sprague-Dawley rats (300g plus) which were sacrificed for other experiments 
were used.  The pancreas was dissected and finely minced and placed in a solution of HBSS 
(containing calcium) with digestive enzymes pronase (1mg/ml) and collagenase P (0.5mg/ml).    92
The pancreas in the digest solution was shaken for 30min at 37º C.  The digested tissue was 
then filtered through nylon mesh [125u John Staniar, UK] and deoxyribonuclease (DNase-
0.1%) was added.  The cell suspension was centrifuged at 1500rpm for 5min to obtain a pellet 
which was then re suspended with Optiprep (Sigma, Poole, UK) 12%v/v in HBSS.  These 
were then placed into a centrifuge tube and a buffering layer of HBSS (2ml) was placed on 
top.  This was centrifuged for 20min at 2000rpm at 4°C.  The stellate cells were collected 
from the band between the Optiprep/HBSS interface.  The cells were pelleted by 
centrifugation (at 500g, for 5min, at 4°C) and re suspended with HBSS in order to remove any 
residue of Optiprep.  The cell suspension was again centrifuged and the pellet obtained was 
re-suspended in DMEM/16% FCS/ PSG.  In order to ensure that cell cultures reached the 
optimum level of growth it is helpful to obtain an accurate cell count and a measure of the 
percentage viability of cell population.  Cell counting was done using a hemocytometer and 
cell viability assessed using trypan blue.  The viable cells are round, refractive and relatively 
small compared to the dead cells which are larger, crenated and non-refractive.  Trypan blue 
is a stain that can cross membranes of non-viable cells and it ensures quantitative analysis of 
the condition of the cells.  A mixture of 75µl cell suspension and 25µl of trypan blue solution 
(0.4%) was slowly drawn into the chamber slide by capillarity.  Using the low power of a 
light microscope the number of cells was counted (stained and unstained) in a 1mm
2 area.  
The cell number and the viability percentage can be analyzed.  The cells were then plated out 
onto either plastic culture flasks and onto Nunc-chamber slides (Lab-Tek®) at density of 100, 
000 per ml.  The cells were maintained in DMEM containing 16% foetal calf serum and 4% 
PSG at 37°C in a humidifying incubator with 5% CO2.  The culture medium was replaced 
every 48 hours.  Regarding human PSC isolations, ethical approval was sought from the 
South West Ethics Committee.  Patients undergoing pancreatic resections would be 
approached for consent for the pancreatic tissue in order to obtain the cells.  Once consent was 
obtained the resected pancreatic tissues were to be used to isolate PSC in a similar fashion to 
rat HSC preparation. 
 
2.2.8 Trypsinization and Passaging Of Pancreatic Stellate Cells 
 
Materials 
Cultured rat or human pancreatic stellate cells 
DMEM, Invitrogen Life Technologies, Paisley, UK 
FCS, Invitrogen Life Technologies, Paisley, UK   93
HBSS (calcium-free), Invitrogen Life Technologies, Paisley, UK 
PSG (Penicillin, Streptavidin, Gentamicin) 
10x trypsin ethylenediaminetetraacetic acid (EDTA), Santa Cruz Biotechnology, Santa Cruz, 
California, USA. 
 
A confluent monolayer of PSC was harvested by trypsinization.  The cells were washed at 
least 5ml HBSS to remove any residue serum and the cells were detached from the plastic 
flask by exposing the cells to TEDTA (1ml-1x) in HBSS at 37 ºC for 5 min.  Once the cells 
were detached from the flask, TEDTA was inactivated with 1ml of 100% FCS. The detached 
cells were collected into 50ml conical flasks and centrifuged (1,500rpm, 7 min, 4 ºC). The 
pellet was then re suspended in 2ml of complete DMEM containing the concentration of cells 
was determined with a haemocytometer and the cells re-plated according to the required 
concentration. 
 
2.2.9 Preparation of conditioned media 
 
To obtain the serum free conditioned media required for many of the experiments described in 
this thesis HSC (rat and human) and PSC (rat and human) that had been cultured for varying 
times in serum containing media were washed three times in serum free DMEM with pre-
incubation in serum free media for 1 hour following the final wash. The cells were then 
incubated in half of their original volume of fresh serum free media containing antibiotics 
(Penicillin, Streptomycin and Gentamicin or PSG) and 0.01% BSA for 24 or 48 hours. The 
media were then collected and clarified by centrifugation at 2,000rpm for 5 min and the cell 
monolayers lysed by the addition of guanidinium isothiocyanate (GIT) for RNA extraction or 
used for analysis of DNA content. 
 
2.2.10 Trypsinization of adherent cells 
 
Trypsinization of adherent cells was performed by washing the monolayer three times in 
calcium free HBSS before briefly exposing the cells to 1 x TEDTA in HBSS pre-warmed to 
37
0C. The duration of exposure required to detach the cell monolayer was determined by light 
microscopy but was usually between 2 and 5 min. Once detached a small volume 
(approximately 5% by volume) FCS was added to the HBSS to inactivate the TEDTA and the 
cells were immediately pelleted by centrifugation and re suspended in DMEM supplemented   94
with 16% FCS and 4% PSG. The required plating density was achieved by determination of 
the total number of cells/ml using a haemocytometer, as described above. 
 
 
2.3 Extraction, Purification and Analysis of RNA 
 
2.3.1 Extraction of RNA 
 
Materials 
Diethyl-pyrocarbonate (DEPC) treated water* 
4M GIT* containing β-mercaptoethanol 
2M sodium acetate pH 4.0 
Phenol 
Chloroform/isoamyl alcohol (49:1 by volume) 
Phenol/chloroform/isoamyl alcohol (25:24:1 by volume) 
3M sodium acetate pH 6.0  
Isopropanol 
75% ethanol (in DEPC treated water) 
Agarose 
Ethidium bromide (1mg/ml) in DEPC treated water 
Formaldehyde (37% volume/volume, v/v) 
10 x MOPS (3-(N-Morpholino) propanesulphonic acid)* 
RNA loading buffer* 
20 x salt sodium citrate (SSC)* 
Sodium hydroxide 
Hybond-N (Amersham) 
 
2.3.2 General precautions for working with RNA 
 
RNA is extremely susceptible to degradation by ubiquitous ribonucleases (RNase) that are 
themselves comparatively resistant to degradation. To minimize this problem the following 
precautions were taken with all RNA work to avoid the loss of RNA integrity. Gloves were 
worn at all times as skin is a major source of RNase, and dedicated glassware used which had 
been baked for 5 hours at 200
0C. Water was pre-treated overnight with DEPC, which 
modifies tyrosine residues and hence inactivates any RNase present and autoclaved (to   95
inactivate the DEPC by degrading it to ethanol and CO2) prior to use (480). Stock solutions 
were prepared from DEPC treated water and molecular biology grade reagents. Any solutions 
or instruments unsuitable for DEPC treatment were autoclaved and non-disposable plastic 
ware including electrophoresis equipment was soaked in 0.5M sodium hydroxide and rinsed 
in deionized (dI) water prior to use. All tips and microcentrifuge tubes were autoclaved prior 
to the procedure. Total RNA was extracted, purified and separated by electrophoresis on a 
denaturing agarose gel, after which it was transferred to a nylon membrane (Northern 
blotting) to permit the detection of specific messenger ribonucleic acid (mRNA) signal by 
hybridisation with radiolabeled complementary DNA (cDNA) probes. 
 
2.3.3 Preparation of GIT lysate 
 
1ml of 4M GIT containing β-mercaptoethanol was added to 75cm
2 flasks of confluent 
cultured HSC (with the volume being varied for sub-confluent cultures or different sizes of 
flasks). The cells bathed in GIT were vigorously agitated on an orbital shaker shaker 
(Beckman) to lyse the cells and denature proteins including RNase. To extract RNA from 
whole liver, approximately 0.5 grams (g) of snap frozen was rapidly homogenised in 5ml GIT 
using a pre-autoclaved polytron homogenizer probe. The tissue homogenates were then 
centrifuged to remove debris and aliquoted. The cell lysates and tissue homogenates were 
stored at -70
0C until required for RNA isolation. 
 
2.3.4 RNA extraction by the acid phenol method 
 
Total RNA was extracted from GIT lysates using a modification of the method described by 
Chomczynski and Sacchi (481). To each 900µl aliquot 90µl of 2M sodium acetate pH 4 was 
added at room temperature and mixed rapidly, followed by 900µl of phenol and 100µl 
phenol/chloroform/iso-amyl alcohol. The suspension was mixed thoroughly by inversion and 
incubated for 15 min on ice. This ensures separation of nucleic acids that, because of their 
phosphate backbone, are strongly negatively charged and will therefore accumulate into an 
aqueous environment where these charges are solvated. Proteins, carbohydrates and lipids 
contain charged and uncharged as well as hydrophobic and hydrophilic regions, and will thus 
accumulate in either a hydrophobic (organic) environment or at the organic/aqueous interface 
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After centrifugation (14,000rpm, 15 min, 4°C), the upper, aqueous phase, of the samples was 
transferred to a fresh tube, 700µl of phenol/chloroform/IAA added and mixed by inversion 
prior to a further incubation on ice for 10 min to ensure the complete removal of proteins 
from the RNA preparation. The supernatant obtained after aqueous/organic phase separation 
by centrifugation (14,000 rpm for 5 min at 4°C) was removed to a fresh micro centrifuge tube 
and 1/20 volume of 3M sodium acetate pH 6 was added and mixed gently. The RNA was then 
precipitated by addition of a 1:1 volume of ice cold isopropanol for at least 1 hour (or 
overnight) at -70°C. 
 
The RNA precipitated in this reaction was recovered by centrifugation at 14,000 rpm at 4°C 
for 20 min, washed twice in 75% ethanol and dried at 65°C on a heater block.  The pellets 
were re suspended in between 20-50µl DEPC treated water and dissolved by heating to 65°C 
for 10 min.  
 
The yield and purity of total RNA was determined by measuring the optical density (OD) at 
260 nanometres (nm) and 280nm.  The integrity of the RNA samples was confirmed by 
electrophoresis through denaturing agarose gels of 2µg aliquots of each RNA sample and 
subsequent visualisation of the 28 S and 18 S ribosomal RNA bands with UV light (section 
2.3.4). Once purified, any RNA not immediately used was aliquoted and stored at -70°C until 
needed. 
 
2.3.5 Electrophoresis of RNA 
 
A 1% horizontal denaturing agarose gel was prepared by dissolving the appropriate amount of 
agarose in 1 x MOPS/DEPC treated water by heating in a microwave oven (Panasonic). After 
allowing cooling, formaldehyde (to give a final concentration of 2.2M) was added and the gel 
cast. Formaldehyde disrupts the secondary structure of RNA and therefore allows accurate 
estimation of the size of RNA molecules. 
 
10µg aliquots of RNA (calculated from the O.D. reading at 260nm), were mixed with an 
equal volume of RNA loading buffer and heated to 65°C for 10 min to denature the RNA. 
Immediately prior to loading 1µl of ethidium bromide (1mg/ml, which intercalates with the 
stacked bases of nucleic acids) was added to the samples to permit visualisation of the pro- 
and eukaryotic ribosomal RNA bands under UV light. In addition to a large increase in   97
fluorescence of the ethidium bromide molecule binding, which is the basis of its use as a stain 
of DNA in gels, the binding causes a local unwinding of the helix by around 26
oC. 
DNA/RNA is stained by the inclusion of ethidium bromide in the gel, or by soaking the gel in 
a solution of ethidium bromide after electrophoresis. The DNA shows up as an orange band 
on illumination by UV light. 
 
The samples were subjected to electrophoresis at 100V for 1-2 hours using 1 x MOPS as 
electrophoresis buffer. RNA molecular weight markers (Promega) were run concurrently. 
After electrophoresis, the gel was viewed under UV light to check for any evidence of 
degradation of the ribosomal bands. 
 
2.3.6 Northern Blotting 
 
RNA was transferred immediately after electrophoresis to a nylon membrane by overnight 
capillary elution (Northern blotting). Prior to transfer the gel was rinsed in DEPC treated 
water for 10min to remove the formaldehyde. It was then rinsed in 50mM sodium hydroxide 
for 20min which improves both the speed and efficiency of transfer by partially hydrolysing 
the RNA. After a further rinse in DEPC treated water the gel was soaked in 10x SSC for 
20min. 
 
Transfer to a nylon membrane (Hybond-N) was achieved using a conventional gel-blotting 
apparatus using 10x SSC as the transfer buffer, with the objective being to draw liquid from 
the reservoir through the gel and the membrane so that RNA molecules were eluted from the 
gel and deposited on the membrane. After transfer the membranes were then air dried and 
exposed to low doses of UV irradiation for 5min to immobilise the nucleic acids through the 
formation of cross-links between a proportion of the bases in the RNA and the amine groups 
on the surface of the membrane. 
 
2.3.7 Hybridisation of Northern Blots with Radiolabeled cDNA Probes 
 
Radiolabeled, random primed cDNA probes were prepared using Amersham’s MegaPrime
TM 
DNA labeling kit. The probes were hybridised overnight with membrane bound RNA on the 
Northern blots. 
 
Materials   98
Hybridisation buffer (“Ultrahyb” Amersham) 
Mega prime 
TM cDNA labeling kit (Amersham) 
[α-
32P] deoxyadenosine triphosphate (dATP, Amersham) 
Template DNA (Section 2.5.4 or 2.6.1.2) 
DEPC treated water* 
Sephadex G-50 
SSC 
 
2.3.8 Pre-Hybridisation of Northern Blots 
 
The membrane, RNA side facing in, was pre-hybridised for 2-3 hours with hybridisation 
buffer at 42
0C in a rotating hybridisation oven (Hybaid). The inclusion of blocking reagent, 
herring sperm DNA and Denhardt’s reagent in the buffer ensured efficient blocking of non-
specific binding sites. Additionally, to maximise the rate of annealing of the probe with its 
target the ionic strength of the hybridisation buffer was high. In experiments where the 
mRNA signal of interest was suspected to be weak Ultrahyb hybridisation buffer was 
sometimes used. 
 
 
2.3.9 Radiolabeling Of cDNA Probes By Random Priming 
 
Random priming is an efficient and simple method to make short cDNA probes. The system 
uses random sequences of hexanucleotides to prime DNA synthesis onto a DNA template that 
has been denatured by heating, with a radioactive nucleotide being substituted into the copy. 
The Klenow reagent extends the primers to create multiple short length (150-200bp) 
complementary sequences radiolabeled with 
32P. 0.1µg of template DNA (Amersham, 
Promega) was added to 5 µl of primer and an appropriate volume of DEPC treated water, to 
give a final reaction volume of 50µl. The DNA was denatured by heating to 95
0C for 5 min, 
as the solution cools the primers anneal in a random fashion with the template. The following 
were then added to the reaction mixture: 5µl reaction buffer, 4µl of each unlabeled nucleotide 
(dCTP [deoxy cytosine triphosphate}, dTTP [deoxy guanine triphosphate], dGTP [deoxy 
thymine triphosphate]), 5µl [α-
32P] dATP (800Ci/mmol) and finally 2µl Klenow fragment 
(lacking 5`-3` exonuclease activity). After mixing, the solution was incubated for 1 hour at 
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Unincorporated [α-
32P] dATP was separated from radiolabeled probes by centrifugation over 
a Sephadex G-50 column. The purified probe was collected in a microfuge tube and denatured 
by heating to 95
0C for 5 min. The heated probe was added to fresh hybridisation buffer and 
immediately exchanged with the pre hybridisation solution. The blot was left to hybridize, 
rotating overnight at 42°C. If the probe and target are 100% identical in sequence, then high 
stringency hybridization can be carried out. The stringency in the hybridization temperature 
and the salt concentration in the hybridization buffer (high temperature and low salt is more 
stringent as only perfectly matched hybrids will be stable). Formamide can be included in the 
hybridisation buffer to reduce the actual hybridization temperature by about 25
oC, from the 
more usual 68
oC to the more convenient 43
oC. Northern blots give information about the size 
of the mRNA and any precursors and can be useful to determine whether a cDNA clone used 
as a probe is full length or otherwise. 
 
 
2.3.10 Stringency washing of Northern blots 
 
After hybridisation, the membrane was washed under stringent conditions to remove unbound 
probe. Any unstable non-specific hybrids with few hydrogen bonds are then disrupted by high 
temperature, low salt conditions. 
 
The membrane was washed for 15 min in 0.2 x SSC/0.2% sodium dodecyl sulphate (SDS) at 
42
0C in the rotating hybridisation oven and then again washed twice for 15 min at 55°C in the 
same solution. Membranes that had been hybridised using Ultrahyb required stringency 
washing in different conditions at 42
0C, namely, 2 x 5 min in SSC / SDS, then 2 x 15 min in 
SSC/SDS. 
 
2.4 Reverse Transcription- Polymerase Chain Reaction (RT-PCR) of Messenger RNA 
Sequences 
 
RT-PCR was used to detect RNA. This is a very efficient reaction and is able to detect 
specific mRNA with a sensitivity of less than one part of 10
8.  A complementary copy of the 
double stranded DNA (cDNA) can be synthesized from total RNA in a 5` to 3` direction using 
reverse transcriptase ( RNA dependent DNA polymerase), together with oligo(dT)15 primer.  
The cDNA was then subjected to PCR which requires 2 primers (a sense and antisense) to 
flank the specific DNA region to be amplified. A heat stable DNA polymerase, Thermus   100
aquatics (Taq) was used to synthesize the extension of the products which are complementary 
to the primers.  Repeated cycles of denaturation, priming and extension caused the rapid 
accumulation of the target fragment. 
 
2.4.1 Synthesis of Double Stranded DNA Copy 
 
Materials 
Deoxynucleotide triphosphate mixture (dNTP) – 100mM diluted to 10mM with DEPC water 
Moloney murine leukaemia virus (M-MuLV) reverse transcriptase, Promega 
Random Hexamers 
Reaction buffer (5x), Promega 
Ribonuclease inhibitor (RNasin), Promega 
Total RNA 
 
The total RNA (2µg) was reverse transcribed by mixing the RNA sample with the following: 
dNTP (10mM), random hexamers (2µl), 5x reaction buffer (4µl), M-MuLV reverse 
transcriptase (20units/µl- 0.1µl), Rnasin (1unit/µl) and the total volume made up to 20µl of 
DEPC treated water.  In the negative control tube, RNA sample was replaced by DEPC 
treated water.  The mixture was then incubated at 37°C for 60 min with the reaction 
terminated by heating the mixture up to 95°C for 2 min.  The reaction mixture was then made 
up to 100µl with DEPC treated water.  The cDNA sample can then be stored at -20°C until 
required. 
 
2.4.2 Polymerase Chain Reaction 
 
Contamination of PCR was avoided by preparing the process in a hood which was UV 
radiated prior to use.  PCR dedicated pipettes and filtered tips were used at all times. 
 
Materials 
Ultra- high Quality water 
Sample of cDNA 
Taq polymerase, Promega, UK 
10x DNA polymerase buffer, Promega, UK   101
dNTP mixture (100mM diluted to 10mM), Promega, UK 
Magnesium Chloride (50mM) 
PCR markers & Specific PCR Primers, Oswell Laboratories. 
For each PCR, 25µl of “master mix” was required containing 10x DNA polymerase (2.5µl), 
Taq Polymerase (0.2µl), dNTP mixture (1µl), forward primers (0.5µM), reverse primer 
(0.5µM) and an optimum concentration of magnesium chloride.   PCR reactions are very 
sensitive to magnesium ions and the optimum concentration (0.8-2.0mM) must be established 
for each pair of primers.  If the magnesium concentration is too low, the primers may 
hybridize non-specifically leading to non-specific fragments however, if the concentration is 
too high the primers will form stable hybrids and no products will be seen.  The tubes were 
placed in an automated PCR cycling apparatus (Perkin Elmer Gene Amp PCR system 2400) 
with a programmable incubation blocks with heated covers.  The temperature, incubation time 
and numbers of cycle can be set accordingly.  Cycling conditions for each PCR were adjusted 
to ensure efficient and accurate amplifications of the desired template.  The following 
parameters were considered for each PCR reaction; the optimum temperature at which Taq 
polymerized, the annealing temperature of the primers, the temperature for the dissociation of 
the cDNA and finally the numbers of cycles of annealing, extension and dissociation of the 
strand.  The products of the PCR reaction were analyzed on a 1.5% agarose/TAE gel (Section 
2.5.3). A PCR molecular weight marker was included in the gel to enable the size of the 
amplified cDNA to be measured. 
 
The membranes were then wrapped in cling film and exposed to either pre-flashed blue 
sensitive x-ray film (Genetic Research Instruments) for 24-72 hours at -70°C or to a Storm 
phosphor screen (Kodak) for 2-24 hours at room temperature which was then developed using 
a Storm phosphor screen image analyser (Molecular Dynamics).  Autoradiographs and Storm 
images were quantified by scanning densitometry. 
 
The membrane was kept moist at all times to enable it to be probed sequentially for a number 
of different mRNA transcripts; this prevented each probe from becoming too tightly bound. 
On completion of experiments, the hybridised probe was removed by immersing the 
membrane in boiling DEPC treated water for 15 min.  To confirm that the probe was 
completely removed, the membrane was again exposed to X-ray film.   102
2.5 Ribonuclease Protection Assays 
 
The ribonuclease protection assay (RPA) is a sensitive method used to detect and quantify 
specific mRNA transcripts in a complex mixture of total RNA or mRNA molecules (482) The 
procedure is straightforward in theory though demands focused attention in the laboratory. 
(Figure 2.1 below). An RNA probe is synthesized through an in vitro transcription reaction. 
These probes must be complementary to the gene sequence of interest and incorporate either 
radioactive or biotinylated nucleotides. The labeled probe is then incubated with a sample of 
total RNA or mRNA to facilitate hybridization of the complementary region of interest to the 
labeled probe. After hybridization, the mixture of single-stranded RNA and double-stranded 
probe-target hybrid is treated with ribonuclease (RNase), which digests all single-stranded 
RNA but no double-stranded RNA molecules. As a result, only the double-stranded gene 
target of interest remains. Usually, the sample is electrophoresed on a denaturing TBE-urea 
polyacrylamide gel and detected by methods specific to the label on the probe (483). 
 
Ribonuclease protection assays (RPA) were used to detect various mRNA transcripts of 
interest, particularly when examining mRNA expression in whole liver as it is more sensitive 
than Northern analysis (484).  This is partly because larger amounts of RNA can be loaded 
(up to 100 µg) and also because hybridisation occurs in solution thus ensuring that the 
maximum number of hydrogen bonds are available. RPA is not as sensitive as RT-PCR but is 
amenable to quantitation of mRNA expression which is not the case for PCR based methods, 
unless all the reactions have appropriate internal standards that are co-amplified and any 
quantitation measurements are restricted to the exponential phase of the reaction. The various 
methods can thus provide complementary information on the expression of mRNAs of 
interest.  
 
The principles of the assay are that the target mRNA is hybridised in solution with a single 
stranded radiolabeled antisense RNA probe (riboprobe).  In the presence of excess riboprobe, 
the number of probe-mRNA hybrids will be proportional to the amount of target mRNA in 
the sample. Following hybridisation, the mixture is treated with RNase to digest any single 
stranded RNA or redundant probe, whilst the double stranded probe-target mRNA hybrids are 
‘protected’.  After inactivation of the RNase the protected fragments are ethanol precipitated, 
suspended in formamide loading buffer and separated on a denaturing polyacrylamide gel. 
Once the gel has been dried the relative abundance of the protected fragment can be visualised   103
by autoradiography and quantitated by scanning densitometry. These steps are summarised 
diagrammatically in Figure X above. The first step of the assay involves the transcription of 
antisense riboprobes that were synthesised from the relevant cDNA that had been inserted 
into plasmids.   104
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2.5.1 Preparation of Radiolabeled Antisense Riboprobe 
 
To transcribe an antisense riboprobe, transcription must proceed from the 3` to the 5` end of 
the cDNA.  Conversely sense riboprobes, identical to the target mRNA and hence non-
complementary, are made from the 5` to the 3` end.  All riboprobes were generated from 
cDNA in plasmids in which the target sequence was flanked by RNA polymerases. Once a 
RNA polymerase has bound to its recognition sequence the enzyme moves along the template 
synthesizing RNA until it either runs out of substrate or reaches the end of the template. Thus, 
to prevent the production of excessively long riboprobes, including some of the plasmid 
sequence, the insert must be completely linearized using restriction enzyme digests as 
described in section 2.6.3. Linearization was confirmed by subjecting a sample of the 
restriction digest to electrophoresis on an agarose/TAE gel (section 2.6.3).  
2.5.2.2 The linearized DNA was then purified by phenol/chloroform extraction and ethanol 
precipitation before being used for the synthesis of riboprobes. 
 
Materials 
DEPC treated water* 
Phenol/chloroform/isoamyl alcohol (49:1 by volume, pH 7.0) 
3M sodium acetate (pH 7.0) 
Isopropanol 
75% ethanol 
Riboprobe In Vitro Transcription Kit (Promega) [rNTP mix (0.2mM UTP, 2.5mM  
CTP, 2.5mM ATP and 2.5mM TTP), 100mM DTT, 5 x transcription buffer, RNA 
polymerases, RNasin Ribonuclease inhibitor, RNase Free DNase] 
[α-32P] α-32P (Amersham) 
 
2.5.2 Phenol chloroform extraction of cDNA templates 
 
To 220µl of plasmid digest 300µl of DEPC treated water and 500µl of phenol/ 
chloroform/isoamyl alcohol were added, vortexed and incubated on ice for 5 min. After 
centrifugation at 14,000g for 10 min at 4
oC, the upper aqueous phase was transferred to a 
clean microfuge tube, 50µl of 3M sodium acetate and 900µl of isopropanol were added and 
mixed and the DNA precipitated overnight at -70
0C. The DNA was pelleted by centrifugation 
(14,000g for 15 min at 4
0C) and the supernatant discarded. The pellet was washed twice with   106
70% alcohol, dried and re suspended in DEPC treated water. The DNA was quantified by 
measuring the OD at 260nm and the integrity checked by running a sample on a 1% agarose / 
TBE gel (section 2.5.3).  
 
2.5.3 In Vitro Transcription of Radiolabeled Antisense Riboprobe 
 
To 1µg of linearized template 4µl of 5x transcription buffer, 2µl of 100mm DTT and 4µl of 
2.5mm dNTP mix were added, mixed and heated to 65
oC for 10 min to enhance the inhibition 
of RNase by DTT. Then 1µl of the appropriate RNA polymerase (see Table 2.1), 0.5µl of 
RNasin Ribonuclease inhibitor and 5µl of [α-32P] dUTP were added and the mixture 
incubated at 30
oC for 1 hour to permit transcription of the RNA. RNase free DNase was then 
added to a concentration of 1U/µg of template DNA and the mixture heated at 37
oC for 45 
min. This digests the template DNA, leaving radiolabeled RNA only. The mixture was then 
heated to 65
0C for 10 min to inactivate the polymerase and the volume increased to 150µl by 
the addition of DEPC treated water.   
 
The riboprobes were precipitated by the addition of 500µl 0.3M sodium acetate, 500µl 
isopropanol with 20µg tRNA, as a carrier, and incubated at -70
oC for 2 hours.  Samples were 
then centrifuged at 14000 rpm for 15 min at 4
oC, the pellet washed twice in 75% ethanol and 
dried at 65
oC.  The riboprobe was then re suspended in 50µl DEPC water. The integrity of the 
riboprobe was assessed by running 5µl on a denaturing 1% agarose/MOPS gel (section 2.3.4) 
and autoradiography see figure 5.4. Scintillation counting (1µl probe in 4ml water) was used 
to determine the radioactivity of the probe. 
 
2.5.4 Protocol for Ribonuclease Protection Assay 
 
Materials 
Ribonuclease Protection Assay Kit (Promega) (Yeast tRNA, RNase ONE) 
DEPC treated water 
RPA Hybridisation buffer* 
RNase digestion buffer* 
RPA Stop solution* 
RPA Gel loading buffer* 
100% / 75% ethanol 
‘Sequi-Gen’ Vertical Sequencing apparatus (Bio-Rad)   107
1% SDS 
Sigmacoat 
Acrylamix (Promega) 
10% Ammonium Persulphate (APS) 
TBE 
3MM filter paper (Whatmann) 
 
 
2.5.5 Sample Preparation 
 
10-50µg of sample RNA or yeast tRNA (negative control) was mixed with 30µl of 
hybridisation buffer and 10
5 cpm of 
32P-UTP radiolabeled riboprobe. The samples were 
heated to 95
0C for 5 min to denature the probe and target mRNA at 42
0C.  Following 
overnight hybridisation un-hybridised probe and non-target RNA were digested by the 
addition of 270µl of ribonuclease digestion buffer containing 10U RNase ONE to each 
sample and incubated at 37
0C for 45 min. The reaction was terminated by the addition of 30µl 
of RPA stop solution (containing yeast tRNA as a carrier and SDS to inactivate RNase ONE) 
and the protected fragments precipitated by the addition of 800µl of ice cold 100% ethanol 
and incubation at -70
0C for 1 hour. The protected RNA-probe fragments were pelleted by 
centrifugation at 14,000g for 15 min at 4
0C and washed once with 75% ethanol before being 
re suspended in 8µl of RPA loading buffer. The samples (including 10
3 probes in RPA 
loading buffer) were heated to 95
oC to denature the RNA, loaded onto a 7M urea 
polyacrylamide gel and subjected to electrophoresis. 
 
2.5.6 Resolution of Protected Fragments on Polyacrylamide Urea Gels 
 
Gels were cast in ‘small’ (maximum 20 samples) or ‘large’ (maximum 40 samples) vertical 
sequencing apparatus. Prior to assembly the equipment was washed sequentially with 1% 
SDS, DEPC treated water and 100% ethanol and the back plate was sialinised with Sigmacoat 
to prevent the gel from sticking and make removal easier. Two gels were made, the first a 
sealing gel to seal the plates and the second a 5% sequencing gel, using materials as detailed 
in Tables 2.1 and 2.2 respectively 
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Table 2.1 Sealing gel materials 
 
  small  large 
Acrylamix (ml)  10  20 
10% APS (µl)  80  160 
 
Table 2.2 5% Sequencing gel materials 
 
  small  large 
Acrylamix (ml)  42  84 
7M Urea (ml)  8  16 
10% APS (µl)  400  800 
 
Once the sequencing gel had polymerised the electrophoresis apparatus was assembled, pre-
warmed TBE added and the gels deionised by pre-running at 50
oC at 1.5-1.8kV for 30 min. 
The prepared samples were added and separated by electrophoresis at 50-55
oC for 
approximately 60-90 min. Following electrophoresis the gel was transferred to a backing of 
3MM filter paper, covered with cling film and vacuum dried. The dried gel was exposed to X-
ray film at -70
oC or to a Storm phosphor screen and the resulting bands analysed by scanning 
densitometry. 
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2.6 Amplification, Purification and Analysis of Plasmid DNA 
 
The full-length cDNA (rat TIMP-1, rat TIMP-2, rat α1 chain procollagen –1) used in this 
thesis were obtained from Professor John Iredale and Dr Chris Benyon and were contained in 
a variety of plasmids. All the plasmids were contained in an ampicillin resistance gene to 
allow for selection of successfully transformed RNase.  Plasmid DNA can be isolated and 
purified for use as a template. I performed all the plasmid preparations myself in terms of 
amplification, purification and analysis of plasmid DNA. 
 
Materials 
Plasmid DNA (rat TIMP-1, pGem 7 containing the full length cDNA) (286) 
Competent E. coli DH5α, Promega, Southampton, UK 
Ampicillin 
Luria-Bertani (LB) Medium* 
Terrific Broth* 
Glycerol 
 
Sterile technique was used throughout the procedure.  Plasmid DNA (2-10 ng) was added to 
100µl of competent E coli. The cells were placed in a water bath at 42
0C for 2 min to promote 
the uptake of the DNA into the bacteria. The cells were then transferred to ice.  This allows 
the repair of membranes and the cells to recover from the transformation.  LB medium 
(100µl) was added to the cells and then it was spread onto the agar plates and left overnight at 
37
0C to allow colonies to grow.  The inclusion of the ampicillin allows for the selection of 
transformed cells. 
 
The following day a single transformed colony was selected and placed in 10 ml of Terrific 
Broth (containing ampicillin 50µg/ml to maintain selection) and left overnight at 37
0C in a 
shaking incubator.  Plasmid stocks were maintained by storing 1ml aliquot of the broth in -
70
0C.  A Miniprep was performed to ensure that the transformation was successful (see 
below) once confirmed, 1ml of the culture was added to 200ml of Terrific broth (contain 
ampicillin) and grown again overnight at 37
0C in a shaking incubator.   110
2.6.1 Purification of Plasmid DNA 
 
Plasmids were isolated and purified using the QIAGEN Mini and Maxi Plasmid Purification 
Systems. Briefly the purification system is based on the modified alkaline lysis procedure.  
The bacteria are lysed in an alkaline buffer followed by neutralization by the addition of 
acidic potassium acetate and the subsequent high salt concentrate causes the SDS to 
precipitate with the denatured proteins, chromosomal DNA and cellular debris trapped in a 
salt-detergent complex, whilst the smaller plasmid DNA remains in solution.  The precipitated 
debris is removed and washed away whilst the plasmid DNA under low salt conditions binds 
to the anion-exchange resin which can then be eluted in a high salt buffer and concentrated by 
isopropanol precipitation.  The plasmids DNA for all the templates are made using the 
protocol described in the Qiagen Maxi prep and Miniprep manufacturer’s handbook.  Once 
the DNA pellet was obtained, the DNA was quantified by measuring the OD at 260nm and a 
restriction digest performed to release the required cDNA. 
 
2.6.2 Restriction Enzyme Analysis of Plasmid DNA 
 
The desired cDNA were isolated by using restriction enzymes digest and the digested DNA 
products analyzed using a gel electrophoresis. 
 
Materials 
DNase free water 
10x Multicore buffer, Promega, Southampton, UK 
Restriction Enzymes: 
Rat TIMP-1 (648 bp) – EcoR 1, KpN 
Rat α-1 procollagen (470 bp) – EcoR 1, HIND III 
DNA ladder, (Promega) 
 
For every µg of plasmid DNA, 5 units of the appropriate restriction enzymes and 0.1 x 
volume of multicore buffer were added and the mixture was made up to 100 µl with DNase 
free water.  A negative control of uncut plasmid was included whereby the restriction 
enzymes were replaced by water.  The mixture was incubated at 37°C for 16 hours.  Equal 
aliquot of DNA digests were then separated on a 1% agarose/TAE gel (Figure 2.1).  The 
separate desired DNA can be purified from the agarose gel using QIA quick gel extraction   111
kits.  This kit is based on the fact that in the presence of high salt buffers and a pH<7.5, DNA 
are adsorbed onto a silica-gel membrane whilst the contaminants can be washed away. The 
purified product can be eluted from the membrane with water.  The purified DNA could then 
be used to synthesize random prime cDNA probes (see section 2.4.4.b). 
 
 
2.6.3 Preparation of Plasmid DNA for cDNA Probes, Riboprobes, Transfections, and 
Nuclear Run Ons 
 
Whilst a great deal of work was performed on nuclear run ons during my research time this 
was unsuccessful. The methods are outlined briefly in Appendix II. 
 
2.6.4 Amplification, Purification and Analysis of Plasmid DNA 
 
 
Throughout this thesis experiments incorporated the use of full or partial-length 
complementary DNA (cDNA) which were obtained from a variety of sources and were 
contained within a variety of plasmids.  Plasmids are autonomously replicating DNA 
incorporated, in this case, within DH5α Escherichia coli (E. coli) unless otherwise stated, 
which replicate independently from chromosomal DNA (original genome) and which form 
recombinant DNA.  Propagation of the host organism containing the recombinant DNA forms 
a set of genetically identical organisms, or a clone.  Subcloning described later involved the 
transfer of a fragment of cloned DNA from one vector to another.  All the plasmids used 
contained an ampicillin resistance gene which facilitated the selection of E coli that had been 
successfully inserted into the relevant plasmid (transformation). The plasmid DNA was then 
isolated and purified for use as a template e.g. for riboprobe.  All plasmid stocks were 
produced by the propagation of transformed competent DH5α E. coli – a long term frozen 
bacterial stock of clone obtained from Promega. 
 
2.6.5 Production of competent cells (DH5α E. coli) 
 
A bacterial culture of untransformed DH5α E. coli (Promega) was streaked out on to a fresh 
Lauria Bertani (LB) agar plate to incubate overnight at 37
0C.  One colony was then taken and   112
10ml of LB media was inoculated and grown in static culture overnight at 37
0C.  1ml from 
this was taken to inoculate 30ml of LB media and placed in an orbital shaker at 37
0C.  The 
incubation proceeded until the absorbance of the overnight static culture reached 0.4-0.5 at 
550nm using sterile LB media as a control, 1ml samples were taken every 15-20 min (usually 
the total time taken was around 2hrs) 
 
The sterile culture was then transferred to sterile centrifuge tubes and placed on ice for 15 
min.  All subsequent steps were carried out at 4
0C.  First the cells were centrifuged at 2000g 
for 10 min whereupon the supernatant was discarded and the pellet re suspended in a solution 
of RFI equal to 1/3 the volume before the supernatant was discarded.  This solution was 
incubated on ice for 15 min before being centrifuged at 2000g for 10 min.  The supernatant 
was again discarded and re-suspended to 1/12.5 the original volume with RF2.  These cells 
were then transformed and could be used directly for transformation or frozen at –70
0C.  
DH5α E. coli were tolerant to slow freezing. 
 
2.6.6 Transformation and Amplification of competent Escherichia coli (E coli) with 
Plasmid DNA 
 
Materials: 
Plasmid DNA 
Competent E Coli DH5α (Promega) 
Ampicillin 
Luria-Bertani (LB) Medium 
Terrific Broth 
Glycerol 
 
Fresh LB plates were prepared.  Ampicillin was added to give a final concentration of 
50µg/ml and the media poured into sterile 90mm petri dishes and allowed to set.  Sterile 
techniques were employed throughout the procedure.  Between 2-10ng of plasmid DNA in a 
volume not greater than 10µl were added to 100µl of competent E coli and the mixture 
immediately placed on ice (promoting the uptake of DNA into the bacteria).  The cells were 
temporarily permeabilized by heat shock treatment by placing in a pre-heated water bath at 
42
0C for 2 min, which induces enzymes involved in the repair of DNA and other cellular 
components allowing the cells to recover from transformation and thus increase the efficiency   113
of the process. The cells were then incubated on ice for 10 min. The competent cells were 
then allowed to warm to room temperature over five min; an equal volume of LB was added 
before incubating shaking at 37
0C for one hour. It was then spread onto the agar plates and 
left overnight at 37
0C to allow the colonies to grow. The inclusion of ampicillin in the media 
allowed for the selection of transformed cells.  The following day a single transformed colony 
was selected and placed in 10ml of LB or Terrific broth (containing ampicillin 50µg/ml) and 
allowed to grow to stationary phase overnight at 37
0C in a shaking incubator.  Aliquots of 1ml 
were then removed for the preparation of bacterial stocks (see below) to be stored at –70
0C. It 
was possible to isolate sufficient plasmid DNA for initial manipulation from a few ml of 
bacterial culture for example to perform a restriction digest to confirm the identity of the 
plasmid.  Such isolation is normally known as a mini-preparation or “Miniprep” (see below).  
After confirmation that transformation had been successful, the main plasmid amplification 
procedure was performed (“Maxi prep”). For this, 10ml of the culture was added to 100ml of 
LB or 30ml Terrific broth (containing ampicillin) and grown overnight at 37
oC in a shaking 
incubator. 
 
2.6.7 Bacterial Propagation 
 
Materials 
90mm Petri dishes 
Competent E Coli DH5α (Promega) 
Ampicillin 
Luria-Bertani (LB) Medium 
Terrific Broth 
Glycerol 
 
Inoculants from freshly transformed DH5α E coli or from frozen bacterial stocks were 
streaked onto LB ampicillin petri dish plates before incubation overnight at 37
oC in order to 
obtain single colonies.  A single colony (clone) from the plate was used to inoculate a sterile 
conical flask containing 100ml of LB or 30ml of Terrific Broth containing ampicillin.  The 
inoculated broth was incubated overnight in an orbital shaker at 220rpm and 37
oC.  E. coli 
inoculants were centrifuged at 220rpm for 30mins at 4
oC to pellet. 
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2.6.8 Production of Bacterial Stock 
 
Materials 
Plasmid DNA 
Competent E Coli DH5α (Promega) 
Ampicillin 
Luria-Bertani (LB) Medium 
Terrific Broth* 
Glycerol 
 
Transformed DH5α E. coli clones were stored frozen.  One clone from a streaked plate was 
used to inoculate 10ml of LB with ampicillin and incubated overnight at 37
0C.  The inoculant 
was then used to form a bacterial stock by the addition of 0.5ml of sterile 30% v/v glycerol to 
0.5ml of the culture.  The bacterial stock in 15% v/v glycerol was mixed before freezing at -
80
0C. 
 
2.6.9 Purification of Plasmid DNA 
 
Plasmids were isolated and purified using the QIAGEN Mini and Maxi Plasmid Purification 
systems. The QIAGEN plasmid purification protocols are based on a modified alkaline lysis 
procedure (485;486). Briefly, the cell pellet is re suspended in a buffer solution which 
contains lysozyme to digest the cell wall of the bacterium.  The cell lysis solution, which 
contains the detergent sodium dodecyl sulphate (SDS) disrupts the cell membranes and 
denatures the proteins; the alkaline conditions denature the DNA and begin the hydrolysis of 
RNA.  The preparation is then neutralized with a concentrated solution of potassium acetate at 
pH 5.0.  This has the effect of precipitating the denatured proteins, along with the 
chromosomal DNA and most of the detergent (potassium dodecyl sulfate is insoluble in 
water). The resulting high salt concentration causes SDS to precipitate and denatured proteins, 
chromosomal DNA and cellular debris become trapped in the salt-detergent complex, whilst 
the smaller covalently closed plasmid DNA remains in solution. The precipitated debris is 
removed and the cleared lysates applied to the QIAGEN tip. Under low salt conditions the 
plasmid DNA binds to the anion-exchange resin in the tip, whilst any contaminants are 
washed away. The plasmid DNA is then eluted in a high salt buffer and concentrated and 
‘desalted’ by isopropanol precipitation.   115
Materials 
Qiagen Maxi prep / Miniprep Plasmid Purification Systems (buffer P1, buffer P2, buffer 
P3, QIAGEN-tip 500, buffer QBT, buffer QC, and buffer QF) 
Isopropanol 
70% ethanol 
DNase free water 
 
The method below describes the Qiagen protocol for the larger scale Maxi prep. The 
Miniprep protocol was executed according to the manufacturer’s instructions.  The bacterial 
cells were harvested by centrifugation at 6,000g for 15 min at 4
0C. The cell pellet was then re 
suspended in 10ml of buffer P1, an equal volume of buffer P2 was added and the mixture 
allowed to incubate for 5 min at room temperature. 10 ml of chilled buffer P3 was then added, 
mixed by inversion and the mixture incubated on ice for 20 min, allowing the precipitation of 
genomic DNA, proteins and cell debris. The sample was next centrifuged at 20,000g for 30 min 
at 4
0C and the supernatant, containing the plasmid DNA removed and placed in a clean tube. The 
supernatant was re-centrifuged at 20,000g for 15 min at 4
0C and the supernatant again removed 
and placed immediately in a QIAGEN-tip 500, which had been pre-equilibrated by the prior 
addition of 10ml of buffer QBT. The column was then washed twice with buffer QC after which 
the DNA was eluted off by the addition of 15ml of buffer QF. The plasmid DNA was 
precipitated by adding 0.7 x volume of isopropanol, the mixture centrifuged at 15,000g for 30 
min at 4
0C and the supernatant discarded. Both Minipreps and Maxipreps were followed 
according to the manufacturer’s instructions except in the final steps of the Maxi prep 
protocol.  Qiagen advises that the final pellet is spun in a single 50ml conical tube: this step 
was modified to increase the DNA yield by aliquoting the suspended DNA in isopropanol into 
several microfuge tubes (typically 16-18) and subsequent centrifuging took place in a 
microfuge to produce a total yield of around 1 gram of material.  The DNA pellets were then 
washed with 5ml 70% ethanol and centrifuged at 15,00g for 10 min at room temperature. After a 
second wash with ethanol the DNA pellets were dried and re suspended in DI water.  DNA was 
quantified by measuring the OD at 260nm and a restriction digest performed to confirm the 
presence of the cDNA in the amplified plasmid.   116
2.6.10 Restriction Enzyme analysis of Plasmid DNA 
 
The plasmid DNA isolated was examined for its pattern of cleavage by restriction enzymes 
(restriction map) and the size of linear DNA molecules was determined by agarose gel 
electrophoresis using marker fragments of known sizes. 
 
Materials 
DNase free water 
10 x Multicore restriction enzymes (Promega) 
Restriction enzymes (Promega) 
DNA ladder (Promega) 
 
To each µg of plasmid DNA, 5 units of the appropriate restriction enzymes and 0.1 x volume 
of buffer were added. The volume was made up with DNAse free water, ensuring that the 
restriction enzyme contributed less than 10% of the final volume. A negative control of uncut 
plasmid that was treated in an identical way except that the restriction enzymes were replaced 
with water was also included. The mixture was incubated at 37
oC unless otherwise stated for 
at least one to two hours (up to 16 hours) and the resulting cut plasmid was run on a 1% 
agarose TAE gel with appropriate plasmid controls and DNA ladder for estimate of size of cut 
fragments.  To isolate the bulk of the cut DNA all the product was run out in a 1% agarose 
TAE gel and the fragment of interest excised and gel purified. 
 
2.6.11 Purification of DNA or PCR products from Agarose Gels 
 
Materials 
Qiagen QIA quick gel extraction kit: (buffer QG, buffer PE, QIAquick spin column,  
3M sodium acetate), Isopropanol, DNAse free water 
 
DNA subjected to a restriction digest or PCR products were isolated from non-specific 
amplification products by separation in a 1% TAE low melting temperature agarose gel. The 
band of interest was excised quickly to minimise damage to the DNA by UV light. The   117
agarose added to a microfuge tube along with 3 volumes of buffer QG for each volume of 
agarose. The agarose was melted by incubation of the mixture at 50
0C for approximately 10 
min, with frequent vortexing during this period.  An equal volume of isopropanol was added 
to the mixture which was then added to a QIAquick column which contains a silica matrix 
that binds DNA.  The DNA was washed by adding 0.75ml of buffer PE to the column for 5 
min, and then centrifuging twice at 13,000 g for 1 minute.  The column was then placed in a 
clean microfuge tube and the DNA eluted using a 30-50µl DNase free water added to the 
centre of the column, followed by centrifugation at 13,000g for 1 minute.  The purity of the 
resulting DNA fragments was examined by running a small aliquot on a TBE gel with 
appropriate DNA markers to check for contamination. The purified DNA could then be used 
for experiments such as synthesis of random primed cDNA probes.  118
2.7 Transfection Protocols 
 
2.7.1 Transfection techniques: Introduction 
 
The ability to introduce nucleic acids into cells has enabled the advancement of our 
knowledge of genetic regulation and protein function within eukaryotic cells, tissues and 
organisms (487;488).  The process of inserting nucleic acids into cells by non-viral methods is 
known as ‘transfection’.  Advancements in techniques for cloning plasmid DNA now 
provides the means to manipulate DNA sequences and the ability to produce virtually 
unlimited amounts of relatively pure DNA for transfection experiments.  The development of 
reporter gene systems and selection methods for stable gene expression of transferred DNA 
has greatly expanded the applications for gene transfer technology 
 
In 1982 Curran et al, initiated the reporter gene concept with the bacterial chloramphenicol 
acetyl transferase (CAT) gene and associated CAT assay system (489).  Using a reporter gene 
that is not endogenous to the cell coupled with a sensitive assay system for that gene product, 
allows investigators to clone regulatory sequences of interest upstream of the reporter gene to 
study expression of the reporter gene under various conditions.  This technology, together 
with the availability of transfection agents provides the foundation for studying promoter and 
enhancer sequences, trans-acting proteins such as transcription factors, mRNA processing, 
protein/protein interactions, translation, and recombination events.  Following the 
introduction of the CAT gene and assay system several other reporter systems have been 
developed for various in vitro and in vivo applications including luciferase, β-galactosidase, 
alkaline phosphatase and green fluorescent protein. 
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Figure 2.2 Reporter gene systems 
 
 
Figure 2.2 Reporter gene systems.  Integration of DNA into the chromosome, or stable episomal maintenance, 
of reporter genes occurs with a relatively low frequency.  The ability to select for these cells is made possible 
using genes that encode resistance to a lethal drug.  In examining transient expression, cells are typically 
harvested 48-72 hours post transfection for studies designed to analyse transient expression of the transfected 
genes.  Extracts are prepared using a reporter lysis buffer and can then be assayed for luciferase, CAT or β-
galactosidase activity. 
 
2.7.2 Luciferase Reporter Assay System 
 
The reporter genes are often used as indicators of transcriptional activity in cells.  Typically a 
reporter gene is joined to a reporter sequence in an expression vector that is transfected.  
Following transfer the cells are assayed for the presence of the reporter by directly measuring 
the amount of reporter mRNA, the reporter protein itself or the enzymatic activity of the 
reporter protein.  A control vector can be used to normalise the transfection efficiency or cell 
lysate recovery between treatment or transfection experiments (490).  The control reporter 
gene is frequently driven by a strong, constitutive promoter and is co-transfected with 
experimental vectors. 
The luciferase enzyme used here is derived from the coding sequence of the luc gene cloned 
from the firefly ‘Photinus pyralis’ (491-493).  The firefly luciferase enzyme catalyses a 
reaction using D-luciferin and ATP in the presence of oxygen and Mg
2+ resulting in light 
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emission.  The total amount of light measured during a given time interval is proportional to 
the amount of luciferase reporter activity in the sample.  This light emission can be quantified. 
 
The ‘dual luciferase reporter assay system’ (Promega) combines two luciferase reporter 
enzymes. The firefly luciferase can be effectively quenched so that the second (derived from 
the sea pansy ‘Renilla reniformis”) can be assayed for its luminescence. 
 
The CAT gene is derived from transposon 9 of Escherichia coli (E.coli) (494).  CAT is a 
trimeric protein comprising three identical subunits of 25kDa (495).The CAT protein is 
relatively stable in mammalian cells, although the mRNA has a comparatively short half life, 
making the CAT reporter especially suited for transient assays designed to assess 
accumulation of expressed protein (496).  CAT catalyses the transfer of the acetyl group from 
acetyl-CoA to the substrate, chloramphenicol.  The enzyme reaction can be quantified by 
incubating cell lysates with [
14C] chloramphenicol and following product formation by 
physical separation with thin layer chromatography (TLC) (497). 
 
The vectors used in these experiments from Promega (pGL3) contain a modified cDNA, 
designated ‘Luc+’ and a vector backbone that has been enhanced to provide reporter gene 
expression but ensuring that there is no spurious transcriptional signals.  The PRL family of 
‘Renilla’ luciferase reactions are used to co-transfect the experimental luciferase reporter 
gene. 
 
The expression of Renilla luciferase can provide an internal control value to which expression 
of the experimental firefly luciferase reporter gene may be normalised.  During the course of 
this work it became obvious that relatively small quantities of the pRL co-reporter gene were 
needed to provide low-level constitutive expression of Renilla luciferase control activity (to 
the extent that ratios of luciferase co-transfection reaction of 50:1 were used). 
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Figure 2.3 pGL3 Basic (promega) 
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2.7.3 Transfection 
 
Materials 
Two transfection kit protocols were incorporated in the body of this work: 
 
1. Lipofection for dual luciferase transfection 
This protocol was used in accordance with a Promega Kit and carried out to the 
manufacturer’s instructions (498;499).  Cells were incubated during transfection, placed in 
serum-free media for at least 6 hours and transfected over a period of 72 hours following 
which they were harvested with a view to freezing and performing a luciferase assay at a later 
date. 
 
2. Effectene for dual luciferase transfection  
This system incorporated a new transfection agent ‘Effectene” based on a proprietary non-
liposomal lipid.  Transfection was carried out according to the manufacturer’s instructions 
(Qiagen).  A serum free step was avoided with this protocol and this proved in subsequent 
work to be a major advantage. The ‘Dual Luciferase Reporter Assay’ system (Promega) 
allowed the dual transfection of reporter genes in a variety of cell types and required the 
measurement of emitted light with a manually operated luminometer (Promega).  All 
protocols were carried out accurately to manufacturer’s instructions. 
 
2.7.4 The Chloramphenicol Acetyl Transferase (CAT) Transfection Assay 
 
All transfection were carried out using the ‘Effectene’ kit by Qiagen outlined above according 
to the manufacturer’s instructions.  After incubation in fresh media transfections were carried 
out over a period of 24-48 hours avoiding a serum free step/ following this the cells were 
scraped off tissue culture plates into media, and pelleted at 1000 rpm for 5min.  The 
supernatant was removed and the cells were re-suspended in 5ml of PBS.  They were then 
pelleted at 1000rpm for 5min; this was then repeated.  Following suspension in PBS a third 
time and pelleting as outlined the cells were re-suspended in 50µl of 0.25M Tris buffer pH7.9.  
Three cycles of freezing in liquid nitrogen for 2 min then thawing at 37
oC for 5min followed 
by vortexing was carried out.  The disrupted cells were then pelleted using a microfuge at 
13000 rpm for 5 min.  The pellet was retained and stored at –20
oC.  A protein assay was 
carried out on 2µl samples of the supernatant.  (To 2µl of sample 18µl of H2O was added; a   123
‘blank’ sample was made up with 2µl of tris and 18µl of water to give the same buffering 
conditions).  A proprietary kit was used to perform the protein assay (DC colorimetric assay 
(BioRad): 100µl of Solution A and 800µl of Solution B was added and the solution was 
incubated at room temperature for 20 min.  5µl of the sample/supernatant was then added to 
15ml of H2O in a cuvette and a protein assay reading was taken at 750nm.  Samples were then 
modified to 25µg in 50µl and to this a mastermix was added (the master mix represented 70µl 
of 1M Tris-HCl pH 7.8, 20µl of Acetyl Coenzyme A 3.25µg/µl and 1µl of 400µCi/ml [
14C] 
35-50mCi/mmol Chloramphenicol (Amersham), for each reaction). 
 
Each sample was ‘flick spun’ using a microfuge at 13000rpm and incubated at 37
oC for 2 
hours.  To each sample 0.5 ml of ethyl acetate was added and the solution vortexed for 30 
seconds and microfuged at 13000 rpm for 5mins.  The top layer was removed into another 
tube and the lower layer discarded.  The top layer was speed vacuum dried and the residual 
precipitate was re-suspended in 15µl of ethyl acetate before being applied to a thin layer 
chromatography plate and allowed to dry.  The plate was run in a chromatography tank 
containing 95% chloroform, 5% methanol.  Imaging was performed by plate exposure to Blue 
Autoradiography X-ray film (GRI) and quantitation was determined by phosphor image 
analysis using a Storm scanner and an “Image Quant” software data analysis package 
(Molecular Dynamics). 
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2.8 Erase-a-Base 
 
The Erase-a-base system by Promega is designed for the rapid construction of plasmid 
containing progressive unidirectional deletions of any inserted DNA.  It is based on a 
procedure developed by Henileott (500) in which the enzyme exonuclease III (Exo III) is used 
to specifically digest insert RNA from a 5 prime (5`) protruding or blunt end restriction site.  
The adjacent primer binding site is protected from digestion by a 4-base 3` overhang 
restriction site.  DNA fragments with a defined length are used as the starting point to obtain 
smaller components by successive deletion from the 5` end. Exo III works at a consistent rate 
and therefore defined time points are incorporated to obtain predictable lengths by simply 
removing timed aliquots from the digestion mix reaction.  
 
Samples of the Exo III digestion are removed at timed intervals and added to the tubes 
containing S1 nuclease, which removes the remaining single stranded tails.  The low pH and 
presence of zinc cations in the S1-nuclease buffer effectively inhibits further digesting by Exo 
III.  After neutralisation and heat inactivation of S1 nuclease, Klenow DNA polymerase is 
added to flush the ends which are then ligated to circularize the deletion containing vectors.  
The ligation mixtures are used directly to transform competent cells.  Each successive time 
point yields a collection of subclones containing clustered deletions extending further into the 
original insert. 
 
For Erase-a-base Solutions, see Appendix 1 for Materials & Solutions.   125
 Figure 2.4 The Erase-A-Base technique
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2.8.1 Erase-a-Base system for restriction digestion of plasmid DNA 
 
A double-digest of 10µg of closed circular DNA with two different restriction enzymes was 
performed: one to generate a 4-base 3`-protrusion protecting the primer binding site and 
another to leave a 5`-protrusion or blunt end adjacent to the insert.   
 
2.8.1.1 Protection of 5`-Protruding Ends with α-Phosphorothioate dNTP Mix  
 
10µg of recombinant DNA was digested to completion with the enzyme chosen for the primer 
protecting site.  This was then phenol:chloroform extracted, precipitated and spun down 
briefly at 13,000rpm for 1 second in a microfuge.  The pellet was rinsed in 70% ethanol. The 
tube was drained and the pellet dried under vacuum.  The pellet was re suspended in 50-
100µ1 of Klenow 1x Buffer. Sufficient α-Phosphorothioate dNTP Mix was added to achieve a 
final concentration of 40µM each.  DTT was added to a final concentration of 1mM and 
Klenow DNA Polymerase to 50u/ml.  The mixture was incubated for 10 min at 37°C.  The 
sample was heated for 10 min at 70°C to inactivate the Klenow DNA Polymerase. The DNA 
was extracted as described above and re suspended in the appropriate restriction endonuclease 
digestion buffer. After performing the second restriction digestion, the DNA was extracted 
again as above, then the main part of the experiment proceeded: Exonuclease III deletion, 
ligation and transformation.  
 
2.8.2 Exonuclease III deletion, ligation and transformation 
 
The DNA pellet was re suspended in 10µl of TE buffer or water and the concentration of the 
DNA estimated by gel analysis.  5µg of DNA was added to 6µ1 10x Exo III Buffer. Water 
was added to a total volume of 60µl.  Meanwhile, for each DNA deletion series, 7.5µl of S1 
nuclease mix was added to each of 24 microcentrifuge tubes and left on ice. The DNA tube 
was warmed to the digestion temperature in a water bath. 300-500 units of Exo III was added 
to the DNA and mixed rapidly. 2.5µl samples were removed at 30 second intervals into the S1 
tubes on ice, with mixing achieved by pipetting.  
 
Once all samples were taken they were incubated at room temperature for 30 min. 1µl of S1 
Nuclease Stop Buffer was added to each tube and which was then heated at 70°C for 10 min 
followed by a brief centrifuge at 13,000rpm for 1 second in a microfuge.  The extent of   127
digestion was determined by gel electrophoresis of 2-3µl samples (40-60ng DNA) from each 
time point.  The samples was precipitated with 0.3 volumes of 7.5M ammonium acetate and 2 
volumes of 100% ethanol and mixed well. It was then incubated at -20°C for 15 min, then 
centrifuged at 12,000 x g for 5 min. The supernatant was carefully removed and the pellet 
washed with 0.5ml of 70% ethanol. Once the tube was drained and the pellet dried the pellet 
was re suspended in 9µl of TE buffer.  The samples were transferred to 37°C; 1µl of Klenow 
mix was added to each sample then incubated for 3 min.  1µl of the dNTP mix was added to 
each sample then they were incubated for a further 5 min at 37°C. The Klenow was heat 
inactivated at 65°C for 10 min.  The samples were transferred to room temperature and 40µl 
of ligase mix was added to each sample. All samples were mixed well and incubated at room 
temperature for 1 hour. The resulting plasmid DNA was transformed into competent cells.  
 
2.9 Sequencing Methods 
 
DNA to be sequenced was denatured with 0.2M NaOH, 0.2M EDTA at 37
0C for 30 min.  The 
denatured protein was precipitated with 3x volumes of 100% ethanol at 70
0C for 15 min.  
Following a centrifuge spin at 14,000 rpm for 30 min at room temperature most of the ethanol 
was removed and the final amount was taken off after a final ‘flick’ spin for 60 seconds.  The 
pellet was dried for 2-5 min and re suspended in a reaction buffer containing water and 
primer. 
 
2.9.1 Chain Termination Sequencing 
 
The ‘T7 Sequenase’ version 2.0 DNA sequencing method (1,2) (Amersham Life Science) 
involves the in vitro synthesis of a DNA strand by a DNA polymerase using a specifically 
primed single-stranded DNA template(501;502). 
 
DNA synthesis is carried out in two steps.  The first is the labeling step in which the primer is 
extended using limiting concentrations of the deoxynucleoside triphosphates, including 
radioactively labeled dATP.  This step continues to virtually complete incorporation of 
labeled nucleotide into DNA chains.  These initial primer extensions are distributed randomly 
in length from several nucleotides to hundreds of nucleotides. 
In the second step, the concentration of all the deoxynucleoside triphosphates is increased and 
a chain terminating nucleotide analogue is added.  These 2`3`- dideoxynucleoside-5`-  128
triphosphates (ddNTPs) lack the 3`-OH group necessary for DNA chain elongation. 
Processive DNA synthesis occurs, with extensions on the average of only several dozen 
nucleotides, until all growing chains are terminated by a ddNTP.  When proper mixtures of 
dNTPs and one of the four ddNTPs are used, enzyme catalysed polymerisation will be 
terminated in a fraction of the population of chains at each site where the ddNTP can be 
incorporated.   
 
Four separate reactions each with a different ddNTP give complete sequence information.  
The sequencing reactions are terminated by the addition of EDTA and formamide, denatured 
by heating, separated from high resolution denaturing acrylamide gel electrophoresis and 
visualised by autoradiography.  
 
Materials 
For 3-dNTP protocol: α labeled dATP such as [α-
32P]dATP or [α-
35S]dATP where the 
specific activity should be 1000-1500Ci/mmol. 
Water (only deionized, distilled water was used for the sequencing reactions).  
Tris-EDTA (TE) buffer: this buffer is 10mM Tris HCl, 1mM EDTA, pH 7.5.  
It is used for template preparation. 
 
For Gel reagents sequencing gels were made only from fresh solutions of acrylamide and bis-
acrylamide. Other reagents were electrophoresis grade materials. 
 
Specialized sequencing primers 
Some sequencing projects required the use of primers which are specific to the project. For all 
sequencing applications, 0.5-1.0pmol of primer was used for each set of sequencing reactions.  
 
Necessary equipment: 
Constant temperature bath 
Sequencing required incubations at room temperature, 37
°C, 65
°C and 75
°C.  The annealing 
step required slow cooling from 65°C to room temperature. 
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Electrophoresis equipment 
While standard, non-gradient sequencing gel apparatus is sufficient for most sequencing 
work, the use of field-gradient ('wedge') gels will allow greater reading capacity on the gel 
(5). A power supply offering constant voltage operation at 2000V or greater was incorporated. 
  
Gel handling 
For 
35S or 
32P sequencing, a large tray for soaking the gel (to remove urea) and a gel drying 
apparatus was necessary. (Gels containing 
35S or 
32P must be exposed dry in direct contact 
with the film at room temperature). 
Autoradiography 
Large format autoradiography film and film cassettes, such as HyperfilmTM or BiomaxTM 
and HypercassettesTM, were used. Development of films was performed according to the 
film manufacturer's instructions. 
 
 
2.9.2 Sequencing Reactions 
 
Two sets of reactions were set up: four forward and four reverse.  For each set of four 
sequencing lanes a single annealing (and subsequent labeling) reaction was used.  Each 
reaction tube contained: 1µl primer, 2µl reaction buffer, 3µl of DNA insert (0.5µg/µl) and 5µl 
distilled water (total volume 10µl).  The capped microfuge tubes were warmed to 61
°C for 2 
min then the whole heating block was switched off and removed from the heating filaments: 
the microfuge tubes were allowed to cool in the block over a period of 45 min.  (Once the 
temperature is below 30
°C annealing is complete).  All tubes were then placed on ice. 
 
2.9.3 Termination Reaction 
 
During the cooling process above the termination reaction was prepared in advance.  One set 
of four microfuge tubes labeled G, A, T and C were obtained for each reaction (eg one set 
each for the TIMP-2 human 2600 ‘forward’ and TIMP-2 human 2600 ‘reverse’ reactions), 
2.5µl of ddGTP termination mix was placed in “G”, similarly the tubes labeled A, T and C 
were made up with ddATP, ddTTP and ddCTP termination mixes respectively.   130
2.9.4 Labeling Reaction 
 
The labeling mix (dGTP) was diluted 5x fold with distilled water eg 4µl mix added to 16µl 
H2O.  2µl of enzymes for the ‘Sequenase’ Version 2.0 Kit were added in a ratio of 1:8 in ice 
cold enzyme dilution buffer.  To the annealed template primer the following was added (on 
ice): 10µl template primer, 1.0µl DTT 0.1M, 2.0µl diluted labeling mix,  
0.5µl [α-
35S]dATP, 2.0µl diluted sequenase and thoroughly mixed.  The resulting solution was 
incubated for 5 min at room temperature. 
 
2.9.5 Termination Reaction 
 
The previously prepared termination mix was warmed to 37
0C for 1 minute.  Following 
completion of the incubation and labeling reaction 5µl was removed and transferred to ‘G’.  
This was repeated for microfuge tubes labeled ‘A’, ‘T’ and ‘C’.  All were returned to the 
water bath at 37
0C for 5 min. ‘STOP’ solution was added to terminate each reaction. 
 
2.9.6 Acrylamide Gel 
 
This was prepared in advance and stored in the dark.  The gel was pre warmed to 55
0C at 35 
watts for 15mins and then run for 35 watts for 5mins.  A gel was run 60mins prior to each 
experiment and loading was performed in the following sequence: 
 
T forward      T reverse 
GATC       GATC 
 
It was then reduced to 30W and run over three hours. 
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2.10 Culture of cells in hypoxic condition 
 
HSC were obtained in the usual way in the liver unit at Southampton and plated out onto 
plastic in order to allow cells to culture in the standard way. Cells were transferred to the 
Rayne Institue, UCL, London in June 1999 where a facility for tissue culture under hypoxic 
conditions was provided by Dr Jill Norman. Primary rat HSC, passaged rat HSC and human 
HSC were provided in DMEM and 16% FCS. Cells were divided into two groups and 
cultured for a variable time course in either control or hypoxic condition for 12, 24, 48 and 
72hrs. Hypoxic conditions consisted of 1% oxygen, 5% CO2, balanced nitrogen (specialist gas 
from BOC) in a humidified atmosphere at 37
0C, the control group cells normoxic controls 
were cultured under the routine incubator conditions ie 21% oxygen, 5% CO2 in a humidified 
atmosphere at 37
0C. (These methods are described in 4.2 Methods).  Cells were harvested for 
RNA extraction at each time point. Northern membranes were made and transferred to 
Southampton.   
 
Table 2.3 Hybridisation protocols differed slightly for these membranes 
 
Prehybridisation (Store in -20
0C freezer)  50ml 
 
20x SSC 
 
10ml 
10% SDS  2.5ml 
Denhardts 50x  5ml 
T50E10:   Tris 50mM 
    EDTA 10mM 
5ml 
 
The prehybridisation fluid was DEPC’d water to final volume. 
 
Prehybridisation took place at 65
0C for at least 2 hours. 
 
Hybridisation Buffer  50ml 
 
20x SSC 
 
10ml 
10% SDS  2.5ml 
Denhardt’s 50x  5ml 
T50E10: Tris 50mM 
  EDTA 10mM 
5ml 
Dextran Sulphate 
(final concentration 10%) 
5g 
   
Poly A
+ 10mg/ml  250µl 
ssDNA 
boiled salmon or herring sperm 
250µl 
32P cDNA  -   132
Hybridisation then was carried out at 65
0C for at least 18 hours.  Four washes were carried out 
using 4x SSC / 0.5% SDS 50
0C – for 20min, shaking. For the stripping blot 0.05x SSC and 
0.01M EDTA (pH8.0) was incorporated and heated to boiling. SDS was added after the 
boiling stage to a final concentration 0.1%. The filter was immersed in hot elution buffer for 
15 minutes. This was repeated with fresh boiling elution buffer. The filters were never 
allowed to dry between batches of elution buffer. The filters were then rinsed briefly in 0.01x 
SSC at room temperature. Most of the liquid was removed from filters by placing on a pad of 
paper towels. The filters were then wrapped in saran paper and exposed to check signal had 
been removed. 
 
2.11 Statistical Analysis 
 
Unless otherwise stated, results are expressed as mean ± standard error of the mean (SEM) 
with the number of independent studies shown (n).  In many of the experiments, the results 
were normalised to the control which is set at 100%, this allows comparisons between the 
experiments to be made.  A comparison of means evaluation was made (Anova test) for data 
depicted in Figure 5.4 (Table 5.2) and a paired Student’s t test was performed for data shown 
in Figure 5.29 (Table 5.8).   133
 
 
 
 
 
 
 
CHAPTER 3 
 
Expression of TIMP and MMP 
Assessed by 
Immunostaining pancreas and liver tissue   134
3.1 INTRODUCTION 
 
 
In the liver the accumulation of extracellular matrix may result not only from increased 
synthesis but also from changes in degradation. The matrix degrading metalloproteinases or 
MMPs are a family of zinc dependent proteinases that are expressed by mesenchymal cells 
and are the major mediators of extracellular matrix degradation (503). Gelatinase A (MMP-2) 
degrades collagen I and partially degraded collagens I and III (gelatins); in addition it 
degrades native collagen IV, a key component of the basement membrane matrix. The activity 
of MMPs is regulated by transcription, proenzyme activation, or inhibition through the non-
covalent binding of the tissue inhibitors of metalloproteinase or TIMP-1 and TIMP-2. In 
addition, TIMP-2 plays a specific role in the activation of gelatinase A by linking the pro 
gelatinase A with the membrane bound MMP activator membrane type metalloproteinase 1 
(MTl-MMP) (504). 
 
Increasing evidence suggests that pancreatic stellate cells (PSC) are the major mediators of 
fibrosis in chronic pancreatic injury and inflammation. Pancreatic stellate cells demonstrate 
many similar features to hepatic stellate cells and glomerular mesangial cells. These features 
include the acquisition of a myofibroblast like phenotype in the context of injury, a process 
known as activation. In the activated state PSC express alpha-smooth muscle actin (αSMA), 
enter the growth cycle and secrete fibrillar collagens, including collagen-1, that characterize 
chronic pancreatic fibrosis. As such the PSC probably represents the wound healing 
myofibroblasts of the pancreas. 
 
Pancreatic fibrosis is associated with an increase in extracellular matrix, predominantly 
interstitial or fibrillar collagens including collagen I and III. Studies presented in abstract form 
suggest that, in addition to the architectural distortion mediated by the increased expression of 
fibrillar collagens, altered cell matrix interactions perpetuate the myofibroblast-like PSC 
phenotype (345). In contrast, by plating PSC onto a model basement membrane like matrix 
(EHS) a more quiescent phenotype develops in which expression of collage-1 and alpha SMA 
are down regulated. These studies suggest that the mechanism of development of pancreatic 
fibrosis may in part depend on critical changes in cell - matrix interactions (314).  
 
The central role played by PSC in pancreatic fibrosis suggests that these cells may express 
mediators of matrix degradation. Indeed previous studies of hepatic fibrosis and renal fibrosis   135
suggest that it is likely that activated PSC would express MMP 2, MTl-MMP, and TIMPs-l 
and -2 (355). PSC have also been shown to express MMPs and TIMPs in culture 
(demonstrated later in this thesis) (3). However less is known about expression of MMPs and 
TIMPs in pancreatic disease. In this chapter I examined the expression of MMPs and TIMPs 
in chronic pancreatitis as compared to the normal pancreas. I also set out to co-localise the 
expression of α-SMA in relations to MMPS and TIMPs. If confirmed this would suggest that 
activated pancreatic stellate cells promote the progression of fibrosis through altering the 
pattern of matrix degradation. 
 
Objectives 
In this part of the thesis my intention was to show the following in human liver and pancreas: 
•  Perform immunohistochemistry on normal and fibrotic liver and pancreatic tissue for 
TIMP-1, TIMP-2, αSMA, Gel A (MMP-2) and MT1-MMP (MMP-14) 
•  In so doing, this will demonstrate parallel fibrotic processes in pancreatic injury in 
comparison to liver fibrosis such as increased expression of αSMA and TIMP-1, 
TIMP-2   136
3.2 Methods 
 
3.2.1 Ethics Approval 
 
Ethics approval for this research was granted through the local Southampton University 
Ethics Committee. Patient consent in written form prior to the time of operations was sought 
in order for archived tissue to be incorporated in experimental work. 
 
3.2.2 Selection of cases - Pancreas 
 
Formalin-fixed and paraffin wax-embedded tissue blocks from six cases of chronic 
pancreatitis and six normal controls were incorporated. All cases were retrieved from the 
histopathology database at Southampton General Hospital. The normal tissue was taken from 
two Whipple’s’ resections, for duodenal adenocarcinoma and a small ACTH-secreting 
neuroendocrine pancreatic tumour. Three specimens were obtained from patients undergoing 
resection of gastroesophageal adenocarcinoma and in which tumour extended close to, or 
focally into, the pancreas. One sample was an open biopsy for a suspicious pancreatic nodule, 
found at cholecystectomy. The last two were from pancreas removed after an 
oesophagogastrectomy for squamous cell carcinoma of the oesophagus and a distal 
pancreatectomy with colectomy for adenocarcinoma of the colon. In each of the six normal 
controls, in the blocks chosen for the study, there was no evidence of tumour involvement or 
chronic pancreatitis. 
 
In the chronic pancreatitis cases, three specimens were resections (one resection of the head of 
pancreas, two distal pancreatectomies) performed for painful alcohol-related chronic 
pancreatitis. One specimen was an open pancreatic biopsy of a nodular pancreas found at 
cholecystectomy. One was a proximal resection of a symptomatic pancreatic mass (idiopathic 
chronic pancreatitis) and one was from an area of obstructive chronic pancreatitis above a 
pancreatic adenocarcinoma   137
Table 3.1 Selection of normal human pancreas (from archived biopsy specimens) 
 
Details of normal human pancreas specimens 
No  Patient Initials   Operation comments, diagnosis and context of pancreas 
        retrieval 
1  LO  
 
Normal pancreas tissue 
2  BM 
 
Pancreatic tumour, but adjacent specimen used for  
normal pancreas tissue 
3  KO 
 
Adeno carcinoma of stomach and esophagogastric junction. 
Normal pancreas tissue 
4  JW  Indication for biopsy: Cushing’s disease, pancreas nodule 
?cause. Results show normal pancreatic tissue 
5  Not Available  Esophagogastric tumour 
Normal pancreatic tissue 
 
6  Not Available  Esophagogastrectomy 
Normal pancreatic tissue 
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Table 3.2 Details of diseased human pancreas (from archived biopsy specimens) 
 
Details of diseased human pancreas specimens  
No  Patient Initials   Operation comments, diagnosis and context of pancreas 
        retrieval 
1  KD  Chronic pancreatis 
 
2  JB  Chronic pancreatitis 
 
3  KM  Chronic pancreatitis 
 
4  EN  Chronic pancreatitis 
 
5  Not Available  Chronic pancreatitis  
 
6  Not Available  Chronic pancreatitis  
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3.2.3 Selection of cases – Liver 
 
Formalin-fixed and paraffin wax-embedded tissue blocks from six cases of chronic liver 
disease and three normal controls were used. All cases were retrieved from the histopathology 
database at Southampton General Hospital.   The normal tissue was taken from two liver 
resections, one for a bile duct tumour invading into the liver parenchyma – tissue here was 
taken from uninvolved tissue; the second for a possible liver mass which was finally 
diagnosed as a haemangioma; one for resection of metastatic colon cancer.  For fibrotic liver: 
2 cases were due to alcohol liver disease, one for active hepatitis C infection, one for ongoing 
autoimmune active hepatitis, and one case of fibrosis secondary to possible alcohol disease.   140
Table 3.3 Selection of diseased human livers (from archived biopsy specimens) 
 
Fibrotic liver details 
  Initials  Diagnosis 
 
1  GM 
 
Alcoholic hepatitis with cirrhosis 
2  RS 
 
abnormal architecture with linking fibrosis,  
grade I siderosis,  
mixed acute/chronic inflamm. 
 
3  MJR 
 
Clincial: alc liver disease 
Micronodular cirrhosis,  
acute steatohepatitis,  
accompanying sinusoidal pericellular fibrosis supporting alc 
liver disease 
 
4  AM 
 
Clincal: HCV infection 
Micronodulat cirrhosis,  
piecemeal necrosis,  
(IPA score 3,3,3). 
 
5  JW 
 
Clin hi alc intake with signs of chronic liver disease 
Severe fibrosis & early cirrhosis;  
predominant lesion - chronic active hepatitis  
(no signs of alc liver disease) 
 
6  JH 
 
Clinical: Autoimmune hepatitis Histology:  
Idiopathic macronodular cirrhosis with low grade activity 
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Table 3.4 Selection of normal human livers (from archived biopsy specimens) 
 
Details of normal human livers  
No  Initials       Operation comments, diagnosis and context of liver 
          retrieval 
1  CB 
 
Normal liver tissue 
2  Not available  Normal liver tissue  
 
3  Not available     Normal liver tissue  
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Six proteins were chosen for study using immunohistochemistry: TIMP-1, TIMP-2, α-SMA, 
Gel-A and MT1-MMP. The optimum dilution of each primary antibody was determined using 
sections from liver known to express each of the molecules under study.  After de-
paraffinising for ten minutes and washing the slides in 100% through to 70% alcohol, for one 
minute each, the endogenous peroxidase activity was inhibited with hydrogen peroxide 
(Merck) for ten minutes.  
 
In order to establish the optimum staining dilution and pre-treatment all the sections 
underwent a pre-treatment antigen retrieval involving either microwave irradiation in 0.01M 
citrate buffer (pH 6.0) (Merck) for thirty minutes at medium power; pressure cooking at 13lb 
pressure for two minutes in 0.01M citrate buffer; or proteolytic enzyme exposure with 
pronase or no treatment (applying 10% bovine serum albumin, BSA for thirty minutes). The 
primary antibodies were applied (at various dilutions) to all sections, except negative controls 
and incubated overnight at +4ºC.   
 
On the second day after the specimens had warmed up to room temperature, secondary 
antibodies were applied for thirty minutes (Dako). The sections were washed in Tris-buffered 
saline (TBS) and pre-prepared Streptavidin-Biotin Peroxidase complexes (Dako) applied for 
thirty minutes. After a further wash with TBS, the sections were stained with 
diaminobenzidine substrate (DAB) (Biogenex) for five minutes. After a two minute wash in 
running tap water and a rinse with 70% alcohol, the sections were counter-stained with 
Harris’s haematoxylin (Merck) for one to two minutes, rinsed for one minute in running tap 
water, differentiated in 1% alcohol for five seconds and finally, blued in running tap water for 
five minutes before dehydrating and mounting with coverslips.   
 
All antibody solutions were diluted from fresh stock solutions, which were kept at +4
0C.  All 
incubations were undertaken at room temperature.  All negative controls were noted to be 
negative. At the end of each staining protocol, cells were mounted and viewed under 
appropriate light with a Zeiss photomicroscope.  Examples of immunstained cells were 
photographed on Kodak Ektachrome film.   143
Table 3.5 Pre-treatment regimes and primary antibody concentrations for 
immunohistochemistry 
 
Antibody  Dilutio
n 
Type  Pre-treatment 
Source 
 
TIMP-1  1:200  Rabbit 
polyclonal 
Pronase  Chemicon International 
 
 
TIMP-2  1:400  Goat 
polyclonal 
Pronase  Chemicon International 
 
 
αSMA   1:200  Mouse 
monoclonal 
Pronase  Sigma 
 
 
Gel A  1:400  Mouse 
monoclonal 
Pronase  Oncogene Research 
Products 
 
MT1-MMP  1:200  Mouse   Pronase  Dako 
 
 
 
 
General Methods are described in Chapter 2 Methods Section 2.1.2. 
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3.3 Results of Immunohistochemistry 
 
Sections from each case underwent immunohistochemical staining using the standard method 
for Streptavidin-Biotin immunostaining outlined in Chapter 2 Methods section 2.1.2. 
Negative controls were performed by omitting the primary antibody as described in 2.1.2. 
 
Slides were initially reviewed and scored by Professor John Iredale at the time of performing 
the immunohistochemistry: the results depicted here are based on these scorings. Subsequent 
to this at the time of writing slides were again reviewed by Dr Adrian Bateman (Southampton 
University Hospitals Trust) and Dr Simon Rasbridge (Royal Bournemouth and Christchurch 
Hospitals Trust). 
 
Table 3.6 depicts the results of staining 6 sections of normal human pancreas and 6 sections 
of fibrotic human pancreas.  An increase in expression of MMP-2, MT1-MMP, αSMA, 
TIMP-1 and TIMP-2 staining was seen in fibrotic pancreas compared to normal pancreas in 
the perivascular stroma and periacinar stroma.  Whilst expression of TIMP-1 and TIMP-2 was 
noted in the pancreatic islets of normal human pancreas the expression of TIMP-1 and TIMP-
2 was increased in the islets of fibrotic pancreas compared to normals.   145
Table: 3.6 In-Vivo expression of MMP-2, MT1-MMP, αSMA, TIMP-1 and TIMP-2 in 
human pancreas 
 
Normal Human Pancreas 
 
Site  αSMA  Gel A  MT1-MMP  TIMP-1  TIMP-2 
 
Perivascular 
Stroma 
++ 6/6  ++ 6/6  ++ 6/6  ++ 6/6  ++ 6/6 
Periacinar 
Stroma 
+/- 2/6  absent  absent  absent  absent 
Area of 
Fibrosis 
absent  absent  absent  absent  absent 
Acini  absent  absent  absent  absent  Absent 
 
Islets  absent  absent  absent  ++ 6/6  ++ 4/6 
 
 
 
Fibrotic Human Pancreas 
 
Site  αSMA  Gel A  MT1-MMP  TIMP-1  TIMP-2 
 
Perivascular 
Stroma 
++ 6/6  ++ 6/6  ++ 6/6  ++ 6/6  ++ 6/6 
Periacinar 
Stroma 
++ 6/6  ++ 6/6  +++ 6/6  ++ 6/6  ++ 6/6 
Area of 
Fibrosis 
+++ 6/6  ++ 6/6  +++ 6/6  +++ 6/6  +++ 6/6 
Acini  absent  absent  absent  absent  absent 
 
Islets  absent  absent  absent  ++++ 6/6  ++++ 4/6 
 
 
(Please note that data is not shown for MT1-MMP in the ensuing figures).   146
Table 3.7 In-Vivo expression of MMP-2, MT1-MMP, αSMA, TIMP-1 and TIMP-2 in 
human liver 
 
Normal Human Liver 
Site  αSMA  Gel A  MT1-MMP  TIMP-1  TIMP-2 
 
Portal tracts  ++6/6  ++6/6  ++ 6/6  ++ 6/6  +6/6 
 
Connective 
tissue 
Weak +ve 
3/6 
Absent  Absent  Absent  Subtle 
background 
only +6/6 
Hepatocytes  Weak +ve 
3/6 
Absent  Absent  Absent  absent 
 
Sinusoids  Weak +ve 
3/6 
Absent  Absent  Absent  Absent 
 
Perisinusoids  Weak +ve 
3/6 
absent  Absent  Absent  absent 
 
 
Fibrotic Human Liver 
 
Site  αSMA  Gel A  MT1-MMP  TIMP-1  TIMP-2 
 
Portal tracts  ++6/6  ++6/6  ++ 6/6  ++ 6/6  +6/6 
 
Connective 
tissue 
+++6/6  +4/6  +4/6  ++6/6  Subtle 
background 
only +6/6 
Hepatocytes  +6/6  +4/6  +4/6  ++6/6  +6/6 
 
Sinusoids  ++6/6  +4/6  +4/6  ++6/6  ++4/6 
 
Peri-
sinusoids 
+6/6  +4/6  +4/6  ++6/6  ++4/6 
 
 
Table Results of staining 6 sections of normal human liver and 6 sections of fibrotic human 
Liver. (Please note that data is not shown for MT1-MMP and αSMA in the ensuing figures). 
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Figure 3.1 TIMP-1 staining in human pancreas 
A) Normal control 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) Fibrotic pancreas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Streptavidin-biotin staining of TIMP-1 in human pancreas.  There is intense cytoplasmic 
expression of TIMP-1 in the pancreatic islets in both A and B but in addition TIMP-1 is also 
localised to fibrotic bands in B. Negative controls (not shown) demonstrated a consistent 
negative stain). Magnification x500 A, x200 B. 
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Figure 3.2 TIMP-2 staining in human pancreas 
A) Normal control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) Fibrotic pancreas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Streptavidin-biotin staining of TIMP-2 in human pancreas.  Although staining was weaker in 
comparison to TIMP-1, again there is cytoplasmic staining of TIMP-2 in the pancreatic islets 
and, in addition, around blood vessels in normal and fibrotic tissue. TIMP-2 is also localised 
to fibrotic bands in B.. Magnification x200 A, x200 B. 
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Figure 3.3 Gelatinase A staining in human pancreas 
A) Normal control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) Fibrotic pancreas  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Streptavidin-biotin staining of Gelatinase A in human pancreateas.  Gel A is seen 
predominantly in the stroma but not in the pancreatic islets in both A and B but in addition is 
also localised to fibrotic bands in B. MT1-MMP (MMP-14, not shown) was noted to stain for 
normal and fibrotic pancreas in a similar pattern to Gelatinase A (MMP-2). 
Magnification x500 A, x200 B. 
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Figure 3.4 α-Smooth Muscle Actin (αsma) staining in human pancreas 
A) Fibrotic pancreas, Low power 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) Fibrotic pancreas, High power 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Streptavidin-biotin staining of αSMA in human pancreas.  Normal pancreas is not shown. 
αSMA was noted in normal perivascular stroma and periacinar stroma but not the islets or 
normal acini. The fibrotic bands stained positively for α-SMA. Magnification x200 A, x500 
B. 
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Figure 3.5 Gelatinase a (MMP-2) staining in fibrotic human liver  
A) Normal Control stain x50 
 
 
B) Fibrotic liver Low power 
 
Streptavidin-biotin staining of Gelatinase A in human liver.  Gel A is seen predominantly in 
the fibrotic bands but also in the liver sinusoids. 
Magnification x50 A, x50 B. 
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Figure 3.6 Gelatinase a (MMP-2) staining in fibrotic human liver 
A) High power 
 
 
A) High power x200 
 
Streptavidin-biotin staining of Gelatinase A in human liver.  Gel A is seen to be strongly 
expressed in both fibrotic bands and the liver sinusoids. MT1-MMP (MMP-14) whilst not 
shown here in normal or fibrotic liver had broadly a similar pattern to Gelatinase-2 (MMP-2).  
1:100 Pronase staining; Magnification x100 A, x200 B.   153
Figure 3.7 TIMP-1 staining in fibrotic human liver 
A) Staining in hepatocytes (Goat staining) Low power 
 
 
B) High power TIMP-1 staining in human fibrotic liver 
 
The main area of staining for TIMP-1 in fibrotic liver shown here is related to the portal tracts 
and the sinusoids. Pronase staining; Magnification A) x50 and B) x200.   154
Figure 3.8 TIMP-1 staining in fibrotic human liver 
High power 
 
 
B) TIMP-1 staining in fibrotic human liver High power 
 
The main area of staining for TIMP-1 in fibrotic liver shown here is related to the sinusoids. 
There is some granular staining in the hepatocytes. In control liver there was no parenchymal 
staining. Pronase staining; Magnification x100 A and x400 B 
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Figure 3.9 TIMP-2 staining in fibrotic human liver 
A) Low power TIMP-2 staining Goat 1:400 
 
B) High power TIMP-2 staining Goat 1:400 
 
Staining of fibrotic liver with TIMP-2 Magnification A) x50 & B x100. Although there is 
evidence of some background staining in addition there is TIMP-2 staining in fibrotic bands. 
This follows a similar pattern to TIMP-1. However there is clear staining here in Figure 3.9 
and Figure 3.10 of staining around the sinusoids. 
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Figure 3.10 TIMP-2 staining in fibrotic human liver 
A) High power TIMP-2 staining Goat 1:400 
 
B) High power TIMP-2 staining Goat 1:400 
 
 
TIMP-2 staining in fibrotic liver Magnification A) x200 B) x400. Although there is some 
subtle background staining there is clear staining around the sinusoids seen best in Figure 
3.10B.
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3.4 Discussion 
 
3.4.1 Pancreas 
 
Six examples of normal human pancreas and six cases of chronic pancreatitis were stained for 
MMP-2, MT1-MMP, TIMP-1 and TIMP-2.  In addition parallel examples were stained for 
αSMA to localize activated pancreatic stellate cells (PSCs) although this also detects vascular 
smooth muscle.  In all 6 fibrotic samples the cell rich stroma dividing up the remnant acini 
and islets was strongly αSMA positive indicating the presence of activated PSCs.  MMP-2 
was detected and localized in the αSMA positive cell rich stroma in each of the six examples 
of chronic pancreatitis.  No MMP-2 was detected in the islets or acini.  MT1-MMP was also 
readily detected in the activated PSC of each specimen (please note this is not shown in the 
figures).  In contrast to the localization of MMP-2 the distribution of MT1-MMP was more 
widespread with expression seen in either the islets or elements within the islets in five 
samples.  In addition in three of the specimens staining of variable intensity was observed in 
the acinar cells.  Expression of TIMP-1 and TIMP-2 was detected in the αSMA positive cells 
within the stroma.  In addition, TIMP-1 was localized to the islets and in four samples TIMP-
2 was also expressed by islet cells. 
 
3.4.2 Liver 
 
Three examples of normal human liver and six cases of fibrotic/cirrhotic liver were stained for 
MMP-2, MT1-MMP, TIMP-1 and TIMP-2.  No cirrhotic liver had a diagnosis of inherited 
disease such as alpha-1 antitrypsin deficiency (as this may have explained some of the 
staining in diseased hepatocytes for TIMP-1 and TIMP-2 had this been the case). In addition 
parallel examples were stained for αSMA to localize to activated hepatic stellate cells (HSCs).   
 
αSMA was positive in some normals which was unexpected. It is possible that in these 
patients they may have had unsuspected liver disease. MT1-MMP showed good staining in 
one or two cases only and there was increased expression in hepatocytes or increased 
background; the majority of needle biopsies were negative. (Please note the αSMA and MT1-
MMP slides are not shown in the figures above). MMP-2 was weakly positive in some 
normals but strongly positive in fibrotic bands in diseased livers. TIMP-2 demonstrated some 
staining of hepatocytes in a granular fashion, weak staining in blood vessels, with a subtle 
increased background in some cases. However there was strong localization to the sinusoid   158
and perisinusoidal areas in fibrotic liver.  TIMP-1 demonstrated some staining of fibrotic 
bands in addition to some stromal staining. There was some granularity in the hepatocytes 
only but strong staining in the sinusoids and perisinusoids. 
 
Activated PSC in vivo during sustained (chronic) pancreatic injury express mediators of 
matrix degradation. Specifically MT1-MMP, Gelatinase A/MMP-2, TIMP-1, and TIMP-2 
were expressed in chronic pancreatitis. These results when obtained were the first description 
of this facet of activated PSC phenotype and demonstrated a further aspect in which these 
cells behave similarly to hepatic HSC and renal mesangial cells. Fibrotic disorders in other 
organs including the liver and kidney are also characterized by increased expression of MMP-
2. These observations have led to speculation that MMP-2 may promote the fibrotic process. 
This appears counter intuitive, and indeed the mechanism(s) for this are not clear, however 
MMP-2 has been implicated in promoting stellate cell proliferation possibly by remodelling 
the matrix and revealing ligands for integrin alpha v beta3 (129). In addition, in models of 
both hepatic and pancreatic stellate cells activation there is evidence to suggest that 
degradation of the normal basement membrane like matrix, which is rich in type IV collagen 
and replacement with a matrix rich in collagen-1 is associated with promotion and 
perpetuation of the activated stellate cell phenotype (296). After liver injury, the Disse space 
matrix remodelling might be initiated by MMPs expressed in early stages of HSC activation 
such as MMP-3 and MMP-13 and then perpetuated by MMP-2 which is expressed in the fully 
activated cells (259) (263). Thus the expression of MMP-2 may be directly pro fibrotic by 
altering matrix degradation in favour of a matrix relatively depleted of collagen IV and rich in 
collagen I. Of interest, in models of hepatic fibrosis there is a clear temporal relationship 
between the progression of fibrosis and expression of MMP-2 and its activator MT1-MMP, 
while spontaneous recovery from fibrosis is associated with a decrease expression of both 
(505). The role of MMPs and TIMPs in injury and fibrosis has been examined extensively in 
the context of liver, but there is far less information in the pancreas. My studies show 
activated PSC as a source of these proteins. However, my samples were limited to either 
normal or advanced fibrosis and only provide a snapshot of antigen expression. More detailed 
information of the temporal and spatial expression of the MMPs and TIMPs as injury 
proceeds to fibrosis will require the establishment of models of progressive fibrosis in 
rodents. Such models could use mice genetically deficient in the various TIMP2 and MMPs. 
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In addition to expression of matrix degrading MMPs, this data demonstrate that PSCs in vivo 
are potent sources of TIMP-1 and TIMP-2. As described previously, TIMP-2 is required for 
the activation of proMMP2 by MT1-MMP. However the activation model is complex and in 
the presence of excess TIMP-2 net matrix degradation is inhibited including MMP-2 activity. 
The additional expression of TIMP-1, which like TIMP-2 has a potent inhibitory effect on all 
activated MMPs including those with collagenase activity, suggests that matrix degradation 
may be significantly inhibited. Although the immunolocalization experiments were 
undertaken to determine the expression of MMPs and TIMPs by PSC, the data with respect to 
islets is particularly interesting. Islet cells were found to express TIMP-1 and 2 at a very high 
level. Moreover this expression was constant across all sections regardless of the extent of 
fibrotic change. The reason for this pattern of expression was highly speculative at that time. 
Nevertheless, Islet cell function is relatively well preserved even in comparatively advanced 
chronic pancreatitis. This suggests that islets are protected from the inflammatory and fibrotic 
damage that is occurring elsewhere in the organ. The expression of TIMPs 1 and 2 may 
represent a mechanism whereby peri-islet matrix is protected from remodeling. An alternative 
and potentially more intriguing possibility is that TIMP-1, which has been shown to have both 
cell growth and survival promoting activities, may be acting to promote the survival of islet 
cells surrounded by an inflammatory and fibrotic process.   160
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
HYPOXIA AND TIMP-2 EXPRESSION 
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4.1 Introduction 
 
 
It has been established that during the fibrogenic progression of chronic liver disease towards 
cirrhosis excess deposition of extracellular matrix and capillarization of sinusoids increases 
the resistance to blood flow and lowers oxygen delivery, thus rendering the tissue hypoxic 
(506). Angiogenesis itself is a hypoxia stimulated and growth factor dependent process 
consisting in the formation of new vascular structures from pre-existing blood vessels. 
Formation of new vessels is known to occur in several organs and to be critical for both 
growth and repair of tissues in several pathophysiological conditions (507). However it has 
become increasingly clear that angiogenesis occurring during chronic wound healing and 
fibrogenesis provides a key contribution to disease progression. Pathological angiogenesis as 
recently reviewed has indeed been described in chronic inflammatory/fibrotic liver diseases of 
different aetiologies (508). 
 
Pathological angiogenesis is associated with fibrogenic progression of chronic liver disease 
(509). Experimental data suggests that hypoxia and vascular endothelial growth factor 
(VEGF) may stimulate proliferation and synthesis of type I collagen in activated rat HSC 
(510). HSC express MMPs and TIMPs under a variety of conditions and evidence discussed 
above indicates TIMP overexpression contributes to fibrosis. Prior to this work there was little 
known on the effect of hypoxia on TIMP expression in HSC. 
 
In collaboration with Dr Jill Norman in University College Hospital (Department of Renal 
medicine, Rayne Institute) primary and passaged cultured rat HSC were transferred to London 
for study under control and hypoxic conditions. Cells were split into two populations, control 
and hypoxia and those in the latter group were cultured in hypoxic conditions for variable 
time points extending from 12, 24, 48 and 72hrs. 
 
4.1.1 Northern Blotting for the detection of α α α α SMA, Procollagen-1, Gelatinase A, TIMPs 
-1 & -2 in Activated rat pancreatic stellate cells (PSC) 
 
In chapter 3 the expression of MMPs and TIMPs in chronic pancreatitis was investigated 
compared to normal controls in vivo.  In this chapter the expression of pancreatic stellate cells   162
cultured on tissue culture plastic was studied for the expression of messenger RNA of alpha 
SMA, procollagen 1, Gelatinase A, Tissue inhibitor of metalloproteinase 1 & 2.  
 
4.1.2 Ribonuclease Protection Assay in human livers for expression of TIMP-2 
 
The ribouclease protection assay is a laboratory technique used in biochemistry and genetics 
to identify individual RNA molecules in a heterogeneous RNA sample extracted from cells. 
The technique can identify one or more RNA molecules of known sequence even at low total 
concentration. The extracted RNA is first mixed with antisense RNA probes that are 
complementary to the sequence or sequences of interest and the complementary strands are 
hybridized to form double-stranded RNA. The mixture is then exposed to ribonucleases that 
specifically cleave only single-stranded RNA but have no activity against double-stranded 
RNA. When the reaction runs to completion, susceptible RNA regions are degraded to very 
short oligomers or to individual nucleotides; the surviving RNA fragments are those that were 
complementary to the added antisense strand and thus contained the sequence of interest 
 
Ethics approval was obtained from the local Southampton University Hospitals Trust. Written 
consent was obtained from all patients. Five samples of liver resection from cirrhotic liver and 
3 samples from normal liver (liver resected for colorectal cancer metastases) were obtained to 
study the expression of human TIMP-2 mRNA in normal and diseased liver. For this 
experiment a ribonuclease protection assay (RPA) was chosen to detect mRNA as it has 
increased sensitivity over Northern Analysis (484). This is partly because larger amounts of 
RNA can be loaded (up to 100µg) and also hybridisation occurs in solution ensuring that the 
maxiumum number of hydrogen bonds are available for hybridisation. As stated above the 
principles of the assay are that a single stranded radiolableled antisense RNA probe is 
hybridised with the target mRNA in solution. In the presence of excess probe, the number of 
probe mRNA hybrids will be proportional to the amount of target mRNA present. After 
hybridisation the mixture is treated with RNAase to digest any single stranded RNA and any 
redundant probe. The probe-target mRNA hybrids are therefore “protected”. After 
inactivation of the RNAase the protected framgents are ethanol precipitated, suspended in 
loading buffer and separated on an RNA denaturing polyacrylamide gel. The abundance of 
the protected fragment can then be visualised by autoradiography of the dried gel and 
analysed by scanning densitometry. 
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Ribonuclease Protection Assays (RPAs) are described in detail in chapter 2 secton 2.5. This 
discusses in detail the following: 
•  Preparation of Radiolabeled Antisense Riboprobe 
•  In Vitro Transcription of Radiolabeled Antisense Riboprobe 
•  Protocol for Ribonuclease Protection Assay & Sample Preparation 
•  Resolution of Protected Fragments on Polyacrylamide Urea Gels 
 
 
The objectives in this chapter therefore included the following: 
 
•  An examination of the role of hypoxia in the expression of TIMP-2 mRNA in rat 
hepatic stellate cells and if the trial protocol was successful to move onto rat 
pancreatic stellate cells both fresh and passaged and finally human liver and human 
pancreas 
•  To test the hypothesis that pancreatic stellate cells express messenger RNA for alpha 
SMA, ProCol-1, Gel-A, TIMP-1 and TIMP-2 
•  Examine the expression of TIMP-2 mRNA in whole liver taken during hepatic 
resections for patients with colorectal cancer metastases (where normal liver segments 
free of metastatic disease were incorporated) in comparison to expression from 
diseased fibrotic human liver. 
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4.2 Methods 
 
Cells were cultured in hypoxic conditions ie in 1% oxygen, 5% CO2, balanced nitrogen 
(specialist gas from BOC) in a humidified atmosphere at 37
0C, normoxic controls were 
cultured under the routine incubator conditions ie 21% oxygen, 5% CO2 in a humidified 
atmosphere at 37
0C. The medium was the standard medium (DMEM) incorporated in the 
laboratory in Southampton for experiments. For the experiments cells were made quiescent 
for 48hr in reduced 0.5% serum, medium was changed to fresh reduced-serum medium 
immediately prior to start of hypoxia/normoxia as previously described (511). Cells were 
grown in dishes or 6 well plates (rather than flasks) for hypoxia culture vessels are placed in 
the modular incubator with the lids off (to facilitate gas exchange in the medium). The 
chamber was gassed for 20mins at 10L/min to ensure complete gas exchange in the modular 
incubator and then sealed. The incubator operating at hypoxic conditions was technically 
known as a Billups Rothenberg Modular Incubator (originally obtained from ICN) (512). 
Cells were generally incubated in the chamber for various time points up to 96 hours (ie 
continuous hypoxia, the chambers were not re-gassed at regular intervals) as previously 
described (513). Total RNA was extracted from frozen tissue sample and cells by guanidium 
thiocyanate based method (section 2.10). 
 
Northern blots were obtained from rat HSC cultured in control and hypoxic conditions as 
described in the methods (section 2.3).  
 
10µg of total RNA were subjected to electrophoresis through a 1.2% agarose formaldehyde 
gel, and blotted onto a nylon membrane filter. After prehybridization the filter was incubated 
overnight at 50
0C in a 50% formamide buffer with a 32P labeled probe. The northern blots 
were probed for β actin and TIMP-2 rat cDNA. The resulting autoradiographs were subjected 
to scanning densitometry. The TIMP-2 values were normalized for beta actin and expressed in 
an Excel spreadsheet chart. 
 
The membranes were prehybridised at 65
0C for at least 2 hours. The cDNA probe was added 
in the hybridisation buffer at 65
0C for at least 18 hours (overnight). The blots were then 
washed with 4x SSC / 0.5% SDS for 20 minutes/ shaking on 4 occasions. The autoradiograph 
was exposed.   165
4.2.1 Methods RNA expression are described in the Methods chapter section 2.27 & 2.3 
 
Freshly isolted HSC were taken to make Northern blots for analysis of TIMP-2 cDNA. 
 
4.2.2 Methods RPAs are described in the Methods chapter 2 section 2.5 
 
In brief, 10µg of each of sample RNA and the negative control RNA (yeast) was mixed with 
30µl of hybridisation buffer containing 10
5 cpm of 
32P-UTP labelled antisense riboprobe. 
Sample RNA was heated to 95
0C for 5 minutes to denature RNase and then left to hybridise at 
42
0C overnight. RNase one was diluted the following morning in its digestion buffer and 
180µl added to each sample, mixed and incubated at room temperature for 60mins. The 
reaction was terminated by the addition of 30µl of stop solution and the protected fragment 
precipitated by the addition of 825µl of ice cold 100% ethanol and chilling at -70
0C for 
60mins. All samples were centrifuged for 15mins at 1400rpm at 40
0C and the supernatants 
removed with a drawn out flask Pasteur pipette. The resulting pellets were then resuspended 
in 8µl gel loading buffer, heated to 95
0C for 5mins to denature RNA and loaded onto 8M 
polyacrylamide gel and subjected to electrophoresis. 
 
Gels were then cast in a Bio-Rad vertical sequencing apparatus. Plates were first washed in 
ethanol and the back plate sialinised with Sigmacote (Sigma UK) to prevent the gel sticking 
and make removal easier. Two gels were made, the first to seal the end of the plates and a 6-
8% sequencing Gel. The gels were polymerised at room temperature by the addition of 
TEMED and freshly prepared 10% APS, with the combs in situe. Once set the gels were then 
assembled in the electrophoresis apparatus. TBE was warmed then added and the gels de-
ionised by being pre-run at 50
0C with 1.5kV for 30mins. The samples were then added and 
fractionated by electrophoresis at 50-55
0C for 90 mins. The gel was transferred to a backing 
of 3MM filter paper. Following coverage with cling film the gel was vacuum dired at 65
0C. 
The dried gel was then placed next to pre-flashed X ray film and left at  -70
0C for 48-96 
hours. After development of the autoradiographe the resultant bands were analysed by 
scanning densitometry. 
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4.3.1 Results 
 
Northern blots were made using 10µg of total rat HSC RNA obtained from cells incubated at 
various time points in control and hypoxic conditions. After hybridization with the [
32P]-ATP 
cDNA for rat TIMP-2 a dual signal was noted at 3.8kb and 1.2kb which persisted after 
washing with 0.2SDS/0.2xSSC at 50
0C (Figure 4.1 depicts a representative of three 
experiments). The autoradiographs were subjected to scanning densitometry and the results 
plotted on an excel spread sheet. Figure 4.2 demonstrates densitometry for the two TIMP-2 
species both in control and hypoxic conditions for 8, 24, 48 and 72hrs. These values are 
graphed in chart format in Figure 4.3. 
 
This experiment was repeated over 3 occasions. On each occasion there was little difference 
between control and hypoxic conditions for the expression of TIMP-2 in rat passaged HSC. 
The average of the three experiments is shown in Figure 4.4 with columns showing the 
standard error of the mean.   167
Figure 4.1 Expression of TIMP-2 in rat HSC cultured in hypoxic conditions 
 
 
 
 
Figure 4.1 A representative northern with B actin and TIMP-2 probes. Ethidium bromide stained RNA is shown 
above to show loading. Northern blots were prepared from 10µg of total RNA from rat HSC cultured in control 
and hypoxic conditions. They were then hybridized with the cDNA of rat TIMP-2; following this the blots were 
subjected to stringency washes with 4x SSC / 0.5% SDS at 50
0C. This was repeated on three occasions each 
wash lasting for 20min washes, shaking. A beta actin probe was used as a control. 
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Figure 4.2 Scanning densitometry 
 
 
 
 
 
Figure 4.2 Autoradiographs were exposed to northerns probed for rat TIMP-2 cDNA for variable time points. 
The resulting autoradiographs were subjected to scanning densitometry. There are two peaks illustrated here 
representative of the 3.8kb and 1.2kb species respectively.   169
Table 4.1 Raw data from scanning densitometry 
 
    Hours  densitometry   
      Timp-2  β-actin 
 
Timp2 / β actin 
x 100% 
1  Control  8  2912  193  1508.808 
      3544  193  1836.269 
2  Hypoxia  8  3240  199  1628.141 
      3219  199  1617.588 
3  Control  24  2638  200  1319 
      4321  200  2160.5 
4  Hypoxia  24  3591  179  2006.145 
      3818  179  2132.961 
5  Control  48  1463  169  865.6805 
      1970  169  1165.68 
6  Hypoxia  48  2679  181  1480.11 
      3880  181  2143.646 
7  Control  72  3162  186  1700 
      3249  186  1746.774 
8  Hypoxia  72  3561  188  1894.149 
      3199  188  1701.596 
 
 
Table 4.1 Raw data from scanning densitometry.  Density values for TIMP-2 were normalized with B actin for 
each of the 3.8kb and 1.2kb species at each of the control and hypoxia time points.   170
Figure 4.3 TIMP-2 mRNA expression in rat HSC cultured in hypoxic conditions  
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Figure 4.3 Graph of data from a single experiment. Both species of TIMP-2 are graphed together from the raw 
data presented earlier. Y axis is in arbitrary units, the X axis denotes the experimental conditions and the various 
time points in hours. No consistent trend is noted from this data.   171
Figure 4.4 Mean of 3 experiments: TIMP-2 expression in hypoxia 
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Figure 4.4 Mean of 3 experiments examining expression of TIMP-2 expression in rat HSC cultured in control 
and hypoxic conditions. Controls included parallel cell cultures in normoxia. Both 3.8kb and 1.2kb species of 
TIMP-2 are depicted with error bars demonstrating Standard error of the Mean. 
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4.3.2 Results 
 
Figure 4.5 Northern Blot detecting α α α α SMA, Procoll-1, Gel a, TIMPs -1 & -2 in activated rat 
pancreatic stellate cells (PSC) 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 MMP / TIMP expression with activation in PSC primary cultures on uncoated tissue culture plastic 
with cells harvested at day 10, subjected to northern analysis, and probed with a MMP / TIMP cDNA probes. 
The experiment was repeated in 4 separate tissue culture experiments. 
        1               2            3              4                               PSC preparations 
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4.3.3 Results 
 
Figure: 4.6 TIMP-2 RPA human fibrotic liver (x5) vs normal human liver (x3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Autoradiograph of a RPA performed 5 fibrotic human liver samples and 3 normal livers. Y depicts 
the negative control. Samples 1-5 are from cirrhotics human livers. Samples a-c are from 3 separate human livers 
which were deemed clinically to be normal. 
  P       Y     1      2    3      4     5          a       b      c 
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4.4 Discussion 
 
Over 8, 24 and 48hrs there was a nominal increase in the expression of the 3.8kb TIMP-2 
subspecies. In contrast the 1.2kb species was unchanged for 8 and 24hr, with a slight rise in 
48hrs and then a fall at 72hr. In all this was felt to be a negative result. These results were 
disappointing and the collaboration with London become difficult as the cells became infected 
frequently with fungus due to the travel time exposure. However these experiments suggest 
that: 
 
1)  TIMP-2 mRNA expression was demonstrated for control and hypoxic conditions 
2)  TIMP-2 mRNA expression did not appear to differ in hypoxia 
 
More recent work has demonstrated in one small study that TIMP-2 expression was shown to 
be enhanced in hypoxic conditions albeit the largest change was noted early at 6hr which was 
short-lived. It is possible that the time points here were too large and therefore the time point 
(6hr) that would document the largest increase in TIMP-2 mRNA expression was missed. 
Given the early published work on TIMP-2 mRNA expression in hypoxia this work would 
merit repeating and specifically to include the following: 
 
1)  Expression of TIMP-2 in primary rat and human HSC culture 
2)  cDNA probes could also be incorporated for the examination of beta actin, TIMP-1, 
procollagen 1 and gelatinase A. 
3)  shorter time intervals would be worth studying such as 4, 6, 8, 12 and 24hrs in early 
experiments both in primary and passaged rat HSC 
 
It is possible that hypoxia has effects at the post transcriptional level therefore methods of 
examining TIMP-2 expression for example with ELISA should be considered.  It would be 
interesting to repeat the experiment and introduce further variables where cells are exposed to 
hypoxia for a period and then returned to routine culture conditions (normoxia) for a 
subsequent period (a loose mimic of ischemia-reperfusion injury). In a recent study hypoxia 
was incorporated to examine HSC growth in low oxygen tension (1% O2). With hypoxia the 
expression of HIF-1alpha and VEGF gene was induced. Western blotting was used to 
examine expression of alpha SMA TIMP-1 and MMP-2 – all of which were noted to increase 
(433). In a separate paper recently hypoxia and fibrosis was examined in the context of   175
chronic pancreatitis in relation to pancreatic stellate cells. Human PSCs were isolated, and 
cultured under normoxia (21% O2) or hypoxia (1 % O2). Hypoxia induced migration, type I 
collagen expression, and VEGF production in PSCs. Conditioned media of hypoxia-treated 
PSCs induced migration of PSCs, which was inhibited by anti-VEGF antibody, but not by 
antibody against hepatocyte growth factor. Conditioned media of hypoxia-treated PSCs 
induced endothelial cell proliferation, migration, and angiogenesis in vitro and in vivo. PSCs 
expressed several angiogenesis-regulating molecules including VEGF receptors, angiopoietin-
1, and Tie-2. The main conclusion from the group was that hypoxia induced profibrogenic 
and proangiogenic responses in PSCs. In addition to their established profibrogenic roles, 
PSCs might play proangiogenic roles during the development of pancreatic fibrosis, where 
they are subjected to hypoxia (514). 
 
In separate mRNA studies it is clear that activated rat PSC express αSMA, gelatinase-A 
(MMP-2), procollagen-I, TIMP-2 and TIMP-1. This was the first instance of this – there were 
no previous reports of this at the time in the published literature in terms of expression of 
TIMP-1, TIMP-2, alpha SMA, MMP-2 in rat PSC when this work was carried out in 2000. In 
this regard the PSCs appears to be behaving in a similar fashion to rat hepatic stellate cells 
(HSC) and rat renal mesangial cells. TIMP-1 & TIMP-2 mRNA are clearly expressed in 
pancreatic islet cells and therefore TIMP-1 and TIMP-2 may play a role in cell survival. 
 
It is known in liver studies that accumulation of extracellular matrix may result not just from 
increased collage synthesis but also changes in degradation. Gelatinase-2 (MMP-2) degrades 
normal basements membrane type IV Collagen and partially degraded Collagens I, III & IV. 
It may also have collagen I degrading activity. MMPs including Gelatinase-A are inhibited by 
Tissue Inhibitors of Metalloproteinases 1 & 2. Again, in rat liver, TIMP-2 plays a specific role 
in the activation of Gelatinase-A (MMP-2) by linking with pro-gelatinase A and with 
membrane type Matrix Metalloproteinase I (MT1-MMP/MMP-14). Studies in liver and renal 
fibrosis suggested that it is likely that PSCs express Gelatinase-A and TIMPs-1 & -2. In this 
chapter there is clear evidence that this is the case, suggesting that PSCs are capable of 
remodeling matrix and via TIMPs may inhibit matrix degradation in chronic pancreatitis. 
 
In the previous chapter in vivo studies examining the expression of alpha SMA, Gelatinase-A 
(MMP-2), MT1-MMP (MMP-14), TIMP-1 and TIMP-2 in human pancreas were carried out. 
The in vivo expression of these proteins together with the activation of PSCs in culure   176
expressing αSMA, procollagen-I, Gelatinase-A, MT1-MMP, TIMP-1 and TIMP-2 suggest 
that PSCs are indeed able to regulate matrix degradation in addition to synthesis and that the 
expression of TIMPs suggest that matrix degradation may be inhibited during chronic 
pancreatitis.  
 
A ribonuclease protection assay was incorporated to study five samples of liver resection 
from cirrhotic liver and 3 samples from normal liver (liver resected for colorectal cancer 
metastases): in this setting the expression of human TIMP-2 mRNA in normal and diseased 
liver was studied. The results of this demonstrate that human TIMP-2 mRNA is upregulated 
in fibrotic liver in comparison to normal liver. This is a finding in contrast to the expected 
result where TIMP-2 has traditionally been conceived as constitutively expressed in a variety 
of cell systems. 
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CHAPTER 5 
 
STUDIES OF THE TIMP-2 PROMOTER 
IN STELLATE CELLS   178
5.1 Introduction 
 
In previous chapters the role of TIMPs and MMP expression has been examined in vivo 
through immunocytochemistry studies on rat hepatic stellate cells and pancreatic stellate cells. 
This chapter documents work that was intended to examine TIMP-2 expression in more detail 
at the molecular level using in vitro experiments. 
 
The active forms of all the matrix metalloproteinases (MMPs) are inhibited by a family of 
specific inhibitors, the tissue inhibitors of metalloproteinases (TIMPs) (229).  Inhibition 
represents a major level of control of MMP activity (515).  A detailed knowledge of the 
mechanisms controlling TIMP gene expression is therefore important (213). 
 
Previous work with the murine TIMP1 gene promoter has identified serum and phorbol ester 
responsive elements including an activating protein 1 (AP-1) and polyoma enhancer A3 
(PEA-3) element proximal to the transcription start site. However, sequences more distal in 
the 5` flanking region, as well as those within intron 1, are likely to have a transcriptional role 
(516) (248).  Recently a genomic clone of the human TIMP-1 gene has been obtained (517) 
enabling the transcription start points to be identified and transient transfection studies have 
been used to map the basal promoter. 
 
In 1996 the human TIMP-2 gene was characterised (518).  The gene is 83 kilobase pairs (Kb) 
long with exon-intron splicing sites located in preserved positions among the three members 
of the TIMP family.  Work, performed on human fibroblasts isolated a 2.6 Kb genomic DNA 
fragment flanking the 5` end of the gene containing several regulatory elements including five 
SP1, two AP-2, one AP-1, and three PEA-3 binding sites (518).  Our department obtained two 
plasmids on a collaborative basis from Prof Yves DeClerck, Professor of Paediatric and 
Biochemical research at the Children’s Centre for Cancer and Blood diseases, Los Angles, 
United States of America.  The first one was the 2.6 Kb segment of the promoter (full 
promoter), the second a 276 base pair of the promoter (short promoter), both constructs 
inserted upstream of the promoter-less luciferase reporter gene in the plasmid pGL3 
(Promega). In commencing this work my initial aim was to transfect the vector constructs into 
hepatic stellate cells however the subsequent difficulties here led to a more detailed analysis 
of the constructs and ultimately to sub cloning the constructs into a different vector.   179
The pGL3 diagrams are depicted in figures 5.1a (basic negative control vector or “Mock”), 
figure 5.1b (positive control vector with a SV40 – simian viral promoter), figure 5.1c (full 
TIMP-2 2600 promoter construct) and figure 5.1d (short TIMP-2 267 promoter construct). 
The structure of the nucleotide sequence of the 2.6kb Pst I genomic fragment containing the 
human (h) TIMP-2 promoter was published in 1996 by Professor DeClerck and is depicted in 
figure 5.2. 
 
The sequence includes part of the first exon. Positions of nucleotides indicated on the left are 
numbered from the major transcription initiation site (nt+1) shown above by an arrow (►). 
Consensus sequences are indicated on the diagram (underlined) and include the following 
binding sites: 
 
•  a TATA like motif 
•  five Sp1 
•  two AP-2 
•  one AP-1 
•  three PEA-3 
 
The initiator ATG is shown at positions +303 to +305. Sequences extending from the 3` -end 
PstI site to position -519 (BamHI site) were published previously (519) 
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Figure 5.1a pGL-3 basic vector (negative control vector) 
 
 
This was used in all experiments and as a negative control vector was termed “mock”.   181
Figure 5.1b pGL-3 basic vector with SV40 promoter 
 
 
This was used in all experiments and as a positive control vector was termed positive (+ve) 
control.   182
Figure 5.1c pGL-3 basic vector with the human (h) TIMP-2 gene promoter of 2600 base 
pairs inserted 
 
 
 
The pGL3 vector with the hTIMP-2 2600 base pair full promoter has Not-1 and Xba-1 
restriction sites spanning either side of it. Downstream from the promoter is the luciferase 
gene itself with a sv40 late polyA gene distal to this. All of the pGL3 vectors used in this 
work had an ampicillin resistance gene incorporated.   183
Figure 5.1d pGL-3 basic vector with the human (h) TIMP-2 gene promoter of 267 base 
pairs inserted 
 
 
 
The pGL3 vector with the hTIMP-2 267 base pair short promoter has Not-1 and Xba-1 
restriction sites spanning either side of it. Downstream from the promoter is the luciferase 
gene itself with a SV40 late polyA gene distal to this. All of the pGL3 vectors used in this 
work had an ampicillin resistance gene incorporated.   184
Figure 5.2 Nucleotide sequence of the 2.6kb Pst-1 genomic fragment containing the human 
(h)TIMP-2 promoter 
 
 
-2243 CTGCAGACTCAACTTCCCCAGGCTCAAGCGATCCTCCCACCGCAGCTTCCCTGTAGCTGG 
-2183 GACTACAAGTGTAGCCATCACGCCCAGCTAATTTTTTTTTTTGTAGAGATGGGGTCTCAG 
-2123 TATGTTCCTCAGGCTGGTCTCAAATCCTGGCCTCAAGGTGATCCTCCCACCTTAGTTTCA 
-2063 CCAAAGTGTTGGGATTACAAGCGTGAGCCACTGCACCTGGCAAGATTTCTGCTTCACTTT 
-2003 TCCTGGGAGCAATTCCAGCCTGTTGTGTGCTGGTGGGGATGACTTCGGGGGAGGGCGTCA 
-1943 CAGGATACAGGTGCGAGGCCTTGGGTTGGAAGTTCCAGTCTCACGCCCCCCCAACCCTGG 
-1883 GCCCAGGCCCCCCTTTCCTCCCAGGTACATCCCACATTGGCCCCACCCCCTTGGCTGTCG 
-1823 GCACCACAACTGCTCTAAGGTATTTATCACCCTAACATGTACCTGATCACTTATATGTAG 
-1763 AGCTTGTCTAAAAGACCGAGAGCCCCTATGCTACCTGTTTTCTATCATGAACTGACAATT 
-1703 GAAACACAAGTTCAACAGCATTTTGTTCCCCCTGTAACCAAAAAGAAGGAAAGAAAACAA 
                     PEA-3 
-1643 TGAAATGGCTGAAGGCAGCCAGCACATAACAATTTTCTGAATTAACTGTACTTTTAAACG 
-1583 TTAGCTTCAAACATCATTTTGTGAACGACCCAACTCTATTTCACGCTAACAAAAACCAAA 
-1523 AAAGTGACTTTGGATTTGTCAGGGTGCTAAAAATAACGGCATTGCTTATTTAAATCTTCT 
    MEF-2 
-1463 CAGAAACTGTCTGTTACAAAACATACACAAACAGAAAGAAGCTGTTTTTCCATTCTTTCA 
-1403 TATTTTCCAAAGTTTCATACCTCAAGCTAGCACTGCTGCACAATTTAGTGGGCAATTCTT 
-1343 AAAAAAAAAAAAAAACAAAAAAAACAAACAAGAGTCTTTCTCTGTCGCCCAGGCTGGAGT 
-1283 GCAGTGGCGCAATCTCGGCTCACTGCAAGCTCCGCCTCCTGGGTTCATGCCATTCTCCTG 
       NF-IL6        Sp1/Rev 
-1223 CCTCAGCCTCCCGAGTAGCTGGGACTACAGGCGCCCACCACCAAGCCCGGCTAATTTTTT 
   Sp1/Rev 
-1163 GTATTTTTAGTAGAGACGGGGTTTCACTGTCTCTACTAAATGCTAGCCAGGCTGGTCTCA 
-1103 AACTCCTGGCCTCAAGTGATCCTCCTGTCGCGCCCTCCCAAAGTGCTGGGATTACAGGCT 
-1043 GCAAGCACGTGCCCGCCCTGATTCTTCCTGTGTCATTTTCTGGGGCTTCCCCTCTCCCTA 
-983  GCTGGACTGCAAACACTCTGGAATGCTGACCTGAGGGCTGGAGTGCTGACCTGAGTGCAG 
-923  CAGTGTCCATGGAGCCCCACGGGGCACACACCAAATGTACAGGGTGGGTGCCCACAGCCG 
-863  CGCACAGGCAGGTTCACAGCCAGGAAGCCGCCCTCACCACCCTACACATGTTCATCTCTT 
            PEA-3 
-803  CATATGCCTGGGTCTTTCCTGGAACACAAAACTGTTTTGGGAAAAGTCCTCCGGCTCCCA   185
Figure 5.3  Nucleotide sequence of the 2.6kb Pst-1 genomic fragment containing the 
human (h)TIMP-2 promoter (Continued from overleaf) 
 
-743  CATTTGTGGACTAAGAGAGGAAACTGTGAGCGGAACCCAGCCAATGCCTCTGCTGCGATC 
           PEA-3      NF-1 
-683  CTACTGGCTCCTGGGCGCCTGGGCCCACCCCCGTCTCTTGTTGGCTGGTCAAAAATATGG 
-623  CCAGTTTATATAAAATCCTGTTTTGTTCACAGTAACCACACCCCCCACCCCCCAACTAAA 
-563  CTGGCCAGGCGCACTTAAAATTCTAAGGCCTCCATTTGAAAAAGGGATCCTGTCAGTTTC 
-503  TCAATAGGCCACCCGCCCACAGAAACGGGGAGGTGGCGACAGGGAACGGCCCCTGCTCCA 
         Sp1/Rev 
-443  AAGGACACCCCTTGGCTCGCCCCGAGGCTGGGCTCGAAGGGACCCCGGGGTGGCGGGGGA 
            Sp1 
-383  CGGAGCAGCGTAGCCCTCCAGAGTCGAGCTGAAGGGGAAAGGGTAGCGGGTGGGTCGCCT 
-323  GGTGCCCTGGAAGAACGGGCGCGAGTCCCACGCGCTGAGTCAGGGACCCCGGGCGCAGAA 
                AP-1  AP-2 
-263  GGCCACGCAGCGGGGACCGGGGTCGGGGGGCTGGGGGCGTCCGGGCGCACCCCCGCGCGG 
             Sp1          AP-2 
-203  GTGCGGGTCGCGGGCGCCAGGTGGTGCGGGAAGCCCCCGACTGTCCAGGCCGGGCACAAC 
           NF-IL6 
-143  AAAAGCGCGGGCTGGGGGGAGGCGCGGGCGGAGGGGGAGGAGGGGGCTGCTGGGAGCGCC 
-83  CAGAGCCTGCATTGGCCGCCAGCCACCGGGAGGAGGAGCAGAAAATCCTCCGAGCGCAAT 
           ►             TATA 
-23  AAAACTGCGGCCCGGCCCAAGCCCGCAGCAAACACATCCGTAGAAGGCAGCGCGGCCGCC 
  Box           +1 
+38  GAGAGCCGCAGCGCCGCTCGCCCGCCTGCCCCCACCCCGCCGCCCCGCCCGGCGAATTGC 
+98  GCCCCGCGCCCCTCCCCTCGCGCCCCCGAGACAAAGAGGAGAGAAAGTTTGCGCGGCCGA 
+158  GCGGGGCAGGTGAGGAGGGTGAGCCGCGCGGGAGGGGCCCGCCTCGGCCCCGGCTCAGCC 
+218  CCCGCCCGCGCCCCCAGCCCGCCGCCGCGAGCAGCGCCCGGACCCCCCAGCGGCGGCCCC 
+278  CGCCCGCCCAGCCCCCCGGCCCGCCATGGGCGCCGCGGCCCGCACCCTGCGGCTGGCGCT 
           Met 
+338  CGGCCTCCTGCTGCCGCTGCTTCGCCCGGCCGAGCGCTGCAG 
 
Figure 5.2 and 5.3 is shown above depicting the whole 2.6kb sequence of the human (h) TIMP-2 promoter. The 
sequence includes part of the first exon. Positions of nucleotides indicated on the left are numbered from the 
major transcription initiation site (nt+1) shown above by an arrow (►). Consensus sequences including a TATA 
like motif, five Sp1, two AP-2, one AP-1, and three PEA-3 binding sites in addition to other binding sites are 
underlined. The initiator ATG is shown at positions +303 to +305. Sequences extending from the 3` -end PstI 
site to position -519 (BamHI site) were published previously (519).   186
5.2 Methods 
 
Isolation of rat hepatic and pancreatic stellate cells 
Isolation methods are described in Chapter 2 section 2.2.1 & 2.2.7 
 
Amplification, purification and analysis of plasmid DNA 
Methods are described in detail in chapter 2 section 2.6.  
This includes details on the following: 
•  Restriction Enzyme Analysis of Plasmid DNA (2.6.2) 
•  Amplification, Purification and Analysis of Plasmid DNA (2.6.4) 
•  Production of competent cells (DH5α E. coli)(2.6.5) 
•  Transformation and Amplification of competent Escherichia coli (E coli) with 
Plasmid DNA (2.6.6) 
•  Bacterial Propagation (2.6.7) 
•  Production of Bacterial Stock (2.6.8) 
•  Purification of Plasmid DNA (2.6.9) 
•  Restriction Enzyme analysis of Plasmid DNA (2.6.10) 
•  Purification of DNA or PCR products from Agarose Gels (2.6.11) 
 
Transfection 
This section is described in detail in Chapter 2 section 2.7. 
This includes details of the following: 
•  The luciferase reporter assay system 2.7.2 
•  The Chloramphenicol Acetyl Transferase (CAT) Transfection Assay (2.7.4) 
 
Systematic deletion of plasmid DNA 
The methods for the Promega “Erase-a-Base” system are described in detail in 2.8. 
Sequencing plasmid constructs is described in detail in section 2.9. 
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5.3 Results 
 
5.3.1 Early Transfection work with the luciferase reporter assay 
 
Transfection is discussed in detail in Chapter 2 section 2.7. Two different transfection 
protocols were incorporated from Promega. The first, described here, was used at the 
beginning of my work “Dual Luciferase Reporter Assay” and unfortunately yielded only 
moderate results. The luciferase enzyme used is derived from the coding sequence of the luc 
gene cloned from the firefly ‘Photinus pyralis’ (491-493).  The firefly luciferase enzyme 
catalyses a reaction using D-luciferin and ATP in the presence of oxygen and Mg
2+ giving in 
light emission.  The light measured in a time interval is directly proportional to that of 
luciferase reporter activity in the sample.  This light emission was quantified using a 
proprietary luminometer purchased from Promega. The “Dual Luciferase Reporter Assay 
System” (Promega) combines two luciferase reporter enzymes. The firefly luciferase can be 
effectively quenched so that the second reporter – an internal control and derived from the sea 
pansy “Renilla reniformis” - can be assayed for its luminescence. Plasmid stocks were 
obtained of the pGL3 basic vector (-ve control), pGLSV40 (positive control), pGL3 TIMP-2 
human 2600 (full promoter) and pGL3 TIMP-2 h276 (shortened promoter). In accordance 
with the current Promega protocol the stocks were defrosted over 30min. 10µg of plasmid was 
added to Microfuge tubes, 0.5µl of PRL (Renilla luciferase) was added for co transfection. 
Rat HSC in flasks were washed in serum free media for 6hrs. DNA and lipofectin/DNA were 
incubated for 10mins at room temperature. This was then added to the flasks of HSC. Flasks 
were incubated for 72hrs then the cells were harvested in order to perform the luciferase 
assay. Using the proprietary Promega Luminometer the light production from individual 
samples was measured once the Luc Assay Reagent was added. The Luciferase was then 
quenched with the Renilla solution and the corresponding activity was measured. The values 
for the firefly were divided by the renilla values. The experiment was repeated on 3 separate 
HSC preparations then expressed in an Excel spreadsheet chart with the standard error of the 
mean (SEM) applied.   188
Table 5.1 Transfection of pGL3 TIMP-2 2600 full promoter and 267 shortened promoter 
into passaged rat hepatic stellate cells 
 
Transfection  Renilla   Firefly  Mean Renilla / Mean Firefly 
1)  pGL3 empty vector  0.035    0.000   
“Mock” or negative 
control 
0.097    0.095   
  0.100    0.000   
  Mean  0.077    0.032  2.41 
 
2)  pGL3 SV40  5.827    0.194   
Positive control  0.641    0.215   
  6.596    0.224   
  Mean  6.28    0.211  29.76 
 
3)  hTIMP-2 276  0.032    0.008   
Short promoter  0.16    0.044   
  0.268    0.027   
  Mean  0.153    0.027  5.67 
 
4)  TIMP-2 2600  0.068    0.029   
Full promoter  0.000    0.04   
  0.000    0.159   
  Mean  0.023    0.076  0.303 
 
Table 5.1: Transfection of pGL3 TIMP-2 2600 full promoter ad 267 shortened promoter into passaged rat 
hepatic stellate cells.  Raw data example of early transfection using ‘Lipofectin’ (PROMEGA).  Transfections 
carried out in single wells only on passaged rat HSC (passage 5).  Each experiment required the initial incubation 
in serum free media for 6 hours prior to transfection.  Cells were then incubated at 37°C for 72 hours.  Cells were 
then harvested and analysed for luciferase & renilla activity.3 readings are taken for each luciferase, 3 readings 
for each firefly and averaged. This experiment was repeated on three occasions. 
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Figure 5.4 Transfection of pGL3 TIMP-2 2600 full promoter and 267 shortened promoter 
into passaged rat hepatic stellate cells (n=3) 
 
"Lipofectin Protocol by Promega" Transfection into passaged 
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Figure 5.4 Graph depicting the mean of three experiments of transfections carried out in single wells on 
passaged rat HSC (passage 5).  The x axis shows the 4 different constructs incorporated, the y axis depicts the 
relative acitivity normalised to the Mock vector with a value of 1.0. The mock depicts the negative control with a 
pGL3 empty vector. SV40 is the positive control. 2600 and 276 depicts the TIMP-2 long (full) and 276 
(shortened) constructs transfected. Each experiment required the initial incubation in serum free media for 6 
hours prior to transfection.  Cells were then incubated at 37°C for 72 hours.  Cells were then harvested and 
analysed for luciferase & renilla activity.3 readings are taken for each luciferase, 3 readings for each firefly and 
averaged. N=3. This data of the mean of 3 experiments was subjected to statistical analysis shown below in 
Table 5.2 
 
Table 5.2 One-way Analysis of Variance (ANOVA) for data shown in Figure 5.3 
 
Comparison  Mean Diff  q  P value  95% Confidence Interval 
From    To 
Mock vs SV40  -23.441  5.008  *  P<0.05  -44.639  -2.242 
Mock vs 2600  -0.02788  0.005956  ns  P>0.05  -21.226  21.170 
Mock vs 276  -0.5611  0.1199  ns  P>0.05  -21.759  20.637 
SV40 vs 2600  23.413  5.002  *  P<0.05  2.215  44.611 
SV40 vs 276  22.88  4.888  *  P<0.05  1.681  44.078 
2600 vs 276  -0.5332  0.1139  ns  P>0.05  -21.731  20.665 
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5.4 Discussion on Early Transfection 
 
Very little consistent activity was noted in the initial transfections.  The SV40 consistently 
showed very positive values demonstrating its quality as a positive control. Relatively little 
activity was noted however for the TIMP-2 full 2.6kb and short 276bp promoters. This was 
disappointing given that DeClerck et al had good results in other cell systems (NIH3T3 and 
HT1080 cells). Their method of transfection incorporated different transfection protocols 
(calcium phosphate). Previous work with this transfection protocol by the liver group in 
previous years had produced only moderate transfection efficiencies. There are a number of 
possible reasons for these results. The promoters may not have been active in passaged rat 
HSC though it is clear in experiments demonstrating  clear evidence of TIMP-2 mRNA 
expression that this is unlikely; equally the promoters may have only been strongly active in 
the early stages of passaging for example after 1-2 days. A human gene reporter may not have 
been as active in a rat HSC system. Further work could have been repeated here in other cells 
systems such has 3T3 and 1080 cells lines as well as performing the experiments on quiescent 
HSC cells both in rat and human HSC preparations.  
 
A reporter system that was cumulative over time may be more appropriate and therefore the 
CAT assay system was chosen for the next set of transfections in hepatic stellate cells.  In 
order to perform CAT assays the human (h)TIMP-2 2600 full promoter construct and hTIMP-
2 276 short promoter construct would need to be sub cloned into a CAT reporter plasmid 
(pBlCAT3).  This work would involve a restriction digest of the hTIMP-2 2600 and 276 
constructs from the pGL3 vectors.  The pBlCAT3 would then need to be linearised, treated 
with alkaline phosphatase and gel purified.  Following ligation of the TIMP-2 inserts into 
pBlCAT3 the resulting plasmids would be transformed into competent cells, and plasmids 
subsequently amplified with the use of ‘MAXIPREPS’ after correct identification with 
‘MINIPREPS’.  The resulting plasmids would need to be subjected to restriction digests to 
map the inserts and sequenced to confirm the orientation within the pBlCAT 3 vector.  Once 
this was achieved only then would CAT transfections be possible.   191
5.5 Subcloning plasmid DNA into another plasmid vector 
 
5.5.1 Aim: Isolation of the TIMP-2 full promoter (2600bp) insert in the pGL3 vector and 
subclone it into the pBlCAT3 vector 
 
In order to subclone the plasmid DNA into another vector (from pGL3 basic to pBLCAT3) 
there were certain steps required in the roadmap in order to achieve this.  The pGL3 TIMP-2 
2600 and pGL3 TIMP-2 276 promoter constructs would need to be characterized in order to 
plan ahead. The key steps therefore included: 
 
•  Restriction digest of 2600/276 fragment from the PGL3 vector 
•  Ligation into a new vector 
•  Preparation of the vector: PST-1 cut/ alkaline phosphate/ gel purification 
•  Transformation into competent cells 
•  Miniprep and Maxi preps 
•  Mapping the new vector with restriction cuts 
•  Sequencing to confirm orientation 
•  Finally: Transfection of the new CAT vector into rat HSC 
 
 
5.5.2 Method for ligating pBlCAT3 
 
pBlCAT3 was linearised with the aid of the enzyme PST-1 (Promega): 10µl of plasmid DNA 
(pBlCAT3) at a concentration of 1µg/µl was incubated with 5µl of 10x buffer (Promega), 30µl 
of distilled water, and 5µl of PST-1 enzyme at 37
0C for two hours.  To prevent vector ends 
from annealing immediately the linearised pBlCAT3 was treated with alkaline phosphatase: 
5µl of a 10x alkaline phosphatase buffer was added with 2µl of calf intestinal alkaline 
phosphatase enzyme to the pBlCAT3 plasmid and incubated at 37
0C for 30 min.  1µl of 
phosphatase buffer was added at this stage and the linearised pBlCAT3 was incubated at the 
same temperature for a further thirty min.  To purify the linearised plasmid it was subjected to 
phenol/chloroform extraction followed by ethanol precipitation.  The DNA was then 
centrifuged at 13,000 for 5 min to obtain a pellet and after discarding the supernatant the 
pellet was dried.  It was assumed that complete recovery was obtained and therefore distilled 
water was added to a final concentration of 100µg/µl.   192
Two sets of microfuge tubes were created for each of the three conditions 
Table 5.3 Ration of plasmid to insert 
 
  1  2  3 
Ratio of Plasmid to Insert  1:1  1:3  3:1 
DNA Insert  1µl  1µl  3µl 
Vector   1µl  3µl  1µl 
Buffer  1µl  1µl  1µl 
Distilled Water  6.5µl  4.5µl  4.5µl 
Ligase  0.5µl  0.5µl  0.5µl 
 
Table 5.3: Ration of plasmid to insert.  Samples of the vector/insert were transformed into competent DH5α E. 
Coli (as outlined in Chapter 2 Methods Section 2.6) and grown on agar plates overnight at 37
0C.  Resultant 
colonies were plated and grown in CB with Ampicillin overnight at 37
0C shaking.  Minipreps were prepared to 
isolate any resulting plasmid DNA. 
 
Competent DH5α E. Coli were taken from 80
0C freezer and thawed on ice.  A sample of 
DNA eg 5µl of TIMP 2600 insert ligated into pBlCAT3 was added to 20µl of DH5α E. Coli 
and incubated on ice for 30 min.  The DH5α E. Coli were then heat shocked at 42
0C for 45 
seconds before being returned to ice for two min.  80µl of sterile LB was added to each 
sample of DH5α E. Coli (with no ampicillin added) and incubated in a water bath at 37
0C for 
30 min.  The DH5α E. Coli/LB both was then streaked onto freshly made agar plates: one at 
20µl and one at 80µl overnight at 37
0C.  Colonies were then ‘picked’ using a sterile Pasteur 
pipette and inserted into LB with (no ampicillin) and incubated in an orbital shaker at 37
0C 
for two hours.  20µl of 25µg/ml ampicillin was then added to each and the LB/colonies were 
incubated shaking overnight at 37
0C.   193
5.5.3 Results 
 
On the first occasion no plasmids were harvested.  Therefore the experiment was repeated 
with the following procedures: 
 
1.  All procedures for linearizing pBlCAT3, performing a restriction digest of the human 
TIMP-2 2600 promoter from the vector pGL3 and ligation of this insert were carried out 
in one day 
2.  No plasmid insert was frozen 
3.  1 control was run without treatment of the pBlCAT3 with alkaline phosphatase 
4.  The reactor: insert ratio was 1:1, 3:1, 10:1 and a control of 1:1 where the control had 
pBlCAT3 with no exposure to alkaline phosphatase. 
 
Table 5.4 Results of colonies 
 
Condition  Amount of plasmid 
added to agar plates 
Growth / No of 
colonies 
1.  DH5 on agar plates: no growth.   
No pBlCAT3 or insert 
 
  No Growth 
2.  Control (pBlCAT3: No alkaline 
phosphatase) 
20µl 
80µl 
35 colonies 
246 colonies 
 
3.  1:1 ratio of pBLCAT3 to insert  20µl 
80µl 
0 colonies 
0 colonies 
 
4.  10:1 ratio of pBLCAT3 to insert  20µl 
80µl 
1 colonies 
3 colonies 
 
5.  3:1 ratio of pBLCAT3 to insert  20µl 
80µl 
1 colonies 
3 colonies   194
5.5.4 Discussion of the initial characterisation of pGL3 – TIMP2 276 Insert 
 
The short promoter pGL3 hTIMP-2 276bp short construct was subjected to restriction enzyme 
analysis.  Competent DH5 α E.coli were transformed with the pGL3 TIMP-2 276bp short 
construct plasmid and subsequently ‘Maxipreps’ were performed.  4µl of plasmid at a 
concentration of 1µg/µl was incubated in a Microfuge tube in a water bath at 37
°C with 2µl of 
restriction enzyme, 2µl of buffer D (Promega) and 12µl of distilled water for two hours.  
Figure 5.5 shows the results on a 1% agarose gel.   
 
With a successful restriction digest, a lower molecular weight discrete insert would be seen 
on the gel. With the exception of a single cut with Xba-1 on the pGL3Basic empty vector or 
“Mock” plasmid no restriction digest could be achieved with Xba-1 and Not-1 on the pGL3-
TIMP-2 short promoter (276bp). The same result was obtained when the experiment was 
repeated under new conditions (new buffers and overnight digests) and with new enzymes.  
The buffers for the respective enzymes were checked with the manufacturers, Promega, 
directly to ensure compatibility. Not-1 was used to cut another plasmid in the laboratory to 
ensure that there was no intrinsic fault with the enzyme (results not shown) and a successful 
digest was confirmed. Figure 5.1 depicts the Promega plasmid map for pGL3 basic vector. 
The Promega catalogues clearly document at least two Xba-1 and NOT-1 restriction sites: one 
on each side of the promoter insert site, on their PGL3 vectors. 
 
The reasons that there was only an Xba-1 cut in the mock plasmid and no Xba-1 and  
Not-1 cut on the short hTIMP-2 276bp promoter is unclear.  However there may be two 
possible explanations for this: one is that the sites were removed when the human TIMP-2 
promoter was sub cloned into the PGL3 vector; the second is that the sites were in some way 
damaged at the cloning process.  Prof Yves DeClerck documented himself two Xba-1 and 
Not-1 sites on his plasmid map. Despite attempts to contact Professor Yves DeClerks group I 
was not able to obtain any more helpful information on this.   195
Figure 5.5 Iinitial characterisation of pGL3 – hTIMP-2 276bp (short promoter) 
 
 
1% Agarose gel in TAE run at 30 watts 25 volts for 30 minutes.  From left to right lanes 1-10 
include: 
1) 1kb DNA markers (Promega) 
2) pGL3-Mock (uncut plasmid) 
3) PGL3-Mock digest with Xba-l 
4) pGL3-Mock digest with Not-1 
5) pGL3 TIMP-2 short construct (276) [uncut plasmid] 
6) pGL3 TIMP-2 short construct (276) digest with Xba-l 
7) pGL3 TIMP-2 short construct (276) digest with Not-1 
8) pBlCAT3 (uncut plasmid) 
9) 1µg of linearised pBlCAT3 
10) 1µg of MT1-MMP 
 
This figure shows that whilst there is a cut with the restriction enzyme Xba-1 on the mock 
plasmid there is no such cut with Not-1.  Similarly, no cuts are noted with Xba-1 or NOT-1, 
on pGL3 TIMP-2 short construct (276) plasmid. 
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5.5.5 Further restriction analysis 
 
The pGL3 hTIMP-2 276bp short construct was subjected to further restriction enzyme 
analysis with KPN-1 and HIND III.  4µl of plasmid (1µg/µl) was incubated in a Microfuge 
tube in a water bath at 37
0C with 1µl of restriction enzyme (or 0.5µl of each enzyme if a 
double digest was performed), 2µl of buffer D (Promega) and 12µl of distilled water for two 
hours.  Neither KPN-1 nor HIND-III linearized the Mock plasmid (-ve vector) or linearized or 
cut out the pGL3 TIMP-2 short 276 promoter despite the use of an image intensifier.  The gel 
is depicted in Figure 5.6. The experimental protocol was repeated for the pGL3 TIMP-2 
2600bp full promoter construct and this is shown in Figure 5.7. This plasmid mapping shows 
linearization of the pGL3-Mock with HIND-III and PST-1 restriction enzymes separately, and 
with HIND-III and PST-1 together as a double digest.  Both HIND-III and PST-1 linearise the 
PGL3 276 plasmid separately and do the same again with a double digest.  No TIMP-2 276 
fragment can be seen on the pGL3-276 double digest.  HIND-III appears to produce a smaller 
fragment in lane 11 on the PGL3 2600 vector whilst PST-1 in lane 12 and PST-1 plus HIND-
III in lane 13 give a double cut: one possibility is that this may be due to PST-1 and HIND-III 
cutting within the 2600 site as well as pGL3 vector. However on examination of the hTIMP-2 
construct sequence the restriction enzyme Pst-1 makes the following cut:  
 
CTGCA
▼G 
G▲ACGTC 
 
From the sequence described in Figure 5.2 it should in theory however only cut at the 
beginning and end of the sequence. See below. 
 
-2243 CTGCAGACTCAACTTCCCCAGGCTCAAGCGATCCTCCCACCGCAGCTTCCCTGTAGCTGG 
+338  CGGCCTCCTGCTGCCGCTGCTTCGCCCGGCCGAGCGCTGCAG 
 
Hind III makes the following cut: 
A
▼AGCTT 
TTCGA▲A 
No cut within the sequence could be noted on scanning the sequence depicted on figure 5.2.   197
Figure 5.6 Restriction digest of pGL3 – TIMP-2 276 short construct with KPN-1 or HIND-
III  
 
 
 
Image intensifier image of a 1% Agarose gel in TAE. Lanes 1-10 as follows:  
 
1) 1kB DNA ladder (Promega) 
2) pGL3-Mock uncut plasmid 
3) pGL3-Mock digest with KPN-1 
4) pGL3-Mock digest with HIND-III 
5) pGL3-Mock double digest with KPN-1 and HIND III 
6) pGL3 TIMP-2 short construct (276) uncut plasmid 
7) pGL3 TIMP-2 short construct (276) digest with KPN-1 
8) pGL3 TIMP-2 short construct (276) digest with HIND-III 
9) pGL3 TIMP-2 short construct (276) double digest with KPN-1 and HIND III 
10) pGL3 TIMP-2 long construct (2600) uncut plasmid 
 
This shows that there is no cut in pGL3-Mock or pGL3 TIMP-2 276 (short promoter) vectors 
with KPN-1 and HIND III.  An image intensifier was used to look for the TIMP-2 276 
fragment.  
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Figure 5.7 Restriction digest of GL3 – TIMP-2 276 short construct plasmid and the pGL3 – 
TIMP-2 2600 long construct plasmid with PST-1 and HIND-III 
 
 
 
1% Agarose gel in TAE canes 1 – 13 are as follows:  
1) 1kb DNA ladder (Promega) 
2) pGL3-Mock (uncut plasmid) 
3) pGL3-Mock digest with HIND-III 
4) pGL3-Mock digest with PST-1 
5) pGL3 double digest with HINDIII/PST1 
6) pGL3-276 uncut plasmid 
7) pGL3-276 plasmid digest with HIND-III 
8) pGL3-276 plasmid digest with PST-1 
9) pGL3-276 double digest with HINDIII/PST-1 
10) pGL3-2600 uncut plasmid 
11) pGL3-2600 digest with HIND-III 
12) pGL3-plasmid digest with PST-1 
13) pGL3-plasmid double digest with HIND-III and PST-1. 
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Figure 5.8 Purification of the pGL3 TIMP-2 2600 full promoter 
 
 
 
 
 
 
 
 
1% Agarose gel in TAE. Lanes 1-4 are as follows: 
1) DNA markers 
2) pGL3-Mock  
3) pGL3 TIMP-2 2600bp uncut plasmid 
4) pGL3 TIMP-2 2600 digest with PST-1 
 
This shows the human pGL3 TIMP-2 2600 full promoter insert cut, purified and run on the 
gel. 
 
1    2    3    4   200
5.5.6 Sequencing of the pGL3 TIMP-2 2600 full promoter and 276bp (short promoter) 
 
With the anomalies encountered with the restriction digest of the human pGL3-TIMP-2 2600 
full promoter and the pGL3- TIMP-2 276 short promoter constructs it was necessary to 
sequence them.  
 
Methods 
This was carried out by the method as described in general methods (2:1:1). 
 
Results 
The sequence is shown in figure 5.9 for the pGL3-TIMP-2 2600 full promoter construct and 
in more detail in figure 5.9b.  
 
5.5.7 Discussion 
 
Whilst I was able to do this successfully the detail on the sequencing gel was not precise 
enough to obtain accurate sequencing of the plasmid. The short promoter sequencing was 
indeed poor (not shown). I elected at this stage to have the sequencing performed 
professionally in an adjacent laboratory. This provided data on the full 2600 and short 276 
constructs that confirmed the sequencing structure of both to be that of the published 
structures (518). (See Figure 5.2 for the sequence of the full human TIMP-2 2600bp 
promoter). 
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Figure 5.9a Sequencing gel of the TIMP-2 2600 and 276 constructs 
 
 
 
 
Figure 5.9a: Sequencing gel of TIMP-2 2600 and 276 Constructs. This gel shows sequencing of the pGL3 
hTIMP-2 2600 and 276 inserts.  Its clear that its impossible to write out the sequence based on this gel, in fact 
the smaller insert did not sequence as well.  Both plasmids were simultaneously sequenced in a neighbouring 
commercial sequencing laboratory in Southampton which confirmed that the inserts were the TIMP-2 2700 and 
276 as originally outlined by Dr Yves DeClerck. 
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5` 
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Figure 5.9b Sequencing gel of the TIMP-2 2600 and 276 constructs 
 
 
 
 
 
 
 
Figure 5.9b: Sequencing gel of TIMP-2 2600 in more detail 
   g        a        t        c      g        a        t      c 
3` 
5` 
Sequence of the hTIMP2 2600 full  
promoter insert in pGL3   203
5.5.8 Subcloning the PGL3 2600 human TIMP-2 full promoter into pBLCAT3 
 
Method  
The experimental detail is provided in chapter 2 section 2.6 but is described here briefly. The 
following was carried out in one day: 
 
1)  The TIMP-2 2600 full promoter insert was cut out from pGL3 Basic vector with a 
PST1 cut: no freezing was carried out in order to minimize damage to the promoter 
insert. 
2)  pBLCAT3 vector was linearized with PST1 and treated with alkaline phosphatase. 
3)  A check gel was performed. 
4)  A phenol chloroform extraction of the TIMP-2 2600 full promoter was carried out. 
5)  The ligation reaction was initiated. 
6)  Bacterial stocks of DH5alpha were transformed and streaked out onto agar plates. 
7)  Following check gels minipreps of cell cultures was carried out. 
8)  1 colony was picked. 
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Figure 5.10 Isolation of the TIMP-2600 insert 
 
 
 
 
1% Agarose TAE gel lane 1-3 as follows 
1) DNA ladder 
2) pGL3-hTIMP2 2600kb full promoter construct (uncut plasmid) 
3) hTIMP-2 2600kb full promoter insert gel purified 
 
5090 
4072 
3054 
2036 
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Figure 5.11 Isolation of the pBLCAT 3 linearised plasmid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1) 1kb DNA marker (Promega) 
2) pBLCAT3 uncut plasmid 
3) linearised pBLCAT3 with a PST-1 cut 
4) human TIMP2-2600 full promoter insert (cut from the pGL3 vector by restriction enzymes, 
isolated and gel purified). 
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Figure 5.12 Ligation of the TIMP-2 2600 insert into the pBLCAT3 vector in 7 out of 18 
colonies 
 
 
 
 
 
 
 
 
 
 
 
 
 
1% Agarose gel in TAE lanes 1-20 as follows: 
1) 1kb DNA ladder (Promega) 
2) pBlCAT3 uncut plasmid 
3) – 20) samples (1-18) of minipreps performed on overnight cultures. 
 
Conclusion:  lanes 3, 5, 8, 10, 16, 17 and 18 have higher molecular weights than the other 
plasmids which appear to be PBLCATS (allowing for gel overloading).  This suggests that the 
TIMP-2 2600 insert may have been sub cloned successfully into the pBLCAT3 vector. 
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Figure 5.13 Characterisation of the new plasmids purported to be pBLCAT3/human 
TIMP2-2600 insert 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1% Agarose gel in TAE. Lanes 1 – 20 Row A are as follows 
1) 1kb DNA ladder (Gibco) 
2) pBlCAT3 uncut plasmid 
3) – 20) 18 samples of plasmid subjected to a restriction digest with a PST-1 digest. 
 
Lanes 1 – 20 Row B as follows 
1) 1kb DNA ladder (Promega) 
2) pBlCAT3 uncut plasmid 
3) –20) 18 samples of plasmid subjected to a restriction digest with a BAM-H1 & HIND-III 
double digest. 
 
Both Row A and Row B in the gel above appear to suggest that the human TIMP2 2600 insert 
has successfully been sub cloned into pBlCAT3 in samples run in lanes 3, 5, 8, 10, 16, 17 and 
18.
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Figure 5.14 Sequencing of pBLCAT3/TIMP2-2600 plasmid 
 
Figure 5.14: DNA sequences of 4 samples corresponding to sample numbers in previous gels.  Sequencing 
performed to ascertain whether the TIMP-2 2600 insert was sub cloned and if so in what orientation.  Samples 8, 
16, and 18 have all been sub cloned in the preferred orientation, 17 has been sub cloned in the reverse 
orientation.   
8              16            17                18 
17                                        18 
G     A      T     C  G      A      T    C 
3` 
3` 
5` 
3` 
5` 
Sequence of the human TIMP2-2600 insert in pBlCAT3 
Reverse     Forward 
Orientation    Orientation 
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Figure 5.15 Maxi prep of TIMP2-2600 in pBLCAT3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1% Agarose gel in TAE showing purified DNA from maxi preps of the human TIMP-2 2600 
full promoter sub cloned in the correct orientation (forward) and incorrect orientation 
(reverse). Lanes are as follows: 
 
Lane 1: 1kb DNA ladder (Gibco) 
Lane 2: pBLCAT3 (uncut) 
 
Lane 3: purified DNA from maxi preps performed in samples 18 - taken from sample outlined 
in Figure 5.13 - (hTIMP-2600 insert sub cloned in forward orientation into pBlCAT3) 
denoted pBLCAT3 TIMP-2 2600forward   Sequencing data for sample 18 is outlined in Figure 
5.14. 
 
Lane 4: purified DNA from maxi preps performed in sample 17 - taken from sample outlined 
in Figure 5.13 - (hTIMP-2600 insert sub cloned in reverse orientation into pBlCAT3 denoted 
as pBLCAT3 TIMP-2 2600reverse.  Sequencing data for sample 17 is outlined in Figure 5.14. 
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5.5.9 Discussion 
 
The human TIMP-2 2600 large promoter originally donated by Professor Yves DeClerck in 
pGL3 basic vector was successfully sub cloned into pBlCAT3.  Due to the problem of 
performing a digest on the PGL3 TIMP2 276 construct I elected to subclone the large 
promoter and then attempt to perform systematic deletions from the 5` end of this construct to 
obtain smaller constructs and obtain one comparable to the 276 minimal promoter provided 
by Prof Yves DeClerck. 
 
I elected to use a proprietary kit from Promega, Southampton called “ERASABASE” which 
claims that several deletions could be obtained in only a few hours.  In order to gain optimal 
conditions for the action of the DNA deletion with “Exonuclease III” or Exo III it is necessary 
to create 3` overhangs (protected from deletion) and a 5` overhang where the Exonuclease III 
initiates its deleting activity. 
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Figure 5.16 Restriction digest of pBLCAT3 and pBLCAT3/2600 TIMP-2 insert with the 
restriction enzymes Sph-1 and Bcl-1 
 
 
 
1% Agarose gel depicting restriction enzyme digests of pBlCAT3 empty vector and 
pBlCAT3/TIMP-2 2600 insert vector with Sph-I and Bcl-1 enzymes. Lanes 2 & 7 are empty; 
lanes 1-9 are as follows: 
 
1) 1kB DNA ladder 
3) PBlCAT3 uncut plasmid (pBlCAT3 in lane 3 is clearly overloaded). 
4) pBlCAT3 cut with Sph-1 
5) pBlCAT3 cut with Bcl-1 
6) pBlCAT3 double digest Sph-l and Bcl-1 
8) pBlCAT3 hTIMP-2 2600 uncut plasmid 
9) pBlCAT3 hTIMP-2 2600 digest with Sph-1 
10) pBlCAT3 hTIMP-2 2600 plasmid cut with Bcl-1 
11) pBlCAT3 hTIMP2 2600 double digest with Sph-1 and Bcl-1. 
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5.5.10 Discussion on Bcl-1 cut of pBLCAT3 
 
Figure 5.16 demonstrates that Bcl-1 failed to cut either pBlCAT3 or pBlCAT3 hTIMP-2 
2600bp.  This experiment was repeated on 2 further occasions and finally with an overnight 
digest with BSA. Bcl-1 cuts at the following site: 
 
5` T
▼GATCA 3` 
3`ACTAG▲T 5` 
 
A new batch of Bcl-l enzyme was obtained from Promega and this produced the same result. 
On further discussion with Promega it was ascertained that Bcl-1 does not cut methylated 
DNA.  All plasmids had recently been produced by DH5α E.Coli which produces methylated 
DNA. DNA methylation involves the addition of a methyl group to DNA – for example, to 
the number 5 carbon of the cytosine pyrimidine ring –with the effect of reducing gene 
expression. Adenosine or cytosine methylation is part of the restriction modification system 
of many bacteria, in which DNAs are methylated periodically throughout the genome. A 
methylase is the enzyme that recognizes a specific sequence and methylates one of the bases 
in or near that sequence. Foreign DNAs (which are not methylated) which are introduced into 
the cell are degraded by sequence specific restriction enzymes. Bacterial genomic DNA is not 
recognized by these restriction enzymes. The methylation of native DNA acts as primitive 
immune system, allowing the bacteria to protect themselves from infection by bacteriophage. 
These restriction enzymes are the basis of the restriction fragment length polymorphisms 
(RFLP) testing, used to detect DNA polymorphisms. 
 
A new bacterial stock was purchased for transformation and Mini/Maxi preparation of the 
pBlCAT3 TIMP-2 2600 in ‘DMI E. Coli’ bacteria (Promega). A further restriction enzyme 
digest of pBLCAT3 TIMP-2 plasmid was repeated after the plasmid was amplified in DM1 
E.coli bacteria. The results are depicted in Figure 5.17 showing a successful linearization 
digest with Bcl-1. Figure 5.18 shows a successful linearization or digest with Sph-1.   213
Figure 5.17 pBLCAT3 plasmid stock grown up in ‘DMI’ E. coli bacteria with a digest using 
Bcl-1 restriction enzyme 
 
 
 
 
 
 
 
 
 
 
 
 
 
1% Agarose gel with lanes 1-4 as follows: 
1) 1kB DNA ladder 
2) pBlCAT3 hTIMP-2 2600 full promoter from DH5α stocks 
3) pBlCAT3 hTIMP-2 2600 full promoter plasmid from DMI stocks 
4) pBlCAT3 hTIMP-2 2600 full promoter plasmid from DMI stocks with a Bcl-1 digest 
 
This gel demonstrates successful linearisation of the pBlCAT3 hTIMP-2 2600 full promoter 
with Bcl-1.  The digest is performed at 50
0C. 
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Figure 5.18 pBLCAT3 plasmid stock grown up in ‘DMI’ E. coli bacteria with a digest using 
Sph-1 restriction enzyme. 
 
 
 
1% Agarose TAE gel.  Lanes 1-5 as follows: 
1) 1kB ladder 
2) Lambda plasmid 1µg/1µl (used a molecular weight marker) 
3) Lambda cut with Sph-1 
4) DM1 stock of pBlCAT3 TIMP-2 2600 uncut plasmid 
5) DMI stock of pBlCAT3 TIMP-2 2600 digest with Sph-1. 
 
This gel shows that incubation at 37
0C with demethylated DNA with Sph-1 allows a 
successful digest. 
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5.6 Successive deletion of the pBLCAT3 hTIMP-2 2600bp insert with “Erase-a-Base” 
 
pBLCAT3 hTIMP-2 2600 full promoter construct was restriction digested first with Bcl-1, 
then with Sph-1 and the resulting insert was subjected to sequential digest from the 5` end by 
Exo III. The Erase-a-base system by Promega is designed for the rapid construction of 
plasmid containing progressive unidirectional deletions of any inserted DNA.  This is 
discussed in detail in chapter 2 section 2.8.  In brief an enzyme (exonuclease III or Exo III) 
digests insert RNA from a 5 prime (5`) protruding or blunt end restriction site.  The adjacent 
primer binding site is protected from digestion by a 4-base 3` overhang restriction site.  The 
2600 base DNA fragment of the human TIMP-2 promoter provided an excellent starting point 
to create smaller proteins of the TIMP-2 promoter by successive deletions from the 5` prime 
end.  The uniform rate of digestion of Exo III allows deletion of predetermined lengths to be 
made by removing timed aliquots from the reaction.   
 
Conveniently the 2600 fragments inserted into pBlCAT3 had two unique restriction sites that 
lie between the end of the insert DNA and the sequencing primer binding sites (SP6/T7), the 
enzyme that cuts closest to the primary site (Bcl-I) leaves 4-base 3` overhanging ends, which 
are resistant to Exo III digestion.  The enzyme that cuts closest to the insert DNA (SP-1) 
leaves blunt ends or 5` overhangs, susceptible to Exo III. Once the reaction mixture was set 
up, samples from the Exo III digestion were removed at timed intervals; S1 nuclease was 
added to remove the single stranded tails. The S1-nuclease buffer inhibits Exo III thereby 
inhibiting any further deletions. Klenow polymerase facilitates ligation of the inserts to 
circularize the deletion containing vectors. The ligation mixtures are then used directly to 
transform competent cells.  Each successive time point yields a collection of subclones 
containing clustered deletions extending further into the original insert. The full hTIMP-2 
2600 bp promoter was transformed and amplified in DM1 stocks purified and “gene cleaned”. 
Successive digest were obtained with Bcl-1 to linearize then Sph-1 to obtain the 2600bp 
insert, see Figue 5.19 and Figure 5.20.  216
Figure 5.19 DMI Stock pBLCAT3 hTIMP-2 2600 insert cut with Bcl-1 
 
 
 
 
 
 
 
 
 
 
 
The pBlCAT3 hTIMP-2 2600bp full promoter insert was transformed and amplified in DM1 
E. coli and purified by ‘Maxipreps’ and ‘gene cleaned’.  Purified plasmid was then cut with 
Bcl-1 at 50
0C for 2 hours.  
 
1% agarose gel; lanes 1-5 as follows: 
1) 1kB DNA ladder 
2) uncut plasmid DM1 pBlCAT3 hTIMP-2 2600 digest with Bcl-1 
3)-5) ‘Maxi prep’ samples 1, 2 and 3 subjected to restriction digests with Bcl-1. 
 
This gel demonstrates clear linearisation with Bcl-1.   
 
The resulting digest was gel purified, ethanol precipitated and a further digest with Sph-1 was 
carried out at 37
0C for 2 hours. 
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Figure 5.20 Isolation of the human TIMP-2 2600 insert with Bcl-1 and Sph-1 restriction 
digest 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1% Agarose gel 1 – 5 as follows: 
1) DNA ladder (lane overloaded) 
2) DM1 plasmid stock of pBlCAT3 hTIMP-2 2600bp uncut plasmid 
3)-5) samples 1, 2 and 3 of pBlCAT3 hTIMP-2 2600pb previously linearized with Bcl-1 and 
now subjected to a digest with Sph-1 at 30
0C for 2 hours.   
 
This gel shows 3 faint signals depicting the human TIMP-2 2600 insert. 
The resulting plasmid hTIMP-2 2600bp insert was gel purified and ethanol precipitated. 
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Figure 5.21 “Erasabase” protocol for systematic truncation of the human TIMP-2 2600 
insert from the 5` end by Exonuclease III 
 
 
 
1% Agarose gel: row A includes lanes 1-14, row B includes lanes 1-14. 
 
Row A lanes 1-14 were as follows:  
1) 1kB DNA ladder 
2) 1µl DM1 hTIMP-2 2600pb insert not exposed to Exo III 
3)-14) samples 1 to 12. 
 
Row B lanes 1-14 were as follows: 
1) 1kB DNA ladder (identical to that used above) 
2) 1µl DM1hTIMP-2 2600bp insert not exposed to Exo III 
3)-14) samples 13 to 24. 
 
This gel shows no cut was seen with Exonuclease III. 
Row A 
Row B 
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Figure 5.22 “Erasabase” protocol for systematic truncation of the control DNA (supplied 
by Promega) from the 5` end by Exonuclease III. 
 
 
Repeat protocol for standard DNA supplied with the Erasabase kit. 
 
Row A Lanes 1-13 as follows: 
1) 1kB DNA ladder 
2) Uncut control DNA 
3)-13) (samples 1-11) attempted successive truncations from the 5` end with Exo III. Each 
sample was terminated at 30 second intervals.  
4) Row B lanes 1)-13)  depict samples 12-22 – again each sample was terminated at 30 
seconds in sequence. 
 
This gel shows that using the supplied DNA from Promega that the protocol gives no 
adequate sequential digests with Exo-III according to their protocol. 
Row A 
Row B 
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Figure 5.23 Erasabase protocol for systematic deletion of the human TIMP-2 2600 insert 
from the 5` end by Exonuclease III 
 
 
The Erasabase protocol experiment was repeated.  Row A Lanes 1-14 as follows:   
 
1) 1kB DNA ladder 
2) Uncut control DNA 
3)-14) (samples 1-12) successive deletions from the 5` end with Exo III.  Each sample was 
terminated at 30 second intervals.   
Row B lanes 1)-14) depict samples 13-23 – again each sample was terminated at 30 seconds 
in sequence.  
 
This demonstrates no Exonuclease III digest of plasmid DNA with DM1 pBlCAT3 TIMP-2 
2600 full promoter. However the recovery of DNA was poor. 
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5.7 Discussion 
 
A number of explanations may account for no apparent deletion of experimental DNA when 
analysed by gel electrophoresis: 
 
1)  If the restriction enzymes cleaving the Exo-III sensitive end failed to cut completely then 
these singly cut molecules will remain the same size as the original starting DNA throughout 
the deletion time course. 
 
2)  There may not be sufficient nucleotides left near the recognition site of the second enzyme 
to allow cleavage. 
 
3)  If the deletion series appears to be degraded (as in this case) the original pBlCAT3 vector 
may contain nicked molecules ant this may allow Exo-III to recognise nicks within the DNA 
template and start to generate deletions from these nicks resulting in a smear. 
 
4)  When no DNA appears on the gel of the deletion series it may be that the loss of DNA 
occurred during the extraction and precipitation stage of DNA following restriction digestion, 
resulting in insufficient DNA being loaded on the gel for deletion; however this would not 
explain why control DNA continued to be present. The control DNA did not demonstrate any 
deletions and so the size remained the same with successive aliquots. 
 
In summary there may have been inadequate DNA or “nicked” DNA could have been the 
crux of the problem due to the suggestion of smearing on one electrophoresis gel. 
Nicked DNA in our lab may be caused by the following: 
 
1)  Use of ethidium bromide in the electrophoresis gels 
2)  High UV light exposure in the electrophoresis gel boxes 
3)  Shearing of DNA at any pipetting stage 
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The procedures were repeated therefore with the following protocols: 
 
1)  Generation of adequate quantities of DNA in the first place 
2)  Minimize conditions that causes ‘nicked’ DNA such as  
•  reducing amounts of ethidium bromide,  
•  low light intensity on the light box for (less than or equal to) 30 seconds,  
•  reducing pipetting at any defined stage 
3)  I elected to create the 3` overhang first with Bcl-1 then extract with phenol-chloroform and 
precipitate with ethanol followed by a Sph-1 digest.   223
Figure 5.24 Restriction digest of pBLCAT3 hTIMP-2 2600bp full promoter construct with 
restriction digest using Bcl-1 and Sph-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
1% Agarose gel with lanes 1-4 as follows:   
1) 1kB ladder 
2) pBlCAT3 hTIMP-2 2600 full promoter grown up in DMI stock, uncut 
3) Sph-1 cut 
4) Bcl-1 & Sph-1 double digest 
1      2      3     4    
TIMP-2 2600 insert 
 
6108 
 
4,072 
3,054 
 
2,036 
1,636 
 
1,018 
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Figure 5.25 Erasabase protocol for systematic deletion of the human TIMP-2 2600 insert 
from the 5` end by Exonuclease III 
 
 
 
1% agarose gel in TAE. Row A Lanes 1-12 as follows: 
 
1) 1kB DNA ladder 
2) uncut plasmid pBlCAT3/2600 
3)-12) denote successive DNA deletions by Exo-III at 30
0C (= 120 base pair cuts per 30 
second intervals).  5µg of plasmid cut at 30 second intervals. Row B Lanes 1) 1kB DNA 
ladder, lanes 2)-12) as follows: samples 14-25 which correspond to later time points of Exo-
III treatment. 
 
This gel shows that there was partial success with Exo-III digestion but that no DNA was seen 
in Row B.  In addition in lane 10 there is smearing suggesting that in at least 1 sample there 
was evidence of ‘nicked’ DNA.  It was concluded that there were continuing problems with 
the ‘Erasabase’ protocol and subsequent work with this was abandoned. 
1      2     3      4      5     6       7     8      9     10   11   12    13  
Row A 
Row B   225
2.7.4 The Chloramphenicol Acetyl Transferase (CAT) Transfection Assay 
 
Methods: these are described in detail in chapter 2 section 2.7.4 
 
The initial transfections using CAT assays were carried out with the pBlCAT3 TIMP-2 2600 
insert sub cloned in the forward and reverse direction. All transfection were carried out using 
the ‘Effectene’ kit by Qiagen outlined above according to the manufacturer’s instructions.  
After incubation in fresh media transfections were carried out over 48 hours with no serum 
free step. Cells were then scraped off tissue culture plates into media, and pelleted.  After 
removing the supernatant and resuspending the cells in 5ml of PBS they pelleted again at 
1000rpm for 5min; this was then repeated on two further occasions before finally 
resuspending the cells 50µl of 0.25M Tris buffer pH7.9. Cells were frozen in liquid nitrogen 
for 2 min then thawed at 37
0C for 5min followed by vortexing: this was repeated for a total of 
3 occasions.  The disrupted cells were then pelleted using a microfuge at 13000 rpm for 5 
min.  The pellet was retained and stored at –20
0C.  A protein assay incorporating a proprietary 
kit was carried out on 2µl samples of the supernatant.  Samples were then modified to 25µg in 
50µl and to this a mastermix was added (the master mix represented 70µl of 1M Tris-HCl pH 
7.8, 20µl of Acetyl Coenzyme A 3.25µg/µl and 1µl of 400µCi/ml [
14C] 35-50mCi/mmol 
Chloramphenicol (Amersham), for each reaction). 
 
Sample were ‘flick spun’ using a microfuge at 13000rpm and incubated at 37
0C for 2 hours.  
To each sample 0.5 ml of ethyl acetate was added and the solution vortexed for 30 seconds 
then microfuged at 13000 rpm for 5mins.  The top layer was removed and was speed vacuum 
dried; the residual precipitate was re-suspended in 15µl of ethyl acetate before being applied 
to a thin layer chromatography plate and allowed to dry.  The plate was run in a 
chromatography tank containing 95% chloroform, 5% methanol.  Imaging was performed by 
plate exposure to Blue Autoradiography X-ray film (GRI) and quantitation was determined by 
phosphor image analysis using a Storm scanner and an “Image Quant” software data analysis 
package (Molecular Dynamics).   226
Figure 5.26 CAT assay – transfection of TIMP-2 insert 2600forward and 2600reverse into 
passaged HSC 
 
 
 
 
This demonstrates thin layer chromatography of CAT transfection into passaged hepatic 
stellate cells at 70% confluence for 72 hours.  Following a CAT assay an autoradiograph was 
laid down for 1, 2 and 8 days.  This 8 day autoradiograph shows lanes as follows  
 
1-3) pBlCAT3 empty vector (n=3) 
4-6) pBLCAT3 hTIMP-2 insert 2600forward vector (n=3) 
7-9) pBLCAT3 hTIMP-2 insert 2600reverse vector (n=3) 
 
No signal for transfection was noted.  This is representative of 2 experiments. 
     1             2            3            4            5             6             7            8             9 
------pBLCAT3------          ---pBLCAT3 TIMP2f---      --pBLCAT3 TIMP2r--   227
Figure 5.27 CAT assay – transfection of TIMP-2 insert 2600forward and 2600reverse into 
passaged 3T3 fibroblasts 
 
 
 
This demonstrates data from CAT transfection into passaged 3T3 fibroblasts at 70% 
confluence for 72 hours.  Following a CAT assay an autoradiograph was laid down for 1, 2 
and 8 days.   
 
This 8 day autoradiograph shows lanes as follows  
 
1-3) pBlCAT3 empty vector (negative control) 
4-6) pBlCAT3 hTIMP-1 (positive control) 
7-9) pBLCAT3 hTIMP-2 insert 2600forward,  
10-12) pBLCAT3 hTIMP-2 insert 2600reverse vector. 
 
This demonstrates no activity on the part of the TIMP-2 insert 2600forward or TIMP-2 insert 
2600reverse vector sub cloned into pBlCAT3.  This is representative of 2 experiments in 3T3 
fibroblasts and 2 experiments in 1080 human cell line. 
1            2            3           4           5           6            7           8            9         10          
11         12 
  -pBLCAT3-                  -pBLCAT3 TIMP-1-        -pBLCAT3 TIMP2f-        -pBLCAT3 TIMP2r-   228
5.75 Discussion 
 
pBlCAT3 hTIMP-1 (positive control) showed evidence of transfection whilst CAT assays 
incorporating the promoters of interest showed no such activity. Clearly there are problems 
with the assay using the constructs though the positive control suggests that the CAT assay 
itself with this current protocol is viable. With problems encountered with CAT assays of the 
pBlCAT3 hTIMP-2 2600 full promotor construct I decided that I should return to an 
examination of the original constructs given to us by Prof Yves DeClerck. 
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Figure 5.28 Assessment of plasmid concentrations for transfections of luciferase and CAT 
constructs 
 
 
 
 
 
 
 
 
 
 
 
 
1% Agarose gel lanes 1-14 as follows:   
1) 1kB DNA ladder 
2) pGL3-TIMP-2 2600 construct 
3) pGL3-TIMP-2 276 construct 
4) pGL3 (empty vector/’mock’) 
5) pRL-SV40 
6) 1kB Luc 
7) pBlCAT3/empty vector 
8) pBlCAT3/TIMP-2 2600forward 
9) pBlCAT3/TIMP-2 2600reverse 
10) pBlCAT3/TIMP-1 wild type 
11) pGL3 TIMP-2 2600 
13) λ-Hind-III 
14) Human TIMP-2 maxi prep. 
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Method for “Effectene” transfection 
 
Introduction 
 
The method for “Effectene” transfection was as follows: freshly isolated or passaged cells 
were obtained and plated to achieve 70% confluence.  A fresh Microfuge tube was obtained 
and to this 6.4µl enhancer, 91.6µl EC buffer and 1µl (= 1µg) of each plasmid was added for 
dual transfections.  The cap was closed and the Microfuge tube vortexed briefly followed by a 
flick spin at 13,000g in a microfuge.  10µl Effectene was added and again a full vortex was 
performed for 10 seconds.  Following a flick spin the mixture was incubated at room 
temperature for 10 minutes.  Fresh media was changed (1ml to 6 well-plates).  The cells were 
returned to the incubator.  500µl DMEM was added to the plasmid in a Microfuge tube (i.e. to 
a total volume of 1.6ml).  This was then added to the wells.  Transfections were performed in 
triplicate wells and took place over a 24 hour period.  All plasmids were transfected at 1µg/µl 
to a total concentration of 1µg.  Prior to cell harvesting the cells were washed once in PBS.  
They were then scraped off the plates and resuspended in 0.75M pH 74 and frozen at -20
0C 
until the luciferase assay took place. 
 
Luciferase Assay 
 
Samples were defrosted. 100µl of LARII buffer (firefly) was added to each sample.  A 20µl 
was taken and inserted into a luminometer (Promega) and three sets of readings were taken.  
20µl of Renilla was then added (quenching the firefly and allowing the ‘Renilla’ to 
luminesce).  Again 3 readings were taken.  All transfections were performed in triplicate 
wells. 
 
Following the protocols described by Yves DeClerck I attempted to confirm data already 
documented in the original papter by Hamani et al in 1994 (518). Human 3T3 fibroblasts and 
nih1080 – a human fibrosarcoma cell line – were used in the ensuing experiments.   231
Table 5.5 Intitial transfections with Effectene Promega Protocol 
 
Vector  Well  Firefly  Renilla 
       
pGL empty vector  1)  0.105  4924 
“Mock”    0.000  4164 
    0.111  3682 
  2)  0.069  6884 
    0.000  6294 
    0.96  5735 
  3)  0.136  8057 
    0.134  7248 
    0.031  6367 
 
pGL SV40   1)  76.11  >9999 
+ve control    75.98  >9999 
    75.63  >9999 
  2)  28.96  >9999 
    28.89  >9999 
    28.39  >9999 
  3)  11.32  >9999 
    11.43  >9999 
    11.11  >9999 
 
pGL3 hTIMP-2 2600  1)  2.228  7318 
“full promoter”    2.102  6350 
    2.200  5545 
  2)  0.993  3381 
    0.82  3003 
    0.717  2690 
  3)  0.727  >9999 
    0.497  >9999 
    0.435  >9999 
 
pGL3 hTIMP-2 276  1)  297.6  4312 
“short promoter”    303.2  3783 
    303.2  3294 
  2)  7.416  3366 
    7.447  2967 
    7.110  2851 
  3)  50.63  >9999 
    51.47  9804 
    53.46  8618 
 
Table 5.5: Transfection of pGL3 basic (empty vector), pGLSV40 positive control, pGL hTIMP-2 2600 (full 
promoter construct), pGL3 hTIMP-2 276 (short promoter construct) transfected into passaged rat hepatic stellate 
cells (representative of n=3). Assays were performed on three different wells and for each well the luminometer 
reading was repeated on three occasions.   232
5.7.9 Discussion 
 
Figure 5.1a depicts the pGL3 basic empty vector. Figure 5.1c demonstrates the pGL3 human 
(h)TIMP-2 2600 full promoter and Figure 5.1c the pGL3 hTIMP-2 276 short promoter. 
 
pGL3 SV40 positive control vector 
Figure 5.1b depicts the positive control pGL3 SV40 promoter. This plasmid has the firefly 
luciferase gene (the same gene that is driven by the TIMP-2 constructs/promoters) driven by a 
simian viral (SV40) promoter, acting as a positive control.  The SV40 promoter luciferase 
genes can be transfected into cells of any type and is therefore an excellent positive control.  
If no firefly activity is seen in the control then the transfection has not taken place 
successfully. 
 
PRL-SV40 
This contains the Renilla luciferase gene under the control of the SV40 (a simian viral 
promoter).  By co-transfecting the cultured cells e.g. 3T3 cells with both an experimental 
plasmid such as pGL3 hTIMP-2600 and the pRL-SV40 construct one can standardise the 
results of transfection efficiency.  For a given assay the firefly luciferase activity is measured 
followed by the Renilla luciferase activity.  The first value is divided by the Renilla value to 
standardise.  
 
Transfections were carried out in the following co-transfections: 
 
1) pGL3 Basic Empty vector + PRL-SV40 (“Mock” or negative control) 
 
2) pGL3 SV40 + PRL-SV40 (positive control) 
 
3) pGL3 TIMP2 2600 + PRL –SV40 (long construct / full promoter) 
 
4) pGL-TIMP 267 + PRL-SV40 (short construct / shortened or truncated promoter) 
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All plasmids were grown into DH5α E.coli strain except where indicated. 
 
The first comment to make on the first transfection above in Table 5.4 is that the Renilla 
values are extremely high and in many occasions were too high to be read by the 
luminometer.  This made Firefly/Renilla calculations impossible. 
 
Secondly there is a discrepancy between some wells transfected.  This experiment was 
therefore repeated on two separate occasions, but this resulted in obtaining the same trend.  
On discussion with Promega it was indicated that the pRL-SV40 plasmid should be 
transfected at 1/50 – 1/100 the concentration of the co-transfected plasmid. 
 
All transfections with pRL-SV40 renilla gene were subsequently performed at 1/50 of the 
previous concentration i.e. 0.2µg. 
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5.7.10 Results 
 
Table 5.5 demonstrates raw data of transfecting the short and full human TIMP-2 promoters 
into quiescent newly harvested and activated rat hepatic stellate cells. Tables 5.6 and 5.7 
depict the results normalized to the negative control. This experiment was repeated on 5 
occasions and the results pooled (Table 5.7) and graphed on an Excel spread sheet with the 
standard error of the mean shown (Figure 5.29).  There is a consistent increase in activity of 
the full promoter compared to the short promoter in quiescent cells. This is reversed for the 
activated cell phenotype.   235
Table 5.6 Transfection into rat Quiescent and Activated Hepatic stellate cells 
 
 
 
QUIESCENT CELLS 
   
    Luc  Renilla  luc/ren  Mean 
  B1  0.01  0.481  0.02079  0.011839 
  B2  0.01  0.679  0.014728   
  B3  0  0.635  0   
           
  C1  0.038  1.518  0.025033  0.025966 
  C2  0.083  1.57  0.052866   
  C3  0  1.067  0   
           
  2600 - 1  0  0.78  0  0.038219 
  2600 - 2  0  3.221  0   
  2600 - 3  0.176  1.535  0.114658   
           
  277 - 1  0  0.863  0  0.011111 
  277 - 2  0.06  1.8  0.033333   
  277 - 3  0  0.975  0   
 
 
 
ACTIVATED CELLS 
   
    Luc  Renilla  luc/ren  Mean 
  B1  0.066  2.503  0.026368  0.018966 
  B2  0.053  1.736  0.03053   
  B3  0  2.385  0   
           
  C1  0.125  1.425  0.087719  0.133806 
  C2  0.148  0.975  0.151795   
  C3  0.221  1.365  0.161905   
           
  2600 - 1  0.006  1.54  0.003896  0.007843 
  2600 - 2  0  1.214  0   
  2600 - 3  0.029  1.477  0.019634   
           
  277 - 1  0.376  5.263  0.071442  0.053436 
  277 - 2  0.014  2.132  0.006567   
  277 - 3  0.252  3.062  0.082299   
 
Table 5.6 Raw data depicting transfection in primary rat hepatic stellate cells at day 0-2 
(quiescent) and in the same cells when 70% confluent at day 10-12 (activated).  B – negative 
control “Mock”, C – positive control, 2600 – full human TIMP-2 promoter, 276 – human 
TIMP-2 short promoter.  Each plasmid was co-transfected with a control vector (pRL-SV40) 
and results were expressed as plasmid divided by co-transfected plasmid.  Results were then 
averaged for three wells and normalized to the negative control.    236
Table 5.7 Transfection into Quiescent and Activated rat Hepatic Stellate Cells 
 
  Quiescent    Activated   
  Value/Mean of B  Value/Mean of B 
B Negative control  1    1   
C +ve control  2.193258    7.055024   
2600 full promoter  3.228205    0.413554   
277 short promoter  0.938503    2.817446   
         
 
Table 5.7 In this single experiment this table depicts data from previous table (Table 5.6) normalized with 
reference to the negative control. 
 
Table 5.8 Mean of 5 experiments with data normalized to negative controls 
 
 
Quiescent 
 
SEM 
 
Activated 
 
SEM 
 
Negative control 
“Mock”  1    1   
SV40  2.359916  0.62418  113.7591  72.58506 
2600  1.964803  0.385353  0.609666  0.270893 
276  0.329461  0.176769  6.567827  2.620291 
         
 
Table 5.8 Depicts the mean of data from 5 different experiments with data normalized to the negative control 
 
In each of the 5 experiments the protocol was identical: transfections were carried out in 
primary rat hepatic stellate cells at day 0-2 (quiescent) and in the same cells when 70% 
confluent at day 10-12 (activated).   
 
B – negative control “Mock” 
C – positive control 
2600 – full human TIMP-2 promoter 
276 – human TIMP-2 short promoter 
 
Each plasmid was co-transfected with a control vector (pRL-SV40) and results were 
expressed as plasmid divided by co-transfected plasmid.  Results were then averaged for three 
wells and normalized to the negative control. Data from 5 experiments was pooled and a 
mean taken. SEM – standard error of the mean.  237
Figure 5.29 Transfection of hTIMP-2 into quiescent and activated rat HSC 
 
Transfection of hTIMP-2 into Quiescent vs Activated cells 
0
1
2
3
4
5
6
7
8
9
10
Quiscent Activated
Quiescent vs Activated rat HSC
L
u
c
i
f
e
r
a
s
e
 
V
a
l
u
e
s
2600
276
 
 
Figure 5.29 Excel spread sheet chart depicting the mean of 5 experiments for the pGL3 
hTIMP-2 2600 full promoter versus the hTIMP-2 276 short/truncated promoter transfected 
into primary rat hepatic stellate cells at day 0-2 (quiescent) and in the same cells when 70% 
confluent at day 10-12 (activated).   
 
B – pGL3 Basic “Mock” or negative control 
C – pGL3 SV40 +ve / positive control 
2600 – pGL3 human TIMP-2 2600 full promoter 
276 – pGL3 human TIMP-2 276 short promoter. 
 
Each plasmid was co-transfected with a control vector (pRL-SV40) and results were 
expressed as plasmid divided by co-transfected plasmid.  Results were then averaged for three 
wells and normalized with the negative control. 
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Table 5.9 Statistical analysis (paired Student’s t test) of data presented in Figure 5.29 
 
Parameter  Quiescent  Activated  Difference 
Mean  1.147  3.589  -2.442 
# of points  2  2  2 
Std Deviation  1.156  4.213  5.369 
Std Error  0.8177  2.979  3.797 
Minimum  0.3295  0.6097  -6.238 
Maximum  1.965  6.568  1.355 
Median  1.147  3.589  -2.442 
Lower 95% CI  -9.242  -34.263  -50.683 
Upper 95% CI  11.536  41.441  45.800 
       
 
Table 5.9: The data shown in figure 5.29 was subjected to statistical analysis with a Student’s 
paired t test. The two-tailed P value is 0.6362 which is not considered significant. T=0.6431 
with 1 degrees of freedom. For a 95% confidence interval the Mean difference = -2.442 
(Mean of paired differences) and the 95% confidence interval (CI) of the difference is: -
50.683 to 45.800  
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5.7.11 Chapter Discussion 
 
In this chapter the transfection of the human TIMP-2 short and full promoters obtained from 
Professor Yves DeClerk was examined in hepatic stellate cells. Initial work was unsuccessful 
and therefore the promoters were sub cloned into a new vector that may have been more 
suitable to the low activity of these promoters. Despite successful subcloning and sequencing 
the promoters I was unfortunately unable to obtain any activity with the pBLCAT hTIMP-2 
promoters. On returning to the original vectors and incorporating new transfection protocols 
from the manufacturer (Promega) low grade activity was noted in both quiescent and 
activated rat HSC. Dual transfections were performed in each case with a Renilla construct 
linked to a SV40 promoter in pGL3-basic (Promega). Each transfection was carried out in 
triplicate wells with the cells harvested at 48hrs. At time 0 activity was noted with the TIMP-
2 promoter (especially the full promoter) in comparison to the short promoter. In activated 
cells TIMP-2 activity was again noted but in this situation the short promoter was more 
active. 
 
Differences in the expression of the hTIMP-2 short and full promoters may be attributable to 
the spatial distribution of the AP-1, PEA-3 and SP-1 motifs within each promoter construct. 
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CHAPTER 6 
 
DISCUSSION   241
6.1 General Discussion 
 
This work was undertaken to focus on the role of TIMP-2 in liver and pancreatic injury. The 
work itself was commenced in September 1997 and finished end June 2000 – around 2 years 
and 10 months were taken in learning techniques and carrying out the experimental work. 
 
In the introduction I reviewed the role of the hepatic stellate cell in the liver injury process. 
Fibrosis and cirrhosis of the liver form a continuum of the injury process where fibrosis can 
be reversed and in the classical view of cirrhosis an irreversible state exists. Recent data from 
the liver group in Southampton challenge this view. 
 
In liver cirrhosis there is a 3-6 fold rise in collagens type I, III and IV. This is especially seen 
in the space of Disse where the basement membrane components are increased and partially 
replaced by fibrillar collagens. 
 
The cell central to this process is the hepatic stellate cell (HSC) located in the space of Disse. 
HSC in the face of liver injury undergo a change from a quiescent state of the myofibroblast 
like phenotype in the response to all forms of liver injury. This is characterised by phenotypic 
changes such as loss of vitamin A and expression of alpha SMA, proliferation and increased 
synthesis of collagens and other ECM proteins, release of matrix metalloproteinases and their 
inhibitors the so called tissue inhibitors of metalol proteinases (TIMPs). 
 
ECM accumulation which is seen in liver injury and pancreatic injury can either be caused by 
excess production or decreased degradation. MMPs are responsible for ECM however. 
Gelatinase A (MMP-2) is capable of degrading the normal subendothelials matrix as well as 
fibrillar collagens. MMP-2 is activated in association with MT1-MMP and TIMP-2. 
Examination of TIMP2 therefore is crucial to the understainding of MMP-2 function and 
therefore of ECM production and turnover. 
 
In the pancreas the corresponding cell type was the pancreatic stellate cell (PSC). In a sense 
whilst this was only recently described when I began my work on the thesis much of the 
protein expression of this cell type was not described but there was a strong belief in early 
work that it too had a pivotal role in ECM production and turnover both in health and fibrotic 
pancreatic injury..   242
6.2 Key Findings 
 
Chapters I and II outline the introduction and the methods incoporated in this thesis. 
 
6.2.1 Summary of Chapter 3 
 
In chapter III work was undertaken to examine the expression of TIMP-1, TIMP-2, αSMA, 
Gelatinase-A (MMP-2) and MT1-MMP (MMP-14) both in liver and pancreatic injury using 
immunohistochemical techniques in archived human specimens of normal and injured liver 
and similarly in pancreas. 3 cases of normal human liver and 6 cases of diseased human liver 
were incorporated; for pancreas 6 normal archived specimens were used in addition to 6 
specimens of fibrotic tissue. TIMP-1 and TIMP-2 expression was noted to be increased in 
liver and pancreatic injury. αSMA was noted to be slightly positive in normal liver which was 
unexpected and possibly may have been secondary to a liver disease process which was not 
documented or appreciated by the clinicians. Whilst not shown, MT1-MMP (MMP-14) 
expression was noted in only one or two cases with a general background in human liver and 
pancreas. Gel-A (MMP-2) was noted to be only weakly positive in normal liver and pancreas 
but strongly positive in fibrotic liver injury and fibrotic pancreas confined to fibrotic bands. In 
normal liver TIMP-2 was noted to be present for example in some hepatocytes and in some 
blood vessels with a subtle increase in background. There was however increased expression 
in the sinusoidal and perisinusoidal areas in fibrotic liver. In fibrotic pancreas there was some 
increased expression of TIMP-2 staining in pancreas injury in the periacinar stroma and 
fibrotic bands with marked staining in 4 out of 6 cases in the Islets (a finding that was also 
noted in normal pancreas specimens). In conclusion Gelatinase A (MMP-2), MT1-MMP 
(MMP-14), TIMP-1 and TIMP-2 are expressed in vivo in chronic pancreatitis as well as in 
liver injury and their expression appears to be localised to alpha SMA positive cells in 
pancreas as well as liver injury. The inference here is that pancreatic stellate cells in a similar 
fashion to hepatic stellate cells are able to regulate matrix degradation in addition to synthesis. 
The expression of TIMPs suggests that matrix degradation may be inhibited during chronic 
pancreatitis. It is possible that the PSC phenotype is similar to other “wound healing 
myofibroblasts” notably Hepatic stellate cells and Renal Mesangial cells.   243
6.2.2 Summary of Chapter 4 
 
6.2.2.1 Hypoxia 
 
In chapter IV the role of hypoxia was examined with regard to TIMP-2 expression in rat 
hepatic stellate cells. In the first instance fresh and passaged rat hepatic stellate cells were 
incorporated to examine and troubleshoot the hypoxic protocol. (Pancreatic stellate cell 
culture in hypoxic conditions was not examined). Early work in this area was unsuccessful 
but this may be due to the early logistical problems experienced in transferring cells to 
London. A nominal increase in the 3.8kb TIMP-2 subspecies was noted in comparison to the 
1.2kb subspecies but this was not considered significant. The experiment did however 
confirm that TIMP-2 expression continues under hypoxic conditions. It is possible that by 
incorporating passaged cells instead of freshly isolated cells that any early subtle early rise of 
TIMP-2 in early activation was missed. Freshly isolated rat HSC was attempted but on two 
occasions unfortunately rapidly became infected with fungus during the transfer. If this 
experiement were to be repeated simple ways to circumvent the logistical issues that were 
faced would be to spend some time up in the London unit – harvest fresh rat HSC there – and 
perform the experiment both for primary rat (and were it to be freely available) fresh human 
HSC for culture. Shorter time frames in primary culture would also be appealing to study 
though for timepoints such as 4, 6, 8 and 12hrs would necessitate probably whole animal liver 
resections. The objectives therefore in chapter 3 in terms of carrying out work in both rat 
pancreatic tissue and human normal and fibrotic liver and pancreatic tissue were never met. 
 
6.2.2.2 Expression of MMP and TIMP protein in activated PSC 
 
In vitro work was undertaken to examine mRNA expression in rat PSC of αSMA, gelatinase-
A (MMP-2), procollagen-I, TIMP-2 and TIMP-1. This had not been previously reported.  
PSC activation on uncoated tissue plastic appears to be behaving in a similar fashion to rat 
hepatic stellate cells (HSC) and rat renal mesangial cells. TIMP-1 & TIMP-2 mRNA are 
clearly expressed in pancreatic islet cells and therefore TIMP-1 and TIMP-2 may play a role 
in cell survival. Gelatinase-A (MMP02) may play a pivotal role in matrix degradation. Whilst 
it degrades Collagen type IV and partially degrades Collagens type I, III and V it is itself 
inhibited by TIMP-1 and TIMP-2. TIMP-2 as has been highlighted earlier plays a role in 
Gelatinase-A activity by linking in with pro-gelatinase A and with membrane type Matrix   244
Metalloproteinase I (MT1-MMP/MMP-14). Whilst chapter three examined the in vivo 
expression of alpha SMA, Gelatinase-A (MMP-2), MT1-MMP (MMP-14), TIMP-1 and 
TIMP-2 in human pancreas and chapter 4 the in vitro expression of αSMA, procollagen-I, 
Gelatinase-A, MT1-MMP, TIMP-1 and TIMP-2 there is an argument that PSCs are indeed 
able to regulate matrix degradation in addition to synthesis and that the expression of TIMPs 
suggest that matrix degradation may be inhibited during chronic pancreatitis.  
 
 
6.2.2.3 Examination of TIMP-2 expression in whole human liver 
 
In a study of human fibrotic livers (x5) compared to 3 normal controls TIMP-2 mRNA 
expression was examined in a ribonuclease protection assay (RPA) analysis. The results of 
this demonstrate that human TIMP-2 mRNA is upregulated in fibrotic liver in comparison to 
normal liver. This is a finding in contrast to the expected result where TIMP-2 has 
traditionally been conceived as constitutively expressed in a variety of cell systems. Recent 
research in a liver fibrosis model in rats has demonstrated an increase in TIMP-1 and TIMP-2 
mRNA and protein rise over a time course of 8 weeks of injection with a fibrotic agent (520). 
 
6.2.3 Summary of results in Chapter 5 
 
Chapter V examined the role of TIMP-2 expression at the promoter level. Early work 
highlighted some technical problems with my transfection protocols which led to the 
promoter being sub cloned into a new plasmid vector. CAT 3 transfections however were also 
unsuccessful therefore I returned to the original constructs and incorporated a new protocol 
from Promega which yielded low grade promoter activity in quiescent and activated HSC. 
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6.3 Conclusions and Overall Discussion 
 
Immunostaining of pancreas has highlighted that TIMP-1 and TIMP-2 are expressed in PSC 
and upregulated in tissue injury. The in vivo work of liver and pancreas immunostaining 
suggests that TIMP-2 may be upregulated during liver and pancreatic injury. In vitro work 
examining the expression of TIMP-2 in normal versus fibrotic human liver also suggests that 
TIMP-2 is upregulated which is contrary to the traditional view that TIMP-2 is a 
constitutively expressed protein in both normal and diseased systems when examined in liver, 
pancreas or renal injury. In conclusion this thesis was undertaken to examine the role of 
TIMP-2 in liver and pancreatic injury. 
 
More questions arise from this work than have been answered. Further work could be 
undertaken examining the role of TIMP-2 in the following areas: 
1)  Knockout mice with an absent TIMP-2 gene 
2)  CCL4 rat model of liver injury and recovery 
3)  DNA footprinting of the promoters that I obtained from Professor Yves DeClerck 
There is emerging work examining the role clinical pharmaceutical agents modifying the 
fibrotic process and I have no doubt that the agents and their interaction with TIMP-2 require 
further elucidation. 
 
My aims in this thesis were the following: 
 
a) Determine the key sequences of the TIMP-2 gene promoter which regulate TIMP-2 
expression during hepatic stellate cell (HSC) activation and pancreatic stellate cell (PSC) 
activation. Whilst this was examined I conclude that I was unsuccessful in this regard. Further 
work on the gene promoter may elucidate this for example with DNA footprinting 
incorporating the short and long constructs that I obtained from Profession Yves De Clerk. 
 
b) Determine at what level the enhanced expression of TIMP-2 mRNA observed in activated 
HSC and activated PSC is regulated using Nuclear Run On assays (studies of mRNA 
production). Again, I was unsuccessful in this regard as I was unable to show consistent 
successful nuclear run on assays during the nine months that I studied this experimental 
modality. 
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c) Perform studies of the TIMP-2 promoter activity in HSC and PSC in collaborative work 
with Dr Yves De Clerk. There is no doubt that this was carried out in the laboratory however 
there was clear evidence that in the transfection systems that I worked in – the TIMP-2 
promoter was weak in most cases which did not allow accurate qualitative or quantitative 
measurements of the human TIMP-2 promoter activity in cells systems to be measured 
accurately. 
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GENERAL REAGENTS
 
 
Sterilization 
All sterilization of equipment such as that used to harvest hepatic stellate cells, homogenize 
tissue, culture prokaryotic and eukaryotic cells and solutions such as culture media and other 
non-heat labile buffers was undertaken by autoclaving for 15 minutes at 121
0C.  Sterilization 
of heat labile solutions was performed by filtration using a 0.22µm Millipore microfilter in a 
sterile hood. 
 
Water 
The water used for dilution of general reagents for non sterile work was obtained from a 
centrally operating distillation facility with reverse osmosis.  Where sterility was necessary or 
nuclease free/high purity conditions required then bottled ultra pure water was used.  For 
RNase free work water was initially treated with DEPC. 
 
Chemicals 
All chemicals were obtained from SIGMA unless otherwise stated. 
 
General Solutions and Buffers 
 
DEPC water 
1 litre of DI water 
Diethyl pyrocarbonate DEPC 1ml 
The bottle was sealed and shaken vigorously then left overnight to allow inactivation of 
RNases prior to autoclaving for 2 hours to inactivate the DEPC. 
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GENERAL BUFFERS 
All buffers were made up to volume with distilled water unless otherwise stated. 
TE (Tris EDTA) 
Tris Base          10mM 
EDTA           1mM 
HCl was used to adjust the pH to 8.0 
 
TBE 5x (Tris Boric Acid EDTA) Electrophoresis Buffer 
Tris Base          54g 
Boric Acid          27.5g 
EDTA 0.5M (pH 8.0) 
The volume was made up to 1 litre with DI H2O 
 
TAE 50x (Tris Acetate EDTA) Electrophoresis Buffer 
Tris-acetate          2M 
EDTA (pH 8.0)        0.1M 
 
Gel loading buffer 6x 
Ficol 400          1.8g 
EDTA 0.5M pH 8.0        1.2ml 
Xylene Cyanol        0.002g 
Orange G          0.002g 
Bromo Phenol Blue        0.002g 
The volume was made up to 10ml using distilled and filter-sterilized water 
 
Phenol/Chloroform 
Phenol           50% 
Chloroform          49% 
Isoamyl alcohol        1% 
Chloroform/isoamyl alcohol 
Chloroform          96% 
Isoamyl alcohol        4% 
Gel extraction buffer 
Ammonium Buffer        0.5M 
EDTA           1mM 
Volumes were adjusted with distilled water and the pH changed to pH 8.0 with acetic acid.   250
BACTERIAL CULTURE 
 
Throughout the majority of this work plasmids were used which contained a gene conferring 
resistance to antibacterial substances.  The most common gene was the amp
r gene, encoding 
the enzyme β-lactamase, which degrades penicillin antibiotics such as ampicillin.  Ampicillin 
was therefore used as a method of bacterial selection.  The ampicillin stock was made at a 
concentration of 50mg/ml in distilled water before filter sterilization.  The stock was stored in 
aliquots at –20
0C and added to re-sterilized culture media where specified at 50µg/ml.  
Repeated freeze thawing of ampicillin aliquots was avoided.  
 
Lauria Bertani (LB) medium (1 litre) 
Tryptone          10.0g 
Bacto Yeast          5.0g 
NaCl            10.0g 
 
The pH was adjusted to pH 7.0 with 5M NaOH (0.2mls); 1.5% w/v agar was added before 
autoclaving for culture plates (LB Agar). 
 
Terrific Medium (‘Terrific Broth’) 200ml 
Tryptone          27g 
Yeast Extract          5.3g 
Glycerol          0.9 
The volume was adjusted with distilled water; the broth autoclaved to sterilize. 
 
Phosphate buffer 
KH2PO4          0.17M 
K2HPO4          0.72M 
Volumes were made up with distilled water, autoclave sterilize add 3ml to each 27ml terrific 
medium culture just prior to inoculation. 
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PRODUCTION OF COMPETENT DH5α α α α E COLI 
 
RF1 
RbCl            100mM 
MnCl2.4H2O          50mM 
Potassium acetate        30mM 
CaCl2.2H2O          10mM 
Glycerol          15% w/v 
 
The pH was adjusted to pH 6.8, made up to volume with distilled H2O and filter sterilized. 
 
RF2 
MOPS           10mM 
RbCl            10mM 
CaCl2.2H2O          75mM 
Glycerol          15% w/v 
NaOH was used to adjust the pH to pH 5.8; the volume made up with distilled H2O and filter 
sterilized. 
 
PLASMID PURIFICATION 
 
Alkaline lysis 
 
Solution 1 (TGE) 
Tris Base          25mM 
EDTA           10mM 
Glucose          50mM 
 
Solution 2 (Lysis buffer) 
SDS            1% w/v 
NaOH           0.2M 
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Solution 3  (Neutralizing buffer) 
Potassium acetate        3M 
Glacial Acetic Acid        5M 
 
DNA Sequencing 
DNA denaturing buffer 
NaOH           200mM 
EDTA (pH 8.0)        200mM 
 
Acrylamide Gel (Sequencing denaturing) 
Acrylamide          8% w/v 
Urea            7M 
TBE            x1 
Ammonium Persulphate (APS)    0.008% w/v 
TEMED          0.16% v/v 
 
Formamide loading buffer 
Formamide          95%v/v 
EDTA           20mM 
Bromophenol Blue        0.05% w/v 
Xylene Cyanol FF        0.05% w/v 
 
Gel fixative 
Methanol          10% v/v 
Glacial Acetic Acid        10% v/v 
 
 
Eukaryotic cell culture 
Hank’s Buffered Saline Solution (HBSS), (with or without Ca
2+)  
Obtained as a 10x stock (Gibco) 
 
HBSS 10x          100ml 
Sodium bicarbonate (7.5%)      4.6ml 
HEPES (1M)          5ml 
Made up to 1 litre with sterile water. 
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Dulbecco’s Modified Eagle Medium (DMEM) 
Obtained as 10x stock (Gibco) 
 
DMEM 10x          500ml 
Glutamine (200mM)        50ml 
Sodium Bicarbonate (7.5%)      250ml 
pH adjusted to pH 7.1 with HCL 
Volume made up to 5L with sterile water and filter sterilized 
 
Serum and Antibiotics 
Fetal Calf Serum (FCS) used at 16% 
Penicillin and Streptomycin used at 500u/ml 
 
Phospate Buffered Saline 
Obtained in tablet form (Sigma) 
Made up to volume in distilled H2O 
 
Nuclear Extraction 
Dignam A (Plasma membrane lysis buffer) 
HEPES          10mM 
MgCl2           1.5mM 
KCl            10mM 
Dithiothreitol (DTT)        0.5mM 
PMSF           0.5mM 
Tergitol NP40         0.2% v/v 
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Dignam C (Nuclear membrane lysis buffer) 
HEPES          20mM 
Glycerol          25% v/v 
NaCl            0.42M 
MgCl2           1.5mM 
Dithiothreitol (DTT)        0.5mM 
EDTA           0.2mM 
PMSF           0.5mM 
Whole cell extraction buffer 
HEPES          10mM 
MgCl2           1.5mM 
KCl            10mM 
Dithiothreitol (DTT)        0.5mM 
PMSF           0.5mM 
 
Added to Dignam A/C and whole cell extraction buffers 
Na3VO4          1mM 
NaF            1mM 
AEBSF          1mM 
Aprotinin          2µg/ml 
 
SDS PAGE and Western Blotting 
 
SDS PAGE sample buffer 
Tris 0.5M pH6.8        12.5% v/v 
Glycerol          10% v/v 
Sodium Lauryl Sulphate (SDS)    2% w/v 
Bromo Phenol Blue        0.004% w/v 
Dithiothreitol (DTT)        10mM 
Volume adjusted with distilled water 
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SDS PAGE 5x Electrophoresis buffer 
Tris Base          124mM 
Glycine          1M 
SDS            0.5% w/v 
Volume adjusted with distilled water, the pH (pH 8.3) was not altered. 
 
 
SDS PAGE 4% Stacking Gel 
Tris 0.5M pH6.8        25% v/v 
SDS            0.1% w/v 
Acrylamide-Bis 37.1        4.0% w/v 
APS            0.1% w/v 
TEMED          0.1% v/v 
 
 
SDS PAGE Running Gel 7.5% 
Tris 0.5M pH 8.8        25% v/v 
SDS            0.1% w/v 
Acrylamide-Bis 37.1        7.5% w/v 
APS            0.055 w/v 
TEMED          0.1% v/v 
 
Transfer Buffer (Western) 
Tris Base          25mM 
Glycine          192mM 
Methanol (BDH)        20% v/v 
Volume adjusted with distilled water, the pH (pH 8.3) was not altered. 
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Tris Buffer Saline (TBS) x20 
NaCl            4M 
Tris            0.4mM 
The volume was made up with with distilled water and the pH adjusted to pH 7.4 HCL 
Ethidium bromide    1mg/ml 
 
Liver Homogenising buffer:  
50nM    Tris HCl pH7.6 
0.25%   Triton X-100 
0.15M    NaCl 
10mM   CaCl2 
0.1mM   Phenylmethylsulfonylfluoride 
10µM    Leupeptin 
10µM    Pepstatin A 
0.1mM   Iodoacetamide 
25µg/ml  Apoptonin 
 
10x MOPS:       
0.2M Morpholino propanosulfonic acid 
50mM sodium acetate 
10mM EDTA 
0.1% DEPC adjusted to pH 7 using NaOH and autoclaved. 
 
 
Trypan blue      0.05% trypan blue 
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ERASE-A-BASE SOLUTIONS 
 
7.5M Ammonium acetate 100ml 
57.81 ammonium acetate 
Dissolve the ammonium acetate in 100ml nuclease-free water (final volume).  Sterilize by 
filtration (0.2µm filter). 
 
dNTP mix 
0.125mM each of dATP, dCTP, dGTP and dTTP 
 
Exo III 10x buffer 
660mM Tris-HCl (pH 8.0) 
6.6mM MgCl2 
 
Klenow mix 
30µl Klenow 1x Buffer 
3-5µl Klenow DNA polymerase 
(Made fresh for each experiment). 
 
Klenow 1x Buffer 
20mM Tris-HCl (pH 8.0) 
100mM MgCl2 
 
Luria Bertani (LB) medium (per litre) 
10g Bacto
®-tryptone 
5g Bacto
®-tryptone 
5g NaCl 
 
2.10.2.5 LB plates with ampicillin (per litre) 
15g was added to 1 litre of LB medium and adjusted to pH 7.0 with NaOH prior to 
autoclaving.  After the medium was allowed to cool to 55
0C, ampicillin was added (100mg/ml 
final concentration).  30-35ml of medium was then poured into 90mm petri dishes and where 
necessary, the surfaces were flamed with a Bunsen burner to eliminate bubbles.  When the 
agar hardened it was stored at room temperature (for 1 week) or at 4
0C (for one month).   258
Ligase mix 
790µl deionized water 
100µl Ligase 10x Buffer 
100µl 50% PEG 
10µl 100mM DTT 
5µl T4 DNA Ligase 
 
Ligase 10x Buffer 
500mM Tris-HCl (pH 7.6) 
100mM MgCl2 
10mM ATP 
 
2M NaCl 
116.9g NaCl 
Nuclease-free water was added to a final volume of 1 litre and sterilized by autoclaving. 
 
S1 nuclease mix (for 25 time points) 
172µl deionized water 
27µl S1 7.4x Buffer 
60u S1 nuclease 
This was made fresh for each experiment. 
 
S1 Nuclease Stop Buffer 
0.3M Tris base 
0.05M EDTA 
 
S1 7.4x Buffer 
0.3M potassium acetate (pH 4.6) 
2.25M NaCl 
16.9mM ZnSO4 
45% glycerol 
SOC medium (per litre) 
10g Bacto
®-tryptone 
5g Bacto
®-tryptone 
5g NaCl   259
10mM MgSO4 
10mM MgCl2 
This was adjusted to pH 7.0 with NaOH; autoclaved then had filter sterilized glucose added to 
a final concentration of 20mM. 
 
2M sodium acetate (pH 4.0) 
Glacial acetic acid was diluted to 2M and adjusted to a pH of 4.0 with NaOH. 
 
3M sodium acetate (pH 5.2) 
40.8g sodium acetate.3H20 
Sodium acetate was dissolved in 80ml of water, adjusted to a pH of 5.2 with glacial acetic 
acid and then water was added to a final volume of 100ml. 
 
TE buffer 
10mM Tris-HCl (pH 8.0) 
1mM EDTA 
 
TE-saturated phenol:chloroform:isoamyl alcohol (25:24:1) 
Equal parts of TE buffer and phenol were mixed and the phases allowed to separate.  1 part 
chloroform:isoamyl alcohol (24:1) was added to 1 part lower phenol phase.   260
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P R O C E D U R E S   R U N   O N   T R A N S C R I P T I O N 
 
 
Day 1   Prehybridisation 
 
 
1.  Defrost hybridisation buffer 
 
2.  Prepare hybridisation tube / hybridisation seal-bag (RNase free) with 0.5M 
  NaOH at 45
0C 
 
3.  Wash with DEPC’d H2O. 
  Add 1x 25ml aliquot of prehybridisation buffer. 
 
4.  Wash filter / membrane with 1x SSC / 0.1% SDS 
 
  5mls 20xSSC /0.1g SDS / 100mls DEPC’d H20 
 
5.  Place filter in just-off-the-boil water for 1 minute 
  Then plunge into ice cooled H2O until use. 
 
6.  Prehybridise one nitrocellulose membrane overnight. 
 
  Ensure rotisserie is on and turning   262
R U N   O N   T R A N S C R I P T I O N 
 
Day 2   Run on transcription 
 
 
PREPARATION: 
 
Make up 5mls Transcription Buffer:  (on ice) 
Make up 10mls Proteinase K Buffer:  (on ice) 
 
Set up sterile screw-top/double top eppendorfs 
 
Defrost:  Intact nuclei 
    Acetylated BSA (-20
0C freezer) 
    Hybridisation buffer 
   
32P UTP behind screen 
    Nucleotides: ATP, CTP, GTP 
 
Water bath  Initially 25
0C for steps 1 & 2 followed by 37
0C 
 
 
Transcription buffer:  (keep on ice) 
 
  Stock  for 5msl 
     
50mM Hepes pH 8.0  1M  250µl 
2mM MgCl2  1M  10µl 
2mM MnCl2  0.5M  20µl 
300mM NH4Cl  1M  1.5ml 
1µl/ml acetylated BSA  1mg/ml  5µl 
Sterile H2O    3.215mls 
 
Proteinase K Buffer    (keep on ice) 
 
  Stock  for 10mls 
     
10mM Tris pH 7.5  1M  100µl 
100mM NaCl  4M  250µl 
2mM KCL  4M  5µl 
1mM EDTA  0.5M  20µl 
0.5% SDS  10%  500µl 
Sterile  H20  RNase free  9.125mls   263
Day 2 continued    R U N   O N   T R A N S C R I P T I O N 
 
 
1.  100µ µ µ µl Transcription Buffer 
 
  50µ µ µ µl Nuclei       (2.5 x 10
6 dilute with nuclei storage buffer) 
 
  2µ µ µ µl RNAse inhibitor    placental ribonuclease inhibitor 
          (Pharmacia 39,300 u/ml / Sigma 40,000 u/ml) 
 
  5µ µ µ µl ATP/GTP/CTP     mix each at 10mM ⇒ 0.4mM each) 
        -   purchase as 100mM individual stocks 
 
  5µ µ µ µl [α α α α- 
32P] UTP     100µCi (800Ci/mmol ⇒ 1µM) 
   
 
2.    Incubate at 
  25
0C in waterbath for 20 minutes after starting reaction with [α-
32P] UTP 
  5µ µ µ µl cold UTP    100µCi (800Ci/mmol ⇒ 1µM) 
  Incubate at 37
0C for 40 minutes. 
 
 
        R N A   I S O L A T I O N 
 
 
Chill:  Absolute ethanol   (freezer) 
  75% ethanol    (freezer) 
  TE 
  Phenol / Chloroform 
  Pre cool cetrifuge to: -8
0C / -9
0C  
 
3.  Add: 
  500µ µ µ µl phenol / chloroform 
  50µ µ µ µl 2M Sodium Acetate 
  Leave on ice for 15 mins. 
Centrifuge at 14000 rpm at 4
0C for 5 minutes. 
 
4.  Remove & keep the upper aqueous phase (contains RNA). 
 
  Re-extract phenol/chloroform by adding: 
  200µ µ µ µl TE buffer pH 8.0) 
 
  Centrifuge at 14000 rpm at -8
0C / -9
0C  for 5 minutes 
  and keep the upper aqueous phase as above. 
 
  (Discard radioactive material/phenol in solid radioactive bin). 
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5.  Pool the two aqueous extracts and add: 
 
  1 x Vol Isopropanol 
  Chill at -70
0C for 90 mins 
  Centrifuge at 14000rpm for 20 minutes at -8
0C / -9
0C. 
 
8.  Discard the supernatant (radioactive) into the sink 
(NB: the pellet may not be visible at this time) 
  1/20 vol 3M NaOAc 
  3 x Vol 100% Ethanol 
  Chill at -70
0C for 90 mins 
Centrifuge at 14000rpm for 20 minutes at -8
0C / -9
0C.  
  Discard the supernatant (radioactive) into the sink 
 
9.  Dissolve pellet in: 
  100µ µ µ µl DEPC water    Perform the Incorporation Test at this stage 
  Pass through a Sephadex G50 spin column to get rid of residual  
nucleotides and very short RNA frags (this last bit is important for  
reducing backgrounds). 
 
Take 2.5-5 ml of the spin through and count in a scintillation counter. 
You should get somehwere between 1-5 x 106 cpm for each reaction 
(quiescent serum-starved cells are always less, so I often do 2 separate 
reactions and pool them at the end). 
 
10.  Add constant radiolabelled RNA - ideally 1-10 x 10
6 dpm - to 1ml 
hybridisation buffer and hybridise at 42
0C for 72 hours. 
Keep the vols low to incerase hybridization. Everyday or so manualy  
squish the contents of the bags around to mix things up even more. 
 
  Ensure rotisserie is on and turning  
 
-o-o-o-o-o-o- 
 
 
Keep the vols low to incerase hybridization. evryday or so i would manualy squish the 
contents of the bags around to mix things up even more. 
 
11.  Day 5/6 
  Wash filters    4 x 5 minutes of 1xSSC/0.1%SDS 
        2 x 15 minutes of 0.2x SSC/0.1% SDS 65
0C 
 
12.  Expose filters to autoradiography 
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I N C O R P O R A T I O N   T E S T 
 
 
 
1.  Take known volume of labelled RNA eg 2µl and add to 200ml 0.2M EDTA 
 
2.  Spot known volume on to 2 Whatman DE81 filter paper discs 
 
  A = total 
 
  B = incorporated:  Wash 4x for 5minutes each 
 
With Na2HPO4 (100-200mls) 
 
        Wash 2x for 1 minute H2O 
 
        Wash 2x for 1 minute 95% ethanol (100mls) 
 
  Dry papers before counting 
 
  Add 10mls scintillant 
 
  Use a control (1 filter with nothing added)i 
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P R E P A R A T I O N   O F   N I T R O C E L L U L O S E 
 
 
 
1.  Denature DNA probe at 95
0C for five minutes after adding 0.25pmoles of  probe in 
100µl of 0.1M NaOH. 
 
 
2.  Add 2 volumes of 2M Na acetate, mix and apply 0.25pmoles/slot using   manifold. 
 
 
3.  Wash with with 6xSSC (from a 20x SSC stock solution) 
 
 
4.  Mark the filters to identify the orientation: cutting the top left hand corner. 
 
 
5.  Bake filters for 2 hours at 80
0C and store well for use (nuclear run on studies) -   in 
fridge. 
 
 
6.  Wash filters with 1x SSC / 0.1% SDS 
 
  (5mls 20xSSC /0.1g SDS / 100mls DEPC’d H20) 
 
 
7.  Place filter in just off the boil water for 1 minute 
  then plunge into ice cooled H2O until use.   267
S O L U T I O N S 
 
 
2M Na Acetate 
82.03g in 500ml sterile H2O and autoclaved 
1x SSC / 0.1% SDS 
5mls 20xSSC /0.1g SDS 
100mls DEPC’d H20 
 
 
0.2x SSC / 0.1% SDS 
1ml 20xSSC / 0.1g SDS 
100mls DEPC’d H20 
 
0.1M NaOH 
2.0g NaOH in 250ml sterile water, 
then autoclave 
 
 
20x SSC 
175.3g NaCl 
88.2g Na Citrate 
1 litre of distilled sterile H2O 
pH adjust to pH 7.0 with HCl 
Add 1 ml of DEPC 
Leave overnight and then autoclave 
 
 
TE buffer    for 10mls 
10mM Tris (pH 8.0)  121mg 
1mM EDTA    29.2mg 
(free acid) 
 
 
 
 
Pre-hybridisation Solution 
 
For 200mls 
     
55% Formamide  110mls  Stock 
4x SSC    40mls  20x SSC Stock 
0.1M NaH2PO4 pH7    20mls  1M Stock 
5x Denhardts    20mls  50x Stock 
0.1% SDS     2mls  10% Stock 
100µg/ml Salmon Sperm DNA     4mls  5mg/ml boiled before use 
H2O     6mls   
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Hybridisation Solution 
 
for 10mls 
     
55% Formamide     5mls  Stock 
4x SSC     2mls  20x SSC Stock 
0.1M NaH2PO4 pH7     1ml  1M Stock 
1x Denhardts  400µls  50x Stock 
0.1% SDS  100µls  10% Stock 
10µ µ µ µg/ml Salmon Sperm DNA    20µls  5mg/ml boiled before use 
H2O      1ml  Sterile 
 
 
 
 
0.5M NH4Cl 
10.7g in 200mls DEPC’d H2O 
Autoclave 
 
 
1M Tris 
1.211g in 10mls DEPC’d H2O 
 
4M NaCl  
2.338g in 10ml DEPC’d H2O 
Autoclave 
 
 
4M KCl 
2.982g in 10ml DEPC’d H2O 
Autoclave 
 
0.5 M EDTA 
1.861g in 10ml DEPC’d H2O 
Autoclave 
 
 
0.2 M EDTA 
0.744g in 10ml o DEPC’d H2O  
Autoclave 
 
0.5M Na2HPO4 
30g in 0.5litres of DEPC’d H2O 
Autoclave 
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